Approval Package for:

APPLICATION NUMBER:
ANDA 40-445

Name: Metaxalone Tablets, 800 mg

Sponsor: Sandoz, Inc.

Approval Date: March 31, 2010
### Reviews / Information Included in this Review

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Labeling Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Medical Reviews</td>
<td></td>
</tr>
<tr>
<td>Chemistry Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Bioequivalence Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Reviews</td>
<td></td>
</tr>
<tr>
<td>Microbiology Reviews</td>
<td></td>
</tr>
<tr>
<td>Administrative &amp; Correspondence Documents</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
ANDA 40-445

APPROVAL LETTER
Sandoz Inc.
Attention: Marcy Macdonald
Director, Regulatory Affairs
4700 Sandoz Drive
Wilson, NC 27893

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Metaxalone Tablets, 800 mg, an amendment for which was received on November 4, 2004.1

Reference is also made to your amendments dated November 8, 2001; June 19, June 21, July 16, October 24, November 15, and December 4, 2002; January 7, 2003; May 10, November 1, and December 15, 2004; September 6, 2006; February 2, 2007; January 26, August 29, 2008; and November 23, December 8, December 23, 2009; January 14, January 27 (2 submissions), and March 9, 2010.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Metaxalone Tablets, 800 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Skelaxin Tablets of King Pharmaceuticals, Inc. (King). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

1 ANDA 040445 was submitted on August 31, 2001 for a 400 mg. strength which was later withdrawn.
The reference listed drug (RLD) upon which you have based your ANDA, King’s Skelaxin Tablets, 800 mg, is subject to periods of patent protection. The following patents and their expiration dates are listed in the agency’s publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) for this drug product:

<table>
<thead>
<tr>
<th>U.S. Patent Number</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,407,128 (the '128 patent)</td>
<td>December 3, 2021</td>
</tr>
<tr>
<td>6,683,102 (the '102 patent)</td>
<td>December 3, 2021</td>
</tr>
<tr>
<td>7,122,566 (the '566 patent)</td>
<td>February 6, 2026</td>
</tr>
</tbody>
</table>

With respect to all three patents, your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the Act stating that each patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Metaxalone Tablets, 800 mg, under this ANDA. You notified the agency that Sandoz complied with the requirements of section 505(j)(2)(B) of the Act, and litigation for infringement of the '128 and '102 patents was brought against Eon Labs (now Sandoz) within the statutory 45-day period in the United States District Court for the Eastern District of New York [King Pharmaceuticals, Inc. v. Eon Labs, Inc., Civil Action No. 04-5540]. You have also notified the agency that the court decided that the '128 and '102 patents are invalid; therefore, under section 505(j)(5)(B)(iii) your ANDA is eligible for approval.²

With respect to 180-day generic drug exclusivity for Metaxalone Tablets, 800 mg, the agency has concluded that Sandoz was the first ANDA applicant to submit a substantially complete ANDA for Metaxalone Tablets, 800 mg, with paragraph IV certifications to the '128 and '102 patents. The agency notes that Sandoz failed to obtain tentative approval of this ANDA within 30 months after the date on which the ANDA was filed. We have determined, however, that this was caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application was filed. Namely, Sandoz submitted its amendment for the 800 mg strength on November 4, 2004, and during the entire time the ANDA was under review, the

² You also notified the agency that litigation for infringement of the '566 patent was brought against Sandoz in the United States District Court for the District of New Jersey [King Pharmaceuticals Inc., King Pharmaceuticals Research and Development Inc., Pharmaceutical IP Holding Inc. v. Sandoz Inc., Civil Action No. 08-CV-05974-GBB-JJH]. Although this litigation is ongoing, because the '566 patent was listed after submission of your ANDA, litigation with respect to it creates no statutory stay of approval of your ANDA.
agency had pending before it a citizen petition that created a review of the appropriate labeling for generic metaxalone in light of certain patent-protected language in the labeling of the RLD.

Therefore, with this approval, the agency has determined that Sandoz is eligible for 180 days of generic drug exclusivity for Metaxalone Tablets, 800 mg. Generic drug exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the Act, begins to run from the date of commercial marketing identified in that section. Please submit correspondence to this ANDA informing the agency of the date commercial marketing begins.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.
Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission as “Miscellaneous Correspondence – SPL for Approved ANDA 040445”.

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA-40445</td>
<td>ORIG-1</td>
<td>SANDOZ INC</td>
<td>METAXALONE</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST
03/31/2010
Deputy Director, for Gary Buehler
APPLICATION NUMBER:
ANDA 40-445

LABELING
Metaxalone Tablets

DESCRIPTION

Metaxalone tablets are available as an 800 mg tablet. Chemically, metaxalone is 5-{(3,5-dimethylphenoxy)methyl}-2-oxazolidinone. The empirical formula is C12H15NO3, which corresponds to a molecular weight of 221.25. The structural formula is:

![Structural formula of metaxalone]

Metaxalone is a white to almost white, odorless crystalline powder freely soluble in chloroform, soluble in methanol and in 95% ethanol, but practically insoluble in ether or water. Each tablet contains 800 mg metaxalone and the following inactive ingredients: corn starch, acesulfame potassium, sodium starch glycolate, magnesium stearate and FD&C red No. 40 aluminum lake.

CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. Metaxalone has no direct action on the contractile mechanism of striated muscles, the motor end plate or the nerve fiber.

Pharmacokinetics

The pharmacokinetics of metaxalone have been evaluated in healthy adult volunteers after single dose administration of metaxalone tablets under fasted and fed conditions at doses ranging from 400 mg to 800 mg.

Absorption: Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours. Doubling the dose of metaxalone tablets from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known.

The single-dose pharmacokinetic parameters of metaxalone in two groups of healthy volunteers are shown in Table 1.

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Cmax (ng/mL)</th>
<th>Tmax (h)</th>
<th>AUC (ng·h/mL)</th>
<th>T1/2 (h)</th>
<th>CL/F (L/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>400</td>
<td>983 (53)</td>
<td>3.3 (35)</td>
<td>7479 (51)</td>
<td>9.0 (53)</td>
<td>68 (50)</td>
</tr>
<tr>
<td>800</td>
<td>1816 (43)</td>
<td>3.0 (39)</td>
<td>15044 (46)</td>
<td>8.0 (56)</td>
<td>86 (51)</td>
</tr>
</tbody>
</table>

1Subjects received 1×400 mg tablet under fasted conditions (N=42)
2Subjects received 2×400 mg tablets under fasted conditions (N=59)

Food Effects: A randomized, two-way, crossover study was conducted in 42 healthy volunteers (31 males, 11 females) administered one 400 mg metaxalone tablet under fasted conditions and following a standard high-fat breakfast. Subjects ranged in age from 18 to 48 years (mean age = 23.5 ± 5.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased Cmax by 177.5% and increased AUC (AUC0-∞, AUC0-τ) by 123.5% and 116.4%, respectively. Time-to-peak concentration (Tmax) was also delayed (4.3 h versus 3.3 h) and terminal half-life was decreased (2.4 h versus 9.0 h) under fed conditions compared to fasted.

In a second food effect study of similar design, two 400 mg metaxalone tablets (800 mg) were administered to healthy volunteers (N=59, 37 males, 22 females), ranging in age from 18 to 50 years (mean age = 25.6 ± 8.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased Cmax by 193.6% and increased AUC (AUC0-∞, AUC0-τ) by 146.4% and 142.2%, respectively. Time-to-peak concentration (Tmax) was also delayed (4.9 h versus 3.0 h) and terminal half-life was decreased (4.2 h versus 8.0 h) under fed conditions compared to fasted conditions. Similar food effect results were observed in the above study when one metaxalone 800 mg tablet was administered in place of two metaxalone 400 mg tablets. The increase in metaxalone exposure coinciding with a reduction in half-life may be attributed to more complete absorption of metaxalone in the presence of a high fat meal (Figure 1).

Figure 1. Mean (SD) Concentrations of Metaxalone following an 800 mg Dose under Fasted and Fed Conditions

Distribution, Metabolism and Excretion: Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites. Hepatic Cytochrome P450 enzymes play a role in the metabolism of metaxalone. Specifically, CYP1A2, CYP2D6, and CYP3A4 are known to metabolize metaxalone.

Metaxalone does not significantly inhibit major CYP enzymes such as CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP3A1, and CYP3A4. Metaxalone does not significantly induce major CYP enzymes such as CYP1A2, CYP2C9, and CYP3A4 in vitro.

Pharmacokinetics in Special Populations

Age: The effects of age on the pharmacokinetics of metaxalone were determined following single administration of two 400 mg tablets (800 mg) under fasted and fed conditions. The results were analyzed separately, as well as in combination with the results from three other studies. Using the combined data, the results indicate that the pharmacokinetics of metaxalone are significantly more affected by age under fasted conditions than under fed conditions, with bioavailability under fasted conditions increasing with age.

The bioavailability of metaxalone under fasted and fed conditions in three groups of healthy volunteers of varying age is shown in Table 2.
Table 2: Mean (CV%) Pharmacokinetics Parameters Following Single Administration of Two 400 mg Metaxalone Tablets (800 mg) under Fasted and Fed Conditions

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Younger Volunteers</th>
<th>Older Volunteers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>25.6 ± 8.7</td>
<td>39.3 ± 10.8</td>
</tr>
<tr>
<td>N</td>
<td>59</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>71.5 ± 5.0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Food</th>
<th>Fasted</th>
<th>Fed</th>
<th>Fasted</th>
<th>Fed</th>
<th>Fasted</th>
<th>Fed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax</td>
<td>1816</td>
<td>2719</td>
<td>2515</td>
<td>3168</td>
<td>3680</td>
<td></td>
</tr>
<tr>
<td>(ng/mL)</td>
<td>(43)</td>
<td>(46)</td>
<td>(55)</td>
<td>(45)</td>
<td>(59)</td>
<td></td>
</tr>
<tr>
<td>Tmax</td>
<td>3.0</td>
<td>3.0</td>
<td>8.7</td>
<td>2.6</td>
<td>6.5</td>
<td></td>
</tr>
<tr>
<td>(h)</td>
<td>(39)</td>
<td>(40)</td>
<td>(61)</td>
<td>(30)</td>
<td>(67)</td>
<td></td>
</tr>
<tr>
<td>AUC0-t</td>
<td>14531</td>
<td>20683</td>
<td>18936</td>
<td>20462</td>
<td>23797</td>
<td>24340</td>
</tr>
<tr>
<td>(ng.h/mL)</td>
<td>(47)</td>
<td>(40)</td>
<td>(37)</td>
<td>(45)</td>
<td>(48)</td>
<td></td>
</tr>
<tr>
<td>AUC0-∞</td>
<td>15045</td>
<td>20833</td>
<td>20400</td>
<td>20815</td>
<td>24104</td>
<td>24704</td>
</tr>
<tr>
<td>(ng.h/mL)</td>
<td>(46)</td>
<td>(41)</td>
<td>(39)</td>
<td>(37)</td>
<td>(44)</td>
<td>(47)</td>
</tr>
</tbody>
</table>

Gender: The effect of gender on the pharmacokinetics of metaxalone was assessed in an open label study, in which 48 healthy adult volunteers (24 males, 24 females) were administered two metaxalone 400 mg tablets (800 mg) under fasted conditions. The bioavailability of metaxalone was significantly higher in males compared to males as evidenced by Cmax (2115 ng/mL versus 1335 ng/mL) and AUC (7884 ng·h/mL versus 10328 ng·h/mL). The mean half-life was 11.1 hours in females and 7.2 hours in males. The apparent volume of distribution of metaxalone was approximately 22% higher in males than in females, but not significantly different when adjusted for body weight. Similar findings were also seen when the previously described combined dataset was used in the analysis.

Hepatic/Renal Insufficiency: The impact of hepatic and renal disease on the pharmacokinetics of metaxalone has not been determined. In the absence of such information, metaxalone tablets should be used with caution in patients with hepatic and/or renal impairment.

INDICATIONS AND USAGE
Metaxalone tablets are indicated as an adjunct to rest, physical therapy and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS
Known hypersensitivity to any components of this product.

WARNINGS
Metaxalone tablets may enhance the effects of alcohol and other CNS depressants.

PRECAUTIONS
Metaxalone should be administered with great care to patients with pre-existing liver damage. Serious liver function studies should be performed in these patients. Positive results of Alport's tests, due to an unknown reducing substance, have been noted. A glucose-specific test will differentiate findings.

Taking metaxalone tablets with food may enhance general CNS depression; elderly patients may be especially susceptible to this CNS effect (See CLINICAL PHARMACOLOGY, Pharmacokinetics and PRECAUTIONS, Information for Patients).

Information for Patients
Metaxalone tablets may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol or other CNS depressants.

Drug Interactions: The sedative effects of metaxalone tablets and other CNS depressants (e.g., alcohol, benzdiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously.

Carcinogenesis, Mutagenesis, Impairment of Fertility: The carcinogenic potential of metaxalone has not been determined.

Pregnancy: Reproduction studies in rats have not revealed evidence of impaired fertility or harm to the fetus due to metaxalone. Post marketing experience has not revealed evidence of fetal injury, although such experience cannot exclude the possibility of in utero or postnatal damage to the human fetus. Safe use of metaxalone has not been established with regard to possible adverse effects upon fetal development. Therefore, metaxalone tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards.

Nursing Mothers: It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use: Safety and effectiveness in children 12 years of age and below have not been established.

ADVERSE REACTIONS
The most frequent reactions to metaxalone include:

CNS: Drowsiness, dizziness, headache and nervousness or "irritability";

Digestive: Nausea, vomiting, gastrointestinal upset.

Other adverse reactions are:

Immune System: Hypersensitivity reaction, rash with or without pruritus.

Hematologic: Leukopenia, hemolytic anemia;

Hepatobiliary: Jaundice.

Though rare, anaphylactoid reactions have been reported with metaxalone.

OVERDOSAGE
Deaths by deliberate or accidental overdose have occurred with metaxalone, particularly in combination with antidepressants and have been reported with this class of drugs in combination with alcohol.

When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratory failure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.

Treatment
Gastric lavage and supportive therapy. Consultation with a regional poison control center is recommended.

DOSAGE AND ADMINISTRATION
The recommended dose for adults and children over 12 years of age is one 800 mg tablet three to four times a day.

HOW SUPPLIED
Metaxalone Tablets are supplied as follows:
800 mg: Rose-colored, capsule-shaped tablets, debossed "449" on one side and scored on the other side and supplied as:
NDC 0185-0446-01 bottles of 100
NDC 0185-0446-10 bottles of 1000
Dispense contents in a light, light-resistant container as defined in the USP with a child-resistant closure, as required.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Sandoz Inc.
Princeton, NJ 08540
OS7750 MF0446ISS10/00 Issued 10/00 MG #17653
APPLICATION NUMBER:
ANDA 40-445

LABELING REVIEWS
This labeling approval summary supersedes the labeling approval summary dated 1/7/2003.

APPROVAL SUMMARY #2
REVIEW OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

ANDA Number: 40-445

Dates of Submission: January 26, 2008 and November 1, 2004

Applicant's Name: Sandoz Inc. (formerly Eon Labs, Inc.)

Established Name: Metaxalone Tablets, 800 mg

APPROVAL SUMMARY

CONTAINER LABELS – Bottles of 100’s and 1000’s:
Satisfactory in FPL as of the January 26, 2008 e-submission.

PROFESSIONAL PACKAGE INSERT:
Satisfactory in FPL as of the January 26, 2008 e-submission.

Revisions needed post-approval:
In the DESCRIPTION section, revise the first sentence to read, “Metaxolone is available as an 800 mg tablet for oral administration.”

Patent Data – NDA 13-217

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6407128</td>
<td>December 3, 2021</td>
<td>U-189</td>
<td>Enhancement of the bioavailability of the drug substance.</td>
<td>IV</td>
<td>None</td>
</tr>
</tbody>
</table>

Exclusivity Data – NDA 13-217

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>None</td>
</tr>
</tbody>
</table>

BASIS OF APPROVAL:

Was this approval based upon a petition? No.
What is the RLD on the 356(h) form: Skelaxin®
NDA Number: 13-217
NDA Drug Name: Skelaxin® (metaxalone) Tablets
NDA Firm: King Pharmaceuticals, Inc.
Date of Approval of NDA Insert and supplement: November 24, 2006; NDA 13-217/S-046
Has this been verified by the MIS system for the NDA? Yes.
Was this approval based upon an OGD labeling guidance? No.
Basis of Approval for the Container Labels: Side-by-side comparison with innovator labels.

FOR THE RECORD:
The following comments are from the previous reviewer:

FOR THE RECORD:

1. This review was based on the labeling for Skelaxin® Tablets: Approved on November 24, 2006; NDA 13-217/S-046.


<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6407128</td>
<td>December 3, 2021</td>
<td>U-189</td>
<td>Enhancement of the bioavailability of the drug</td>
<td>IV</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>substance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exclusivity Data– NDA 13-217

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>None</td>
</tr>
</tbody>
</table>

3. Storage/Dispensing Conditions:

NDA: Store at controlled room temperature between 15 to 30°C (59 to 86°F)
ANDA: Store at \[(b) (4)\]
NDA: Dispense in a well-closed container.
ANDA: This is a bulk package. Dispense in tight, light-resistant containers as defined in the USP. With a child-resistant closure, (as required).

Note that requested revisions to the storage/temp conditions were made to be in accord with comments from Dr. Rich Adams.

4. Product Line:

The innovator markets their product in two strengths (400 mg and 800 mg). They are packaged in bottles of 100 and 500 tablets.
The applicant proposes to market their product \[(b) (4)\] tablets.

5. The tablet imprinting have been accurately described in the HOW SUPPLIED section as required by 21CFR 206, et al. (Imprinting of Solid Oral Dosage Form Products for Human Use; Final Rule, effective 9/13/95. (See pgs 0556 in volume B. 1.3)

6. Inactive Ingredients:

The listing of inactive ingredients in the DESCRIPTION section of the package insert appears to be consistent with the listing of inactive ingredients found in the statement of components appearing on page 0054, Vol B. 1.1.

7. Container/Closure (See page 0380 in Vol. B. 1.3)

Containers: HDPE
Closure: CRC closures for 100 count bottles and non-CRC for the \[(b) (4)\] 1000 count bottles.

8. All manufacturing will be done by Eon Laboratories, Inc. (page 0205 in vol. B. 1.2)

9. The drug product submitted for this ANDA is scored as is the RLD’s drug product.

10. APPLICANT ADDRESS AND CONTACT INFORMATION

Sandoz Inc.
4700 Sandoz Drive
Wilson, NC  27893
Dietrich Bartel
11. BIOEQUIVALENCE

The following information was extracted from the 11/9/2007 bioequivalence review:

1. The bioequivalence studies (fasted & fed) conducted by PRACS Institute for Eon Labs Inc. on its metaxalone 800 mg tablet have been found acceptable to the Division of Bioequivalence.

2. The firm's in vitro dissolution testing is acceptable. The dissolution testing should be conducted in 900 mL of 0.5% SLS in water at temp, 37°C ± 0.5°C using the USP apparatus II (paddle) at 100 rpm. The test product should meet the following specification: NLT (\(\frac{80}{85}\%\)) (Q) of metaxalone in the dosage form is dissolved in 60 minutes.

3. Division of Bioequivalence deems the test product Metaxalone Tablet 800 mg, manufactured by Eon/Sandoz to be bioequivalent to the reference product, Skelaxin®, 800 mg Tablet manufactured by Jones Pharma Inc/ King Pharms.

12. The firm has withdrawn the 400 mg tablet.

Date of Review: September 30, 2008
Dates of Submission: January 26, 2008 and November 1, 2004
Primary Reviewer: Postelle Birch-Smith, Pharm.D.
Team Leader: John Grace

cc: ANDA: 40-445
Review
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------------------
Postelle Birch-Smith
9/30/2008 02:57:36 PM
LABELING REVIEWER

John Grace
10/1/2008 11:23:34 AM
LABELING REVIEWER
This approval summary supersedes the labeling approval summary dated 1/26/08 and 11/1/04.

APPROVAL SUMMARY #3
REVIEW OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

ANDA Number:    040445
Dates of Submission:  November 23, 2009
Applicant's Name:    Sandoz Inc. (formerly Eon Labs, Inc.)
Established Name:   Metaxalone Tablets, 800 mg

APPROVAL SUMMARY

CONTAINER LABELS – Bottles of 100’s and 1000’s:
Satisfactory in FPL as of the January 26, 2008 e-submission.

PROFESSIONAL PACKAGE INSERT:
Satisfactory in FPL as of the November 23, 2009 e-submission.

Revisions needed post-approval:

BASIS OF APPROVAL:

Was this approval based upon a petition?   No.
What is the RLD on the 356(h) form: Skelaxin®
NDA Number: 013217
NDA Drug Name: Skelaxin® (metaxalone) Tablets
NDA Firm: King Pharmaceuticals, Inc.
Date of Approval of NDA Insert and supplement: October 31, 2008; NDA 013217/S-053
Has this been verified by the MIS system for the NDA?   Yes.
Was this approval based upon an OGD labeling guidance?   No.
Basis of Approval for the Container Labels: Side-by-side comparison with innovator labels.
FOR THE RECORD:

The following comments are from the previous reviewer:

FOR THE RECORD:

1. This review was based on the labeling for Skelaxin® Tablets: Approved on October 31, 2008; NDA 013217/S-053.

2. Patent Data – NDA 013217

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6407128</td>
<td>December 3, 2021</td>
<td>U-189</td>
<td>Enhancement of the bioavailability of the drug substance.</td>
<td>IV</td>
<td>None</td>
</tr>
</tbody>
</table>

Exclusivity Data – NDA 013217

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>None</td>
</tr>
</tbody>
</table>

UPDATE (12/8/09):

Patent Data

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>013217</td>
<td>003</td>
<td>6407128</td>
<td>Dec 3, 2021</td>
<td></td>
<td></td>
<td>U-189</td>
<td></td>
</tr>
<tr>
<td>013217</td>
<td>003</td>
<td>6683102</td>
<td>Dec 3, 2021</td>
<td></td>
<td></td>
<td>U-189</td>
<td></td>
</tr>
<tr>
<td>013217</td>
<td>003</td>
<td>7122566</td>
<td>Feb 6, 2026</td>
<td></td>
<td></td>
<td>U-915</td>
<td></td>
</tr>
</tbody>
</table>

Exclusivity Data

There is no unexpired exclusivity for this product.

The Sandoz pending ANDA includes Paragraph IV certifications to all three patents currently listed in the Orange Book in connection with Skelaxin®, namely, U.S. Patent Nos. 6,407,128 (the ’128 patent), 6,683,102 (the ’102 patent), and 7,122,566 (the ’566 patent). Sandoz’s ANDA does not include any “(viii) statements” that seek to omit patent-protected labeling information in the labeling of the RLD.
Final approval of the Sandoz ANDA is not delayed by any non-patent exclusivity periods or by the 180-day exclusivity rights of a generic competitor. Final ANDA approval is also not delayed by any litigation stays resulting from lawsuits pursuant to receipt of notices of Sandoz Paragraph IV certifications. With regard to the '128 and '102 patents, the 30-month litigation delays of final ANDA have long expired. As stated and documented in the Sandoz Patent Amendment dated June 26, 2009, the last notice of Paragraph IV certification was received on November 9, 2004. Moreover, as also stated and documented in that Patent Amendment, the federal district court held, on January 20, 2009, that all claims of both patents are invalid.

The '566 patent did not issue until October 17, 2006, long after the Sandoz ANDA was submitted to FDA and accepted for substantive review. Thus, no litigation stay is available with regard to the '566 patent. See 21 U.S.C. § 355(j)(5)(B)(iii) (as amended by MMA § 1101(a)(2)(A)(ii)(I), applicable to patent information submitted to FDA for Orange Book listing on or after August 18, 2003, see MMA § 1101(c)(3)).

3. Storage/Dispensing Conditions:
   NDA: Store at controlled room temperature between 15 to 30°C (59 to 86°F)
   ANDA: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
   NDA: Dispense in a well-closed container.
   ANDA: Dispense in tight, light-resistant containers as defined in the USP with a child-resistant closure, as required.

Note that requested revisions to the storage/temp conditions were made to be in accord with comments from Dr. Rich Adams.

4. Product Line:
   The innovator markets their product in two strengths (400 mg and 800 mg). They are packaged in bottles of 100 and 500 tablets.
   The applicant proposes to market their product as 800 mg packages in bottles of 100 and 1000 tablets.

Update (11/23/09): The innovator markets their product in 800 mg packages in bottles of 100 and 500 tablets.

The applicant proposes to market their product as 800 mg packages in bottles of 100 and 1000 tablets.

5. The tablet imprinting have been accurately described in the HOW SUPPLIED section as required by 21 CFR 206, et al. (Imprinting of Solid Oral Dosage Form Products for Human Use; Final Rule, effective 9/13/95. (See pgs 0556 in volume B. 1.3)

6. Inactive Ingredients:
   The listing of inactive ingredients in the DESCRIPTION section of the package insert appears to be consistent with the listing of inactive ingredients found in the statement of components appearing on page 0054, Vol B. 1.1.

7. Container/Closure (See page 0380 in Vol. B. 1.3)
   Containers: HDPE
   Closure: CRC closures for 100 count bottles and non-CRC for the 1000 count bottles.

8. All manufacturing will be done by Eon Laboratories, Inc. (page 0205 in vol. B. 1.2)

9. The drug product submitted for this ANDA is scored as is the RLD’s drug product.
10. APPLICANT ADDRESS AND CONTACT INFORMATION

Sandoz Inc.
4700 Sandoz Drive
Wilson, NC  27893
Dietrich Bartel
(252)234-2212

11. BIOEQUIVALENCE

The following information was extracted from the 11/9/2007 bioequivalence review:

1. The bioequivalence studies (fasted & fed) conducted by PRACS Institute for Eon Labs Inc. on its metaxalone 800 mg tablet have been found acceptable to the Division of Bioequivalence.

2. The firm's in vitro dissolution testing is acceptable. The dissolution testing should be conducted in 900 mL of 0.5% SLS in water at temp, 37°C + 0.5°C using the USP apparatus II (paddle) at 100 rpm. The test product should meet the following specification: NLT (%)(Q) of metaxalone in the dosage form is dissolved in 60 minutes.

3. Division of Bioequivalence deems the test product Metaxalone Tablet 800 mg, manufactured by Eon/Sandoz to be bioequivalent to the reference product, Skelaxin®, 800 mg Tablet manufactured by Jones Pharma Inc/ King Pharms.

12. The firm has withdrawn the 400 mg tablet.

Date of Review: December 8, 2009
Dates of Submission: November 23, 2009
Primary Reviewer: Burhan Nour
Team Leader: John Grace
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BURHAN A NOUR
12/08/2009

JOHN F GRACE
12/08/2009
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 40-445

CHEMISTRY REVIEWS
CHEMISTRY REVIEW NO. 3 (three)

ANDA # 40-445

NAME AND ADDRESS OF APPLICANT
Sandoz, Inc.
227-15 North Conduit Avenue
Laurelton, NY 11413
Tel: 718-276-8600

LEGAL BASIS FOR SUBMISSION
RLD: Skelaxin® tablets (Metaxalone Tablets) 800 mg, NDA 13-217 manufactured by Jones Pharma, Inc.
Patent IV certification
Eon Labs acknowledges that US patent # 6407128 and US patent # 6683102 associated with NDA 13-217 for Skelaxin® tablets, 800 mg. The patent will expire on December 3, 2021.
Eon Labs certify under Section 505 (j)(2)(A)(vii)(IV) of the federal food, drug and cosmetic act that US patent # 6407128 and US patent # 6683102 are invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of Metaxalone Tablets 800 mg, for which this application is submitted.
Exclusivity
There is no exclusivity associated with NDA 13-217 Skelaxin® tablets, 400 mg and 800 mg.

SUPPLEMENT(s)
None

PROPRIETARY NAME
None

NONPROPRIETARY NAME
Metaxalone Tablets, 400 mg and 800 mg

AMENDMENTS AND OTHER DATES:
Date of submission: August 31, 2001
Acceptable for filing: November 7, 2001
Bio amendment: June 19, 2002
Minor amendment: June 21, 2002
Telephone amendment: October 24, 2002
Telephone amendment: November 15, 2002
Telephone amendment: December 4, 2002
Major amendment: November 1, 2004
(new strength was submitted for 800 mg tablets)
Acceptable for filing (800 mg strength): 12/28/04
Correspondence (change of ownership): 7/21/05

PHARMACOLOGICAL CATEGORY
As an adjunct to rest, physical therapy, and other measures to the relief of discomforts associated with acute, painful musculoskeletal conditions.

Rx or OTC
Rx

RELATED IND/NDA/DMF(s)
RLD: Skelaxin® tablets (Metaxalone Tablets) 400 mg, and 800 mg NDA 13-217 manufactured by Gannick Laboratories, Division of Elan Pharmaceuticals.
13. **DOSAGE FORM**
   Tablet

14. **POTENCY**
   400 mg and 800 mg

15. **CHEMICAL NAME AND STRUCTURE**

   Chemical name: 5-[(3,4-dimethylphenoxy) methyl]-2 oxazolidinone

16. **RECORDS AND REPORTS**
   None

17. **COMMENTS**
   This application is not approvable.

18. **CONCLUSIONS AND RECOMMENDATIONS**
   This application is not approvable.

19. **REVIEWER:**
   Liang-Lii Huang, Ph.D.
   Endorsed by James Fan

   **DATE COMPLETED:**
   Nov 15, 2005
   Nov 15, 2005

Following this page, 19 pages withheld in full - (b)(4)
Chemistry Comments to be Provided to the Applicant


DRUG PRODUCT: Metaxaone Tablets, 400 mg and 800 mg

The deficiencies below represent MINOR deficiencies.

A. Deficiencies:

1. Please establish both the

   Please provide an updated

   Please reconcile

   these differences.

2. 

3. Please revise the

   for the drug product.

4. 

   data.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. Please provide all available long-term stability data.

2. Your Labeling information is pending review. Deficiencies, if any, will be communicated to you separately.
3. Bioequivalence deficiencies were communicated to you via facsimile on May 9, 2005. You should address the issues in the May 9 communication prior to or concurrent with your response to this communication.

Sincerely yours,

Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research
cc: ANDA 40-445
ANDA DUP 40-445
DIV FILE
Field Copy
Endorsements (Draft and Final with Dates):

HFD-627/Liang-Lii Huang, Ph.D./11/15/05; 11/17/05  
HFD-627/James Fan, Team Leader/11/15/05; 11/17/05
HFD-617/ Ann Vu, Project Manager /11/17/05; 11/18/05

V:\FIRMSNZ\SANDOZ\LTRS&REV\40445 rev3.doc
November 17, 2005

CHEMISTRY REVIEW – not APPROVABLE
1. CHEMISTRY REVIEW NO.  4 (four)

2. ANDA # 40-445

3. NAME AND ADDRESS OF APPLICANT
Sandoz, Inc.
4700 Sandoz Drive
Wilson, NC 27893
Tel: 303-438-4599

4. LEGAL BASIS FOR SUBMISSION
RLD: Skelaxin® tablets (Metaxalone Tablets) 800 mg, NDA 13-217 manufactured by Jones Pharma, Inc.
Patent IV certification
Eon Labs acknowledges that US patent # 6407128 and US patent # 6683102 associated with NDA 13-217 for Skelaxin® tablets, 800 mg. The patent will expire on December 3, 2021.
Eon Labs certify under Section 505 (j)(2)(A)(vii)(IV) of the federal food, drug and cosmetic act that US patent # 6407128 and US patent # 6683102 are invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of Metaxalone Tablets 800 mg, for which this application is submitted.
Exclusivity
There is no exclusivity associated with NDA 13-217 Skelaxin® tablets, 400 mg and 800 mg.

5. SUPPLEMENT(s)
None

6. PROPRIETARY NAME
None

7. NONPROPRIETARY NAME
Metaxalone Tablets, 800 mg

8. SUPPLEMENT(s) PROVIDE(s) FOR:
None

9. AMENDMENTS AND OTHER DATES:
Date of submission: August 31, 2001
Acceptable for filing: November 7, 2001
Bio amendment: June 19, 2002
Minor amendment: June 21, 2002
Telephone amendment: October 24, 2002
Telephone amendment: November 15, 2002
Telephone amendment: December 4, 2002
Major amendment: May 10, 2004
(New strength was submitted for 800 mg tablets)
Acceptable for filing (800 mg strength): 12/28/04
Correspondence (change of ownership): 7/21/05
Amendment: February 02, 2007
Sandoz submitted a withdrawal letter to the Agency on September 6, 2006, withdrawing the 400 mg
strength of the drug product. Their responses to the OGD’s deficiency comments therefore only address the 800 mg strength.

Telephone amendment: August 29, 2008
Compliance with USP <467> requirements for residual solvents
  Telephone amendment: 12/23/09
  Telephone amendment: 1/14/10
  Telephone amendment: 1/27/10
  Site withdrawal telephone amendment: 1/27/10
  Telephone amendment: March 9, 2010

10. PHARMACOLOGICAL CATEGORY
    As an adjunct to rest, physical therapy, and other measures to the relief of discomfors associated with acute, painful musculoskeletal conditions.

11. Rx or OTC
    Rx

12. RELATED IND/NDA/DMF(s)
    RLD: Skelaxin® tablets (Metaxalone Tablets) 800 mg NDA 13-217 manufactured by Canrick Laboratories, Division of Elan Pharmaceuticals.

13. DOSAGE FORM
    Tablet
14. POTENCY
    800 mg

15. CHEMICAL NAME AND STRUCTURE

    Chemical name: 5-[(3,4-dimethylphenoxy) methyl]-2 oxazolidinone
    MW 221.25    muscle relaxant
16. RECORDS AND REPORTS
None

17. COMMENTS
This application is approvable.
The drug substance and drug product meet the ICH limits.

18. CONCLUSIONS AND RECOMMENDATIONS
This application is approvable.

19. REVIEWER:
Liang-Lii Huang, Ph.D. January 27, 2010
Endorsed by James Fan January 27, 2010

Following this page, 25 pages withheld in full - (b)(4)
cc:
ANDA 40-445
ANDA DUP 40-445
DIV FILE
Field Copy
Endorsements (Draft and Final with Dates):

HFD-627/Liang-Lii Huang, Ph.D./12/8/09; 1/27/10
HFD-627/James Fan, Team Leader /12/8/09; 1/27/10
HFD-617/T. Tran, Project Manager /12/8/09; 1/27/10

January 27, 2010

CHEMISTRY REVIEW – APPROVABLE
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA-40445</td>
<td>ORIG-1</td>
<td>SANDOZ INC</td>
<td>METAXALONE</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIANG LII HUANG
03/12/2010

TRANG Q TRAN
03/15/2010

JAMES M FAN
03/18/2010
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 40-445

BIOEQUIVALENCE REVIEWS
I. Executive Summary

This submission pertains to metaxalone 800 mg and 400 mg tablets. The sponsor has previously introduced an 800 mg tablet. At the time of the original submission, the 800 mg Skelaxin® had not yet been approved.

The present submission includes one fasting and one fed BE study on the 800 mg tablet. The fasting study is a single-dose, two-way crossover study using 60 healthy normal male and female volunteers given a dose of 800 mg. The results (point estimate, 90% CI) of the fasting BE study are LAUCt of 97.2, 91.2-103%; LAUCI of 96.9, 91.0-103%; and LCmax of 92.9, 84.1-103%.

The fed BE study is a single-dose two-way crossover study using 60 healthy normal male and female volunteers given a dose of 800 mg. The results (point estimate, 90% CI) of the fed BE study are LAUCt of 103, 96.5-109; LAUCI of 99.6, 94.2-105 and LCmax of 92.6, 81.4-105.

Dissolution testing data was submitted using the DBE interim method. The dissolution specification was met, however, the sponsor should provide an explanation for this.

From the bioequivalence viewpoint, this application is incomplete.
II. Table of Contents

I. Executive Summary ......................................................... 1
II. Table of Contents ............................................................ 2
III. Submission Summary ........................................................ 2
    A. Drug Product Information .............................................. 2
    B. PK/PD Information ....................................................... 3
    C. Contents of Submission ............................................... 3
    D. Pre-Study Bioanalytical Method Validation .......................... 4
    E. In Vivo Studies ........................................................... 5
        1. Single-dose Fasting Bioequivalence Study ....................... 5
        2. Single-dose Fed Bioequivalence Study ............................ 6
    F. Formulation ....................................................................... 6
    G. In Vitro Dissolution ....................................................... 7
    H. Waiver Request(s) .......................................................... 7
    I. Deficiency Comments ..................................................... 7
    J. Recommendations .......................................................... 7
IV. Appendix ........................................................................... 9
    A. Individual Study Reviews ............................................... 9
        1. Single-dose Fasting Bioequivalence Study ....................... 9
            a) Study Design ......................................................... 9
            b) Clinical Results .................................................... 10
            c) Bioanalytical Results .............................................. 11
            d) Pharmacokinetic Results ........................................ 12
        2. Single-dose Fed Bioequivalence Study ............................ 16
            a) Study Design ......................................................... 16
            b) Clinical Results .................................................... 17
            c) Bioanalytical Results .............................................. 18
            d) Pharmacokinetic Results ........................................ 19
    B. Formulation Data .......................................................... 23
    C. Dissolution Data ........................................................... 24
    D. Consult Reviews ........................................................... 26
    E. SAS Output ................................................................. 26

III. Submission Summary

A. Drug Product Information

<table>
<thead>
<tr>
<th>Test Product</th>
<th>Metaxalone tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference Product</td>
<td>Skelaxin® tablet</td>
</tr>
<tr>
<td>RLD Manufacturer</td>
<td>Jones Pharma Inc. (subsidiary of King Pharmaceuticals)</td>
</tr>
<tr>
<td>NDA No.</td>
<td>13-217</td>
</tr>
<tr>
<td>RLD Approval Date</td>
<td>13 Aug 1962 (400 mg); 30 Aug 2002 (800 mg)</td>
</tr>
<tr>
<td>Indication</td>
<td>Relief of discomforts associated with acute, painful musculoskeletal conditions</td>
</tr>
</tbody>
</table>
B. PK/PD Information

Bioavailability  
Not known, per PDR

Food Effect  
There is a significant increase in Cmax; also an increase in AUC

Tmax  
3.3 hrs (fasted); 4.3 hrs (fed)

Metabolism  
Hepatic

Excretion  
Renal

Half-life  
9.2 hrs ± 4.8 hrs (fasted); 2.4 hrs ± 1.2 hrs (fed)

Relevant OGD or DBE  
The two bio-studies contained in this submission represent the second set of bio-studies for this application. Previously, the sponsor had

This submission contains those new bio-studies. Since, at the time of the original submission, an 800 mg metaxalone tablet had not yet been approved, the original bio-studies were conducted on the 400 mg tablet. Presently, however, the 800 mg Skelaxin® is the designated RLD and the new bio-studies have been conducted using the 800 mg strength tablets.

Drug Specific Issues (if any)  
Fasted and fed bio-studies are currently recommended for this drug product.

C. Contents of Submission

<table>
<thead>
<tr>
<th>Study Types</th>
<th>Yes/No?</th>
<th>How many?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single-dose fasting</td>
<td>y</td>
<td>1</td>
</tr>
<tr>
<td>Single-dose fed</td>
<td>y</td>
<td>1</td>
</tr>
<tr>
<td>In vitro dissolution</td>
<td>y</td>
<td>2</td>
</tr>
<tr>
<td>Waiver requests</td>
<td>y</td>
<td>1</td>
</tr>
</tbody>
</table>
### D. Pre-Study Bioanalytical Method Validation

<table>
<thead>
<tr>
<th>Metaxalone</th>
<th>Metaxalone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analyte name</td>
<td>Metaxalone</td>
</tr>
<tr>
<td>Internal Standard</td>
<td>(b) (c)</td>
</tr>
<tr>
<td>Method description</td>
<td>RP-HPLC/UV; organic extraction</td>
</tr>
<tr>
<td>QC range</td>
<td>30 to 6000 ng/ml</td>
</tr>
<tr>
<td>Standard curve range</td>
<td>10 to 7500 ng/ml</td>
</tr>
<tr>
<td>Limit of quantitation</td>
<td>10 ng/ml</td>
</tr>
<tr>
<td>Average recovery of Drug (%)</td>
<td>105.7</td>
</tr>
<tr>
<td>Average Recovery of Int. Std (%)</td>
<td>101.8</td>
</tr>
<tr>
<td>QC Intraday precision range (%)</td>
<td>0.75 to 3.85%</td>
</tr>
<tr>
<td>QC Intraday accuracy range (%)</td>
<td>85.0 to 99.9%</td>
</tr>
<tr>
<td>QC Interday precision range (%)</td>
<td>2.04 to 5.89%</td>
</tr>
<tr>
<td>QC Interday accuracy range (%)</td>
<td>100 to 104%</td>
</tr>
<tr>
<td>Bench-top stability (hrs)</td>
<td>5 hr 52 min</td>
</tr>
<tr>
<td>Stock stability (days)</td>
<td>12</td>
</tr>
<tr>
<td>Processed stability (hrs)</td>
<td>50</td>
</tr>
<tr>
<td>Freeze-thaw stability (cycles)</td>
<td>4</td>
</tr>
<tr>
<td>Long-term storage stability (days)</td>
<td>133</td>
</tr>
<tr>
<td>Dilution integrity</td>
<td>Y</td>
</tr>
<tr>
<td>Specificity</td>
<td>Y</td>
</tr>
<tr>
<td>SOPs submitted</td>
<td>Y</td>
</tr>
<tr>
<td>Bioanalytical method is acceptable</td>
<td>Y</td>
</tr>
</tbody>
</table>
E. In Vivo Studies

1. Single-dose Fasting Bioequivalence Study

<table>
<thead>
<tr>
<th>Study No.</th>
<th>R04-0159</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Design</td>
<td>2 treatment, 2 period, 2 sequence</td>
</tr>
<tr>
<td>No. of subjects enrolled</td>
<td>60</td>
</tr>
<tr>
<td>No. of subjects completing</td>
<td>60</td>
</tr>
<tr>
<td>No. of subjects analyzed</td>
<td>60</td>
</tr>
<tr>
<td>Subjects (Healthy or Patients?)</td>
<td>Healthy</td>
</tr>
<tr>
<td>Sex(es) included (how many?)</td>
<td>Male: 37 Female: 23</td>
</tr>
<tr>
<td>Test product</td>
<td>Metaxalone tablet</td>
</tr>
<tr>
<td>Reference product</td>
<td>Skelaxin® tablet</td>
</tr>
<tr>
<td>Strength tested</td>
<td>800 mg</td>
</tr>
<tr>
<td>Dose</td>
<td>1 x 800 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Point Estimate</th>
<th>90% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC$_{0-t}$</td>
<td>97.2</td>
<td>91.2; 103</td>
</tr>
<tr>
<td>AUC$_{\infty}$</td>
<td>96.9</td>
<td>91.0; 103</td>
</tr>
<tr>
<td>Cmax</td>
<td>92.9</td>
<td>84.1; 103</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reason why assay was repeated</th>
<th>Number of samples reanalyzed</th>
<th>Number of recalculated values used after reanalysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Actual number</td>
<td>% of total assays</td>
</tr>
<tr>
<td>T</td>
<td>R</td>
<td>T</td>
</tr>
<tr>
<td>pharmacokinetic fit</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>no IS response</td>
<td>21</td>
<td>1</td>
</tr>
<tr>
<td>poor chromatography</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>instrument malfunction</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>processing error</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>10</td>
</tr>
</tbody>
</table>

Did use of recalculated plasma concentration data change study outcome? No
The 90% confidence intervals were still acceptable when original values for the PK repeats were used.
2. Single-dose Fed Bioequivalence Study

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Point Estimate</th>
<th>90% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC0-t</td>
<td>103</td>
<td>96.5; 109</td>
</tr>
<tr>
<td>AUC∞</td>
<td>99.6</td>
<td>94.2; 105</td>
</tr>
<tr>
<td>Cmax</td>
<td>92.6</td>
<td>81.4; 105</td>
</tr>
</tbody>
</table>

Reanalysis of Study Samples, Fed Bioequivalence Study
Additional information in Appendix, Table 17

<table>
<thead>
<tr>
<th>Reason why assay was repeated</th>
<th>Number of samples reanalyzed</th>
<th>Number of recalculated values used after reanalysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Actual number</td>
<td>% of total assays</td>
</tr>
<tr>
<td></td>
<td>T R</td>
<td>T R</td>
</tr>
<tr>
<td>pharmacokinetic fit</td>
<td>4 -</td>
<td>0.17 -</td>
</tr>
<tr>
<td>no IS response</td>
<td>1 3</td>
<td>0.04 0.13</td>
</tr>
<tr>
<td>poor chromatography</td>
<td>1 1</td>
<td>0.04 0.04</td>
</tr>
<tr>
<td>instrument malfunction</td>
<td>- 3</td>
<td>- 0.13</td>
</tr>
<tr>
<td>Total</td>
<td>6 7</td>
<td>0.26 0.30</td>
</tr>
</tbody>
</table>

Did use of recalculated plasma concentration data change study outcome? No.
The 90% confidence intervals were the same when original values for the PK repeats were used.

F. Formulation

The test product formulation is detailed in Table 1 of the Appendix.
G. In Vitro Dissolution (DBE interim)

USP apparatus II (paddle) @ 100 rpm
900 ml of 0.5% SLS in water
NLT detached dissolved in 60 minutes

H. Waiver Request(s)

<table>
<thead>
<tr>
<th>Strengths for which waivers requested</th>
<th>400 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulation cited</td>
<td>21 CFR 320.22 (d)(2)</td>
</tr>
</tbody>
</table>

| Proportional to strength tested in vivo (yes or no) | 4 |
| Dissolution is acceptable (yes or no)               | yes |
| Waiver granted (yes or no)                          | N |

I. Deficiency Comments

1. 

J. Recommendations

1. The bioequivalence studies (fasted & fed) conducted by PRACS Institute for Eon Labs Inc. on its metaxalone 800 mg tablet have been found acceptable to the Division of Bioequivalence.

2. The in-vitro dissolution testing data is also acceptable. The dissolution testing should be incorporated into the firm's manufacturing controls and stability program. The dissolution testing should be conducted in 900 ml of 0.5% SLS in water at 37°C using
USP XXVII apparatus II (paddle) at 100 rpm. The test product should meet the following specification:

Not less than $0(4)$% of the labeled amount of the drug in the tablet is dissolved in 60 minutes

3. The waiver request for the 400 mg tablet will not be granted at this time due to comment #1.

The sponsor should address comment #1.

J. Lee, Branch II

G. Singh, Ph.D., Team Leader, Branch II

Dale P. Conner, Pharm. D.
Director, Division of Bioequivalence
Office of Generic Drugs
IV. Appendix

A. Individual Study Reviews

1. Single-dose Fasting Bioequivalence Study

<table>
<thead>
<tr>
<th>Study Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Number</strong></td>
</tr>
<tr>
<td><strong>Study Title</strong></td>
</tr>
<tr>
<td><strong>Clinical Site</strong></td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
</tr>
<tr>
<td><strong>Study/Dosing Dates</strong></td>
</tr>
<tr>
<td><strong>Analytical Site</strong></td>
</tr>
<tr>
<td><strong>Analytical Director</strong></td>
</tr>
<tr>
<td><strong>Analysis Dates</strong></td>
</tr>
<tr>
<td><strong>Storage Period (no. of days from the first day of sample collection to the last day of sample analysis)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment ID</th>
<th>A</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test or Reference</strong></td>
<td>Test</td>
<td>Reference</td>
</tr>
<tr>
<td><strong>Product Name</strong></td>
<td>Metaxalone</td>
<td>Skelaxin®</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
<td>Eon Labs, Inc.</td>
<td>Jones Pharma Inc.</td>
</tr>
<tr>
<td><strong>Batch/Lot No.</strong></td>
<td>RDW00470</td>
<td>ES803121A</td>
</tr>
<tr>
<td>** Manufacture Date**</td>
<td>Feb, 2004</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Expiration Date</strong></td>
<td>N/A</td>
<td>Apr, 2005</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>800 mg</td>
<td>800 mg</td>
</tr>
<tr>
<td><strong>Dosage Form</strong></td>
<td>Tablet</td>
<td>Tablet</td>
</tr>
<tr>
<td><strong>Batch Size</strong></td>
<td>(b)(4) dosage units</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Production Batch Size</strong></td>
<td>(b)(4) dosage units</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Potency</strong></td>
<td>99.5%</td>
<td>99.1%</td>
</tr>
<tr>
<td><strong>Content Uniformity (mean, %CV)</strong></td>
<td>99.6% (0.5%)</td>
<td>99.3% (1.1%)</td>
</tr>
<tr>
<td><strong>Dose Administered</strong></td>
<td>1 x 800 mg</td>
<td>1 x 800 mg</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>Oral</td>
<td>Oral</td>
</tr>
</tbody>
</table>
No. of Sequences | 2
No. of Periods | 2
No. of Treatments | 2
No. of Groups | 1
Washout Period | 7 days
Randomization Scheme | AB - subj #1, 3, 5-8, 14, 15, 17, 20, 24, 25, 27, 30, 31, 33-36, 38, 41, 43, 45, 46, 50, 51, 53, 57, 58, 60 BA - subj #2, 4, 9-13, 16, 18, 19, 21-23, 26, 28, 29, 32, 37, 39, 40, 42, 44, 47-49, 52, 54-56, 59
Blood Sampling Times | 0 (pre-dose) 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 16, 24, 30 and 36 hrs
Blood Volume Collected/Sample | 10 ml
Blood Sample Processing/Storage | Cool centrifuged; plasma stored at ≤-20°C
IRB Approval | Y
Informed Consent | Y
Subjects Demographics | See Table 1
Length of Fasting | 10 hrs prior to dosing
Length of Confinement | Through the 24 hr blood draw
Safety Monitoring | Vital signs measured pre-dose and at 12 and 24 hrs post-dose

Comments on Study Design: none

b) Clinical Results

Table 1  Demographics of Study Subjects

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>Weight (lb)</th>
<th>Age Groups Range</th>
<th>Gender % Sex</th>
<th>% Category</th>
<th>% Race</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean 22.4</td>
<td>Mean 165</td>
<td>18-40</td>
<td>Male 98.3</td>
<td>62</td>
<td>Afr. Amer. 93.3</td>
</tr>
<tr>
<td>SD 5.5</td>
<td>SD 828</td>
<td>41-64</td>
<td>Female 1.7</td>
<td>38</td>
<td>Hispanic 1.7</td>
</tr>
<tr>
<td>Range 18-42</td>
<td>Range 117-217</td>
<td>65-75</td>
<td></td>
<td></td>
<td>Asian 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;75</td>
<td></td>
<td></td>
<td>Others</td>
</tr>
</tbody>
</table>

Table 2  Dropout Information

<table>
<thead>
<tr>
<th>Subject No</th>
<th>Reason</th>
<th>Period</th>
<th>Replaced?</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3 Study Adverse Events

<table>
<thead>
<tr>
<th>Adverse Event Description</th>
<th># in Test Group</th>
<th># in Ref. Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>headache, fatigue</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>stomachache</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>sore throat</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total:</strong></td>
<td><strong>2</strong></td>
<td><strong>4</strong></td>
</tr>
</tbody>
</table>

Table 4 Protocol Deviations

<table>
<thead>
<tr>
<th>Type</th>
<th>Subject #s (Test)</th>
<th>Subject #s (Ref.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>taking of ibuprofen for cramps</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Comments on Dropouts/Adverse Events/Protocol Deviations: All adverse events were mild in nature. The protocol deviation would not compromise outcome or validity of study in the opinion of the clinical investigators.

c) Bioanalytical Results

Table 5 Assay Quality Control – Within Study

<table>
<thead>
<tr>
<th>QC Conc. (ng/ml)</th>
<th>30.0 - 6000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inter day Precision (%CV)</td>
<td>3.4 - 6.6%</td>
</tr>
<tr>
<td>Inter day Accuracy (%)</td>
<td>101 - 102%</td>
</tr>
<tr>
<td>Cal. Standards Conc. (ng/ml)</td>
<td>10.0 - 7500 (7 pts)</td>
</tr>
<tr>
<td>Inter day Precision (%CV)</td>
<td>0.64 - 5.6%</td>
</tr>
<tr>
<td>Inter day Accuracy (%)</td>
<td>99.5 - 101%</td>
</tr>
<tr>
<td>Linearity Range ($r^2$)</td>
<td>$\geq 0.9992$</td>
</tr>
</tbody>
</table>

Comments on Study Assay Quality Control: none

<table>
<thead>
<tr>
<th>Any interfering peaks in chromatograms?</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were 20% of chromatograms included?</td>
<td>Y</td>
</tr>
<tr>
<td>Were chromatograms serially or randomly selected?</td>
<td>serial</td>
</tr>
</tbody>
</table>

Comments on Chromatograms: none
Table 6 SOP’s dealing with analytical repeats of study samples

<table>
<thead>
<tr>
<th>SOP No.</th>
<th>Date of SOP</th>
<th>SOP Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>090-01</td>
<td>13 Jun 02</td>
<td>Sample Re-analysis</td>
</tr>
</tbody>
</table>

Table 7 Additional Comments on Repeat Assays

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were all SOPs followed?</td>
<td>Y</td>
</tr>
<tr>
<td>Did recalculation of plasma concentrations change the study outcome?</td>
<td>N</td>
</tr>
<tr>
<td>Does the reviewer agree with the outcome of the repeat assays?</td>
<td>Y</td>
</tr>
<tr>
<td>If no, reason for disagreement</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions, Study Assays: acceptable

d) Pharmacokinetic Results

Table 8 Arithmetic Mean Pharmacokinetic Parameters

Mean plasma concentrations are presented in Table 11 and Figure 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Test</th>
<th>Reference</th>
<th>T/R</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean</td>
<td>%CV</td>
<td>Mean</td>
</tr>
<tr>
<td>AUC0-t</td>
<td>(ng*hr)/ml</td>
<td>13277</td>
<td>53</td>
<td>13445</td>
</tr>
<tr>
<td>AUC∞</td>
<td>(ng*hr)/ml</td>
<td>14396</td>
<td>55</td>
<td>14551</td>
</tr>
<tr>
<td>Cmax</td>
<td>ng/ml</td>
<td>1450</td>
<td>55</td>
<td>1562</td>
</tr>
<tr>
<td>Tmax</td>
<td>hr</td>
<td>4.64</td>
<td>35</td>
<td>4.04</td>
</tr>
<tr>
<td>T1/2</td>
<td>hr</td>
<td>8.21</td>
<td>44</td>
<td>8.78</td>
</tr>
<tr>
<td>Kel</td>
<td>1/hr</td>
<td>0.10</td>
<td>39</td>
<td>0.10</td>
</tr>
</tbody>
</table>

Table 9 Geometric Means and 90% Confidence Intervals

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test</th>
<th>Reference</th>
<th>T/R</th>
<th>90% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>%CV</td>
<td>Mean</td>
<td>% CV</td>
</tr>
<tr>
<td>AUC0-t</td>
<td>11821</td>
<td>5.1</td>
<td>12167</td>
<td>4.9</td>
</tr>
<tr>
<td>AUC∞</td>
<td>12740</td>
<td>5.1</td>
<td>13147</td>
<td>4.9</td>
</tr>
<tr>
<td>Cmax</td>
<td>1262</td>
<td>7.5</td>
<td>1358</td>
<td>7.8</td>
</tr>
</tbody>
</table>
Table 10 Additional Study Information

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Root mean square error, AUC</td>
<td>0.2041</td>
</tr>
<tr>
<td>Root mean square error, Cmax</td>
<td>0.3234</td>
</tr>
<tr>
<td>Ke and AUCi determined for how many subjects?</td>
<td>all</td>
</tr>
<tr>
<td>Do you agree or disagree with firm's decision?</td>
<td>Y</td>
</tr>
<tr>
<td>Indicate the number of subjects with the following:</td>
<td></td>
</tr>
<tr>
<td>-measurable drug concentrations at 0 hr</td>
<td>2</td>
</tr>
<tr>
<td>-first measurable drug concentration as Cmax</td>
<td>0</td>
</tr>
<tr>
<td>Were the subjects dosed as more than one group?</td>
<td>N</td>
</tr>
</tbody>
</table>

Comments on Pharmacokinetic Analysis: There was one subject (#30, per II, ref) who had a zero hour sample concentration >5% of his Cmax. That subject was excluded from the statistical analyses.

Summary and Conclusions, Single-Dose Fasting Bioequivalence Study: acceptable
Table 11 Mean Plasma Concentrations, Single-Dose Fasting Bioequivalence Study

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>N</th>
<th>Mean</th>
<th>Std Dev</th>
<th>CV</th>
<th>T/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>59</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td>59</td>
<td>54.4</td>
<td>69.2</td>
<td>127.1</td>
<td>0.84</td>
</tr>
<tr>
<td>1</td>
<td>59</td>
<td>211.5</td>
<td>249.6</td>
<td>118.0</td>
<td>0.76</td>
</tr>
<tr>
<td>1.5</td>
<td>59</td>
<td>415.9</td>
<td>404.8</td>
<td>97.3</td>
<td>0.70</td>
</tr>
<tr>
<td>2</td>
<td>59</td>
<td>648.3</td>
<td>541.5</td>
<td>83.8</td>
<td>0.75</td>
</tr>
<tr>
<td>2.5</td>
<td>59</td>
<td>808.5</td>
<td>627.8</td>
<td>77.6</td>
<td>0.74</td>
</tr>
<tr>
<td>3</td>
<td>59</td>
<td>906.0</td>
<td>637.7</td>
<td>70.4</td>
<td>0.78</td>
</tr>
<tr>
<td>3.5</td>
<td>59</td>
<td>1002.3</td>
<td>627.2</td>
<td>62.6</td>
<td>0.87</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>1030.7</td>
<td>655.2</td>
<td>63.6</td>
<td>0.91</td>
</tr>
<tr>
<td>4.5</td>
<td>59</td>
<td>1199.4</td>
<td>711.2</td>
<td>59.3</td>
<td>1.01</td>
</tr>
<tr>
<td>5</td>
<td>59</td>
<td>1227.0</td>
<td>721.2</td>
<td>58.8</td>
<td>1.08</td>
</tr>
<tr>
<td>5.5</td>
<td>59</td>
<td>1139.1</td>
<td>658.9</td>
<td>57.8</td>
<td>1.13</td>
</tr>
<tr>
<td>6</td>
<td>59</td>
<td>1046.5</td>
<td>625.3</td>
<td>59.8</td>
<td>1.15</td>
</tr>
<tr>
<td>7</td>
<td>59</td>
<td>868.3</td>
<td>554.7</td>
<td>63.9</td>
<td>1.12</td>
</tr>
<tr>
<td>8</td>
<td>59</td>
<td>744.3</td>
<td>474.9</td>
<td>63.8</td>
<td>1.11</td>
</tr>
<tr>
<td>12</td>
<td>59</td>
<td>437.2</td>
<td>292.0</td>
<td>63.9</td>
<td>1.13</td>
</tr>
<tr>
<td>16</td>
<td>59</td>
<td>271.0</td>
<td>191.8</td>
<td>70.8</td>
<td>1.00</td>
</tr>
<tr>
<td>24</td>
<td>59</td>
<td>156.2</td>
<td>106.1</td>
<td>67.9</td>
<td>0.90</td>
</tr>
<tr>
<td>30</td>
<td>59</td>
<td>116.5</td>
<td>106.0</td>
<td>91.0</td>
<td>0.85</td>
</tr>
<tr>
<td>36</td>
<td>59</td>
<td>72.4</td>
<td>96.1</td>
<td>132.8</td>
<td>1.02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>N</th>
<th>Mean</th>
<th>Std Dev</th>
<th>CV</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>59</td>
<td>0.2</td>
<td>1.9</td>
<td>768.1</td>
</tr>
<tr>
<td>0.5</td>
<td>59</td>
<td>64.5</td>
<td>93.9</td>
<td>145.5</td>
</tr>
<tr>
<td>1</td>
<td>59</td>
<td>279.6</td>
<td>329.9</td>
<td>118.0</td>
</tr>
<tr>
<td>1.5</td>
<td>59</td>
<td>593.4</td>
<td>635.1</td>
<td>107.0</td>
</tr>
<tr>
<td>2</td>
<td>59</td>
<td>860.5</td>
<td>744.7</td>
<td>86.5</td>
</tr>
<tr>
<td>2.5</td>
<td>59</td>
<td>1089.7</td>
<td>836.0</td>
<td>76.7</td>
</tr>
<tr>
<td>3</td>
<td>59</td>
<td>1167.3</td>
<td>816.3</td>
<td>69.9</td>
</tr>
<tr>
<td>3.5</td>
<td>59</td>
<td>1157.3</td>
<td>752.3</td>
<td>65.0</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>1132.7</td>
<td>700.6</td>
<td>61.9</td>
</tr>
<tr>
<td>4.5</td>
<td>59</td>
<td>1190.8</td>
<td>713.8</td>
<td>59.9</td>
</tr>
<tr>
<td>5</td>
<td>59</td>
<td>1138.4</td>
<td>669.0</td>
<td>58.8</td>
</tr>
<tr>
<td>5.5</td>
<td>59</td>
<td>1009.7</td>
<td>585.3</td>
<td>58.0</td>
</tr>
<tr>
<td>6</td>
<td>59</td>
<td>912.2</td>
<td>550.7</td>
<td>60.4</td>
</tr>
<tr>
<td>7</td>
<td>59</td>
<td>775.2</td>
<td>558.6</td>
<td>72.1</td>
</tr>
<tr>
<td>8</td>
<td>59</td>
<td>668.0</td>
<td>521.1</td>
<td>78.0</td>
</tr>
<tr>
<td>12</td>
<td>59</td>
<td>405.9</td>
<td>274.2</td>
<td>67.5</td>
</tr>
<tr>
<td>16</td>
<td>59</td>
<td>271.6</td>
<td>160.0</td>
<td>58.9</td>
</tr>
<tr>
<td>24</td>
<td>59</td>
<td>172.8</td>
<td>119.4</td>
<td>69.1</td>
</tr>
<tr>
<td>30</td>
<td>59</td>
<td>136.8</td>
<td>93.2</td>
<td>68.1</td>
</tr>
<tr>
<td>36</td>
<td>59</td>
<td>70.9</td>
<td>58.1</td>
<td>81.9</td>
</tr>
</tbody>
</table>
Figure 1  Mean Plasma Concentrations, Single-Dose Fasting Bioequivalence Study
(800 mg)

Mean Plasma Concentration (0 - 36 hours)
N=59
2. Single-dose Fed Bioequivalence Study

a) Study Design

<table>
<thead>
<tr>
<th>Study Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Number</td>
<td>R04-0160</td>
</tr>
<tr>
<td>Study Title</td>
<td>A relative bioavailability study of 800 mg metaxalone tablets under non-fasting conditions</td>
</tr>
<tr>
<td>Clinical Site</td>
<td>PRACS Institute, Fargo, North Dakota</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>James D. Carlson, Pharm.D.</td>
</tr>
<tr>
<td>Study/Dosing Dates</td>
<td>Per I - 14 Mar 04; per II - 21 Mar 04</td>
</tr>
<tr>
<td>Analytical Site</td>
<td>PRACS Institute</td>
</tr>
<tr>
<td>Analytical Director</td>
<td></td>
</tr>
<tr>
<td>Analysis Dates</td>
<td>25 Mar 04 - 12 Apr 04</td>
</tr>
<tr>
<td>Storage Period (no. of days from the first day of sample collection to the last day of sample analysis)</td>
<td>30 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment ID</th>
<th>Test Product</th>
<th>Reference Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test or Reference</td>
<td>Test</td>
<td>Reference</td>
</tr>
<tr>
<td>Product Name</td>
<td>Metaxalone</td>
<td>Skelaxin *</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Eon Labs, Inc.</td>
<td>Jones Pharma Inc.</td>
</tr>
<tr>
<td>Batch/Lot No.</td>
<td>RDW00470</td>
<td>ES803121A</td>
</tr>
<tr>
<td>Manufacture Date</td>
<td>Feb, 2004</td>
<td>N/A</td>
</tr>
<tr>
<td>Expiration Date</td>
<td>N/A</td>
<td>Apr, 2005</td>
</tr>
<tr>
<td>Strength</td>
<td>800 mg</td>
<td>800 mg</td>
</tr>
<tr>
<td>Dosage Form</td>
<td>Tablet</td>
<td>Tablet</td>
</tr>
<tr>
<td>Batch Size</td>
<td>(b)(4) dosage units</td>
<td>N/A</td>
</tr>
<tr>
<td>Production Batch Size</td>
<td>(b)(4) dosage units</td>
<td>N/A</td>
</tr>
<tr>
<td>Potency</td>
<td>99.5%</td>
<td>99.1%</td>
</tr>
<tr>
<td>Content Uniformity (mean, %CV)</td>
<td>99.6% (0.5%)</td>
<td>99.3% (1.1%)</td>
</tr>
<tr>
<td>Dose Administered</td>
<td>1 x 800 mg</td>
<td>1 x 800 mg</td>
</tr>
</tbody>
</table>
### Metaxalone tablet

<table>
<thead>
<tr>
<th>No. of Sequences</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Periods</td>
<td>2</td>
</tr>
<tr>
<td>No. of Treatments</td>
<td>2</td>
</tr>
<tr>
<td>No. of Groups</td>
<td>1</td>
</tr>
<tr>
<td>Washout Period</td>
<td>7 days</td>
</tr>
</tbody>
</table>
| Randomization Scheme | AB - subj #4, 7, 8-10, 13, 15, 18, 19, 21-24, 27-30, 32, 36, 37, 39-41, 43, 48, 49, 53, 56, 57, 59  
BA - subj#1-3, 5, 6, 11, 12, 14, 16, 17, 20, 25, 26, 31, 33-35, 38, 42, 44-47, 50-52, 54, 55, 58, 60 |
| Blood Sampling Times | 0 (pre-dose) 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 16, 24, 30 and 36 hrs |
| Blood Volume Collected/Sample | 10 ml |
| Blood Sample Processing/Storage | cool centrifuged; plasma stored at ≤-20°C |
| IRB Approval     | Y |
| Informed Consent | Y |
| Subjects Demographics | See Table 12 |
| Length of Fasting before Meal | overnight |
| Length of Confinement | through the 24 hr blood draw |
| Safety Monitoring | vital signs measured pre-dose and at 12 and 24 hrs post-dose |
| Standard FDA Meal Used? | Y |

#### Comments on Study Design: none

#### b) Clinical Results

### Table 12 Demographics of Study Subjects

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>Weight (lb)</th>
<th>Age Groups</th>
<th>Gender</th>
<th>Race Category</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Range</td>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>24.8</td>
<td>&lt;18</td>
<td>Male</td>
<td>Caucasian</td>
<td>89</td>
</tr>
<tr>
<td>SD</td>
<td>6.5</td>
<td>18-40</td>
<td>Male</td>
<td>Afr. Amer.</td>
<td>3</td>
</tr>
<tr>
<td>Range</td>
<td>18-45</td>
<td>41-64</td>
<td>Female</td>
<td>Hispanic</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>65-75</td>
<td></td>
<td>Asian</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;75</td>
<td></td>
<td>Others</td>
<td></td>
</tr>
</tbody>
</table>
Table 13 Dropout Information

<table>
<thead>
<tr>
<th>Subject No</th>
<th>Reason</th>
<th>Period</th>
<th>Replaced?</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>personal reasons</td>
<td>I</td>
<td>N</td>
</tr>
<tr>
<td>43</td>
<td>personal reasons</td>
<td>prior to per II check-in</td>
<td>N</td>
</tr>
</tbody>
</table>

Table 14 Study Adverse Events

<table>
<thead>
<tr>
<th>Adverse Event Description</th>
<th># in Test Group</th>
<th># in Ref. Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>dry throat</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>headache</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>fatigue</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 15 Protocol Deviations

Subjects #33 and 55 took OTC medications to relieve cramps and cold symptoms. In the opinion of the clinical investigators, the medication use was not expected to compromise the outcome or validity of the study.

Comments on Adverse Events/Protocol Deviations: All adverse events were mild/moderate in nature.

c) Bioanalytical Results

Table 16 Assay Quality Control – Within Study

<table>
<thead>
<tr>
<th>QC Conc. (ng/ml)</th>
<th>30.0 - 6000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inter day Precision (%CV)</td>
<td>1.6 - 3.9%</td>
</tr>
<tr>
<td>Inter day Accuracy (%)</td>
<td>92.6 - 99.0%</td>
</tr>
<tr>
<td>Cal. Standards Conc. (ng/ml)</td>
<td>10.00 - 7500 (7 pts)</td>
</tr>
<tr>
<td>Inter day Precision (%CV)</td>
<td>0.72 - 3.30%</td>
</tr>
<tr>
<td>Inter day Accuracy (%)</td>
<td>92.7 - 104%</td>
</tr>
<tr>
<td>Linearity Range (r²)</td>
<td>≥0.9976</td>
</tr>
</tbody>
</table>

Comments on Study Assay Quality Control: none
Any interfering peaks in chromatograms?  N
Were 20% of chromatograms included?  Y
Were chromatograms serially or randomly selected?  serial

Comments on Chromatograms: OK

Table 17 SOP’s dealing with analytical repeats

<table>
<thead>
<tr>
<th>SOP No.</th>
<th>Date of SOP</th>
<th>SOP Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>090-01</td>
<td>13 Jun 02</td>
<td>Sample Re-analysis</td>
</tr>
</tbody>
</table>

Table 18 Additional Comments on Repeat Assays

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Were all SOPs followed?</td>
<td>Y</td>
</tr>
<tr>
<td>Did recalculation of plasma concentrations change the study outcome?</td>
<td>N</td>
</tr>
<tr>
<td>Does the reviewer agree with the outcome of the repeat assays?</td>
<td>Y</td>
</tr>
<tr>
<td>If no, reason for disagreement</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions, Study Assays: acceptable

d) Pharmacokinetic Results

Table 19 Arithmetic Mean Pharmacokinetic Parameters

Mean plasma concentrations are presented in Table 22 and Figure 2

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Test</th>
<th>Reference</th>
<th>T/R</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean</td>
<td>%CV</td>
<td>Mean</td>
</tr>
<tr>
<td>AUC0-t</td>
<td>(ngxhr)/ml</td>
<td>18016</td>
<td>47</td>
<td>17913</td>
</tr>
<tr>
<td>AUC∞</td>
<td>(ngxhr)/ml</td>
<td>17944</td>
<td>41</td>
<td>18905</td>
</tr>
<tr>
<td>Cmax</td>
<td>ng/ml</td>
<td>1901</td>
<td>63</td>
<td>2206</td>
</tr>
<tr>
<td>Tmax</td>
<td>hr</td>
<td>12.56</td>
<td>61</td>
<td>12.37</td>
</tr>
<tr>
<td>T1/2</td>
<td>hr</td>
<td>4.31</td>
<td>41</td>
<td>4.85</td>
</tr>
<tr>
<td>Kel</td>
<td>1/hr</td>
<td>0.1913</td>
<td>44</td>
<td>0.1781</td>
</tr>
</tbody>
</table>
Table 20 Geometric Means and 90% Confidence Intervals

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test</th>
<th>Reference</th>
<th>T/R</th>
<th>90% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>% CV</td>
<td>Mean</td>
<td>% CV</td>
</tr>
<tr>
<td>AUC0-t</td>
<td>16102</td>
<td>5.1</td>
<td>15692</td>
<td>5.2</td>
</tr>
<tr>
<td>AUC∞</td>
<td>16784</td>
<td>4.7</td>
<td>16850</td>
<td>5.0</td>
</tr>
<tr>
<td>Cmax</td>
<td>1567</td>
<td>8.8</td>
<td>1692</td>
<td>9.7</td>
</tr>
</tbody>
</table>

Table 21 Additional Study Information

| Root mean square error, AUC | 0.1971 |
| Root mean square error, Cmax | 0.4149 |
| Ke and AUCi determined for how many subjects? | 54 for trt A; 56 for trt B |
| Do you agree or disagree with firm’s decision? | Y |
| Indicate the number of subjects with the following: | none |
| -measurable drug concentrations at 0 hr | 1 |
| -first measurable drug concentration as Cmax | none |
| Were the subjects dosed as more than one group? | N |

Comments on Pharmacokinetic Analysis: Possibly due to the fact that AUC_{inf} could only be calculated for 54 subjects out of the 58 subjects completing the study (trt A), AUC_{inf} is smaller than AUC for the arithmetic mean pharmacokinetic parameters.

Summary/Conclusions, Single-Dose Fed Bioequivalence Study: acceptable
### Table 22 Mean Plasma Concentrations, Single-Dose Fed Bioequivalence Study

**Mean Drug Levels**  
(ng/ml)

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>N</th>
<th>Mean</th>
<th>Std Dev</th>
<th>CV</th>
<th>T/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>58</td>
<td>0.27</td>
<td>2.1</td>
<td>761.6</td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td>58</td>
<td>70.1</td>
<td>84.2</td>
<td>120.2</td>
<td>2.47</td>
</tr>
<tr>
<td>1</td>
<td>58</td>
<td>231.7</td>
<td>244.3</td>
<td>105.5</td>
<td>2.16</td>
</tr>
<tr>
<td>1.5</td>
<td>58</td>
<td>370.3</td>
<td>371.7</td>
<td>100.4</td>
<td>1.55</td>
</tr>
<tr>
<td>2</td>
<td>58</td>
<td>518.4</td>
<td>511.9</td>
<td>98.8</td>
<td>1.23</td>
</tr>
<tr>
<td>2.5</td>
<td>58</td>
<td>592.6</td>
<td>501.4</td>
<td>84.6</td>
<td>1.05</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>655.5</td>
<td>533.9</td>
<td>81.5</td>
<td>0.92</td>
</tr>
<tr>
<td>3.5</td>
<td>58</td>
<td>746.2</td>
<td>664.9</td>
<td>89.1</td>
<td>0.83</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>826.7</td>
<td>821.8</td>
<td>99.4</td>
<td>0.78</td>
</tr>
<tr>
<td>4.5</td>
<td>58</td>
<td>996.7</td>
<td>1037.3</td>
<td>104.1</td>
<td>0.72</td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>1026.0</td>
<td>1006.1</td>
<td>98.1</td>
<td>0.65</td>
</tr>
<tr>
<td>5.5</td>
<td>58</td>
<td>1057.5</td>
<td>1002.0</td>
<td>94.7</td>
<td>0.69</td>
</tr>
<tr>
<td>6</td>
<td>58</td>
<td>1116.1</td>
<td>1018.2</td>
<td>91.2</td>
<td>0.75</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>1104.8</td>
<td>1071.2</td>
<td>97.0</td>
<td>0.93</td>
</tr>
<tr>
<td>8</td>
<td>58</td>
<td>1067.3</td>
<td>999.1</td>
<td>93.6</td>
<td>1.06</td>
</tr>
<tr>
<td>12</td>
<td>58</td>
<td>946.4</td>
<td>685.6</td>
<td>72.4</td>
<td>1.49</td>
</tr>
<tr>
<td>16</td>
<td>58</td>
<td>300.3</td>
<td>235.6</td>
<td>78.5</td>
<td>1.38</td>
</tr>
<tr>
<td>24</td>
<td>58</td>
<td>457.3</td>
<td>693.9</td>
<td>151.7</td>
<td>0.90</td>
</tr>
<tr>
<td>30</td>
<td>58</td>
<td>155.4</td>
<td>388.4</td>
<td>250.0</td>
<td>0.81</td>
</tr>
<tr>
<td>36</td>
<td>58</td>
<td>51.2</td>
<td>104.3</td>
<td>203.6</td>
<td>0.55</td>
</tr>
</tbody>
</table>

**Trt B (Skelaxin)**

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>N</th>
<th>Mean</th>
<th>Std Dev</th>
<th>CV</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>58</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0.5</td>
<td>58</td>
<td>28.4</td>
<td>48.6</td>
<td>171.2</td>
</tr>
<tr>
<td>1</td>
<td>58</td>
<td>107.3</td>
<td>151.1</td>
<td>140.9</td>
</tr>
<tr>
<td>1.5</td>
<td>58</td>
<td>239.5</td>
<td>338.4</td>
<td>141.3</td>
</tr>
<tr>
<td>2</td>
<td>58</td>
<td>420.4</td>
<td>592.0</td>
<td>140.8</td>
</tr>
<tr>
<td>2.5</td>
<td>58</td>
<td>563.8</td>
<td>777.9</td>
<td>138.0</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>709.4</td>
<td>1049.7</td>
<td>148.0</td>
</tr>
<tr>
<td>3.5</td>
<td>58</td>
<td>894.3</td>
<td>1315.9</td>
<td>147.1</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>1055.2</td>
<td>1498.0</td>
<td>142.0</td>
</tr>
<tr>
<td>4.5</td>
<td>58</td>
<td>1394.0</td>
<td>1739.1</td>
<td>124.8</td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>1585.8</td>
<td>1867.9</td>
<td>117.8</td>
</tr>
<tr>
<td>5.5</td>
<td>58</td>
<td>1530.0</td>
<td>1745.2</td>
<td>114.1</td>
</tr>
<tr>
<td>6</td>
<td>58</td>
<td>1482.4</td>
<td>1659.9</td>
<td>112.0</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>1191.8</td>
<td>1318.5</td>
<td>110.6</td>
</tr>
<tr>
<td>8</td>
<td>58</td>
<td>1003.4</td>
<td>1082.4</td>
<td>107.9</td>
</tr>
<tr>
<td>12</td>
<td>58</td>
<td>636.8</td>
<td>701.0</td>
<td>110.1</td>
</tr>
<tr>
<td>16</td>
<td>58</td>
<td>218.4</td>
<td>258.8</td>
<td>118.5</td>
</tr>
<tr>
<td>24</td>
<td>58</td>
<td>506.7</td>
<td>650.0</td>
<td>126.3</td>
</tr>
<tr>
<td>30</td>
<td>58</td>
<td>193.0</td>
<td>226.2</td>
<td>117.2</td>
</tr>
<tr>
<td>36</td>
<td>58</td>
<td>93.8</td>
<td>116.4</td>
<td>124.1</td>
</tr>
</tbody>
</table>
Figure 2  Mean Plasma Concentrations, Single-Dose Fed Bioequivalence Study
(800 mg)

Mean Plasma Concentration (0 - 36 hours)
N=58
B. Formulation Data

<table>
<thead>
<tr>
<th>COMPONENT</th>
<th>400 MG</th>
<th>800 MG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount per Tablet, mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% w/w</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metaxalone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acacia, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FD &amp; C Red # 40 Aluminum Lake</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corn Starch, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alginic Acid, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium Starch Glycolate, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium Stearate, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Tablet Weight</td>
<td>926.0</td>
<td>100.00</td>
</tr>
</tbody>
</table>

metaxalone 800 mg - rose-colored, capsule-shaped tablets. Debossed "E448" on one side and scored on the other side.

Skelaxin® 800 mg - oval, scored pink tablet inscribed with 8667 on the scored side and "S" on the other.

Skelaxin® 400 mg - pale rose tablet, inscribed with 8662 on the scored side and "C" on the other.
### C. Dissolution Data

#### Table 1

**IN-VITRO DISSOLUTION TESTING**

<table>
<thead>
<tr>
<th>Method Ref.</th>
<th>DBE interim</th>
<th>Medium:</th>
<th>water w/0.5% SLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP 27 Apparatus:</td>
<td>II</td>
<td>Volume:</td>
<td>900 mL</td>
</tr>
<tr>
<td>RPM:</td>
<td>100</td>
<td>Tolerance:</td>
<td>NLT 450 in 60 min.</td>
</tr>
<tr>
<td>No. Units Tested:</td>
<td>12</td>
<td>Assay Method:</td>
<td>UV</td>
</tr>
<tr>
<td>Reference Drug:</td>
<td>Skelaxin® tablet</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sampling Times (Minutes)</th>
<th>Test Product:</th>
<th>Ref Product:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lot No.:</td>
<td>Lot No.: ES40349A, exp.</td>
</tr>
<tr>
<td></td>
<td>Strength: 400 mg</td>
<td>10/2006</td>
</tr>
<tr>
<td></td>
<td>Strength: 400 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Times (Minutes)</th>
<th>Mean (%)</th>
<th>Range</th>
<th>% CV</th>
<th>Mean (%)</th>
<th>Range</th>
<th>% CV</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(b) (4)
**Figure 3** Dissolution Profiles

![Dissolution Profiles Graph](image-url)
D. Consult Reviews

N/A

E. SAS Output

Fasted study

<table>
<thead>
<tr>
<th>metaxalone</th>
<th>Metaxf8.txt</th>
</tr>
</thead>
</table>

Fed study

<table>
<thead>
<tr>
<th>metaxalone</th>
<th>Metaxfd8.txt</th>
</tr>
</thead>
</table>
BIOEQUIVALENCE DEFICIENCIES TO BE PROVIDED TO THE APPLICANT
ANDA: 40-445  APPLICANT: Eon Labs Inc.

DRUG PRODUCT: Metaxalone tablets; 400 mg and 800 mg

The Division of Bioequivalence has completed its review of your submission(s) acknowledged on the cover sheet. The following deficiency has been identified:

Sincerely yours,

Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research
CC: ANDA 40-445
ANDA DUPLICATE
DIVISION FILE
FIELD COPY
DRUG FILE

Endorsements:
HFD-655/Reviewer 5-3-05
HFD-655/Bio Team Leader 5-3-05
HFD-617/Project Manager
HFD-650/Dale Conner 5-4-05

V:\firmsam\Eon\trs&rev\4044SN1104.doc

BIOEQUIVALENCE - DEFICIENCIES

1. Fasting Study (STF)
   Clinical: PRACS Institute
   Analytical: same
   Outcome: AC
   Strengths: 800 mg

2. Food Study (STP)
   Clinical: PRACS Institute
   Analytical: same
   Outcome: AC
   Strengths: 800 mg

7. Dissolution Waiver (DIW)
   Strengths: 400 mg
   Outcome: IC

Outcome Decisions:
AC - Acceptable
WC - Without Charge
UN - Unacceptable
IC - Incomplete

WinBio Comments
Fasted & fed studies are acceptable. Waiver incomplete for the 400 mg tablet pending appropriate explanation for...
**DIVISION OF BIOEQUIVALENCE REVIEW**

<table>
<thead>
<tr>
<th><strong>ANDA No.</strong></th>
<th>40445</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Product Name</strong></td>
<td>Metaxalone Tablet</td>
</tr>
<tr>
<td><strong>Strength(s)</strong></td>
<td>Originally for 800 mg and 400 mg (400 mg is being withdrawn)</td>
</tr>
<tr>
<td><strong>Applicant Name</strong></td>
<td>Originally Eon now Sandoz</td>
</tr>
<tr>
<td><strong>Address</strong></td>
<td>506 Carnegie Center, Princeton NJ 08540</td>
</tr>
<tr>
<td><strong>Applicant’s Point of Contact</strong></td>
<td>Sadie Ciganek</td>
</tr>
<tr>
<td><strong>Contact’s Telephone Number</strong></td>
<td>609-627-8728</td>
</tr>
<tr>
<td><strong>Contact’s Fax Number</strong></td>
<td>609-627-8673</td>
</tr>
<tr>
<td><strong>Original Submission Date(s)</strong></td>
<td>Aug 31, 2001</td>
</tr>
<tr>
<td><strong>Submission Date(s) of Amendment(s) Under Review</strong></td>
<td>Sept 6, 2006 (withdrawal of the 400 mg Tablet)</td>
</tr>
<tr>
<td><strong>Reviewer</strong></td>
<td>Surendra Shrivastava</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study Number (s)</strong></th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Type (s)</strong></td>
<td>Not Applicable</td>
</tr>
<tr>
<td><strong>Strength (s)</strong></td>
<td>Not Applicable</td>
</tr>
<tr>
<td><strong>Clinical Site</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Clinical Site Address</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Analytical Site</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Analytical Site Address</strong></td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**OUTCOME DECISION** | ACCEPTABLE |
1 EXECUTIVE SUMMARY

Sandoz/Eon has ANDA 40445 for the 800 mg and 400 mg Tablets. The RLD (NDA 13217) is the 800 mg Skelaxin® tablet from Jones Pharma Inc a subsidiary of Kings Pharms. To accept both strengths the DBE requires acceptable single dose, BE studies (fasting and fed) on the 800 mg Tablet, acceptable data as per the 21 CFR 320.22 (d)(2) on the 400 mg Tablet.

As per our last review of submission dated November 1, 2004, the firm had submitted:

i) Acceptable BE studies (fasting and fed) on the 800 mg Tablet.

ii) [Blank]

iii) Incomplete comparative dissolution testing.

In this submission, the firm has elected to withdraw the 400 mg Tablet without prejudice. This means that the firm has submitted acceptable BE requirements for the 800 mg Tablet. Thus, the ANDA 40445 (only for the 800 mg Tablet) is complete and acceptable to DBE without any deficiencies.

No Division of Scientific Investigations (DSI) inspection is pending or necessary.
2 TABLE OF CONTENTS

1 Executive Summary ........................................................................................................2
2 Table of Contents ...........................................................................................................3
3 Submission Summary .......................................................................................................3
  3.1 Contents of Submission ...............................................................................................3
  3.2 Formulation ................................................................................................................4
  3.3 In Vitro Dissolution .....................................................................................................4
  3.4 Waiver Request(s) .......................................................................................................4
  3.5 Deficiency Comments ................................................................................................5
  3.6 Recommendations ......................................................................................................5
  3.7 Comments for Other OGD Disciplines .......................................................................5
  3.8 Outcome Page ............................................................................................................7

3 SUBMISSION SUMMARY

(Please see V:\firmsam\Eon\Itrs&rev\40445N1104.doc)

3.1 Contents of Submission

<table>
<thead>
<tr>
<th>Study Types</th>
<th>Yes/No?</th>
<th>How many?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single-dose fasting</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Single-dose fed</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Steady-state</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>In vitro dissolution</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Waiver requests</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>BCS Waivers</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Clinical Endpoints</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Failed Studies</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Amendments</td>
<td>Yes</td>
<td>1</td>
</tr>
</tbody>
</table>
### 3.2 Formulation

<table>
<thead>
<tr>
<th>Location in appendix</th>
<th>[V:\firmsam\Eon\ltrs&amp;rev\40445]</th>
</tr>
</thead>
<tbody>
<tr>
<td>If a tablet, is the RLD scored?</td>
<td>Yes</td>
</tr>
<tr>
<td>If a tablet, is the test product biobatch scored</td>
<td>Yes</td>
</tr>
<tr>
<td>Is the formulation acceptable?</td>
<td>FORMULATION ACCEPTABLE</td>
</tr>
<tr>
<td>If not acceptable, why?</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

### 3.3 In Vitro Dissolution

<table>
<thead>
<tr>
<th>Location of DBE Dissolution Review</th>
<th>[V:\firmsam\Eon\ltrs&amp;rev\40445]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source of Method (USP, FDA or Firm)</td>
<td>FDA</td>
</tr>
<tr>
<td>Medium</td>
<td>0.5% SLS in water</td>
</tr>
<tr>
<td>Volume (mL)</td>
<td>900</td>
</tr>
<tr>
<td>USP Apparatus type</td>
<td>II (paddle)</td>
</tr>
<tr>
<td>Rotation (rpm)</td>
<td>100</td>
</tr>
<tr>
<td>DBE-recommended specifications</td>
<td>NL{T}_{0.01}(Q) in 60 minutes</td>
</tr>
<tr>
<td>If a modified-release tablet, was testing done on ½ tablets?</td>
<td>Not applicable</td>
</tr>
<tr>
<td>F2 metric calculated?</td>
<td>For the 800 mg Tablet (T vs. R = 65.83)</td>
</tr>
<tr>
<td>If no, reason why F2 not calculated</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Is method acceptable?</td>
<td>METHOD ACCEPTABLE</td>
</tr>
<tr>
<td>If not then why?</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostudy Strength</th>
<th>Other Strength</th>
<th>F2 metric for test</th>
<th>F2 metric for RLD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3.4 Waiver Request(s)

<table>
<thead>
<tr>
<th>Strengths for which waivers are requested</th>
<th>Not Applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportional to strength tested in vivo?</td>
<td></td>
</tr>
<tr>
<td>Is dissolution acceptable?</td>
<td></td>
</tr>
<tr>
<td>Waivers granted?</td>
<td>Not applicable</td>
</tr>
<tr>
<td>If not then why?</td>
<td>The firm withdrew the lower strength</td>
</tr>
</tbody>
</table>
3.5 Deficiency Comments

None

3.6 Recommendations

Standard BE Studies

1. The bioequivalence studies (fasted & fed) conducted by PRACS Institute for Eon Labs Inc. on its metaxalone 800 mg tablet have been found acceptable to the Division of Bioequivalence.

2. The firm’s in vitro dissolution testing is acceptable. The dissolution testing should be conducted in 900 mL of 0.5% SLS in water at temp, 37°C ± 0.5°C using the USP apparatus II (paddle) at 100 rpm. The test product should meet the following specification:

   NLT (Q) of metaxalone in the dosage form is dissolved in 60 minutes.

3. Division of Bioequivalence deems the test product Metaxalone Tablet 800 mg, manufactured by Eon/Sandoz to be bioequivalent to the reference product, Skelaxin®, 800 mg Tablet manufactured by Jones Pharma Inc/ King Pharms.

3.7 Comments for Other OGD Disciplines

<table>
<thead>
<tr>
<th>Discipline</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
<td></td>
</tr>
</tbody>
</table>
BIOEQUIVALENCE COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 40-445
APPLICANT: Sandoz (Eon)
DRUG PRODUCT: Metaxalone Tablet 800 mg

The Division of Bioequivalence has completed its review and has no further questions at this time.

The Division of Bioequivalence acknowledges that you will conduct the dissolution testing in 900 mL of 0.5% SLS in water at temp, 37°C ± 0.5°C using the USP apparatus II (paddle) at 100 rpm. The test product should meet the following specification:

NLT (%)(Q) of metaxalone in the dosage form is dissolved in 60 minutes.

Please note that the bioequivalence comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalence information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

{See appended electronic signature page}

Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research
3.8 Outcome Page

ANDA: 40445

**Completed Assignment for 40445 ID: 786**

10/30/2007 2:55:42 PM

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Shrivastava, Surendra</th>
<th>Date Completed:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verifier</td>
<td>Shriniwas Nerurkar</td>
<td>Date Verified: 10/30/2007</td>
</tr>
<tr>
<td>Division</td>
<td>Division of Bioequivalence</td>
<td></td>
</tr>
<tr>
<td>Description</td>
<td>Metaxalone Tablets Sandoz (Previously Eon)</td>
<td></td>
</tr>
</tbody>
</table>

### Productivity:

<table>
<thead>
<tr>
<th>ID</th>
<th>Date Entered</th>
<th>Productivity Category</th>
<th>Sub Category</th>
<th>Productivity</th>
<th>Subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>786</td>
<td>9/6/2006</td>
<td>Other</td>
<td>Study Amendment</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Bean Total: 1
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Surendra P. Shrivastava
11/6/2007 09:27:30 AM
BIOPHARMACEUTICS

Shriniwas G. Nerurkar
11/6/2007 09:40:23 AM
BIOPHARMACEUTICS

Barbara Davit
11/9/2007 02:28:39 PM
BIOPHARMACEUTICS
APPLICATION NUMBER:
ANDA 40-445

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
August 31, 2001

Gary J. Buehler
Director
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: Original ANDA
Metaxalone Tablets, 400 mg

Dear Mr. Buehler:

Pursuant to section 505(j) of the Federal Food, Drug and Cosmetic Act, enclosed is an original Abbreviated New Drug Application for Metaxalone Tablets, 400 mg. This application consists of the following volumes:

Volume 1    Debarment, patent and exclusivity certifications, Section 505(j)(2)(A) information, labeling, dissolution profiles, signed disclosure statement, certificates of analysis, and components and composition.

Volume 2    Raw material control data, manufacturing and packaging records including Executed Batch Record.

Volume 3    Container/closure information, finished product controls, methods validation, stability data, and environmental impact statement.

Volume 4 through 8    Bioequivalence study summary and test results. (Also included is one diskette containing the raw data).

A full table of contents precedes each appropriately paginated volume.

We have also enclosed three (03) copies of analytical methods validation package in a separate volume.

In addition to the archival and review copies, we are submitting a certified true copy of the chemistry, manufacturing and controls data to the District Field Office, Jamaica, New York.

G. Buehler  August 31, 2001
Subsequent amendments or supplements containing chemistry, manufacturing and controls data will also be submitted to the District Field Office.

If there are any comments or questions about this application, please contact me at (718) 276-8600, extension 330.

Sincerely,
Eon Labs Manufacturing, Inc.

[Signature]

Sadie M. Ciganek
Vice President, Regulatory Affairs
Bon Labs Manufacturing, Inc.
Attention: Sadie M. Ciganek
227-15 North Conduit Avenue
Laurelton, NY  11413

Dear Madam:

Please refer to your abbreviated new drug application (ANDA) dated August 31, 2001, submitted under Section 505(j) of the Federal Food, Drug and Cosmetic Act for Metaxalone Tablets, 400 mg.

We have given your application a preliminary review, and we find that it is not sufficiently complete to merit a critical technical review.

We are refusing to receive this ANDA under 21 CFR 314.101(d)(3) for the following reasons:

It appears that your proposed

Thus, it will not be received as an abbreviated new drug application within the meaning of Section 505(j) of the Act.
Upon receipt of this communication, you may either amend your application to correct the deficiencies or withdraw your application under 21 CFR 314.99. If you have any questions please call:

Saundra T. Middleton  
Project Manager  
(301) 827-5862

Sincerely yours,

Wm Peter Rickman  
Acting Director  
Division of Labeling and Program Support  
Office of Generic Drugs  
Center for Drug Evaluation and Research

ANDA 40-455  
cc:  DUP/Jacket  
Division File  
HPD-92  
Field Copy  
HPD-610/R. West  
HPD-610/P. Rickman  
HPD-615/MBennett

Endorsement:  HFD-615/GDavis, Chief, RSB  
HFD-615/SMiddleton, CSO  
Word File  
V:\FIRMSAM\EON\LTRS&REV\40445.RTF  
F/T File BEH 10/15/01  
ANDA Refuse to Receive!
November 2, 2001

Ms. Saundra Middleton
Project Manager
Regulatory Support Branch
Office of Generic Drugs, HFD-615
Center for Drug Evaluation and Research
7500 Standish Place
Metro Park North II
Rockville, MD 20857

- GENERAL CORRESPONDENCE -

Re: Metaxalone Tablets, 400 mg
ANDA 40-445

Dear Ms. Middleton:

Reference is made to the Refusal-to-Receive letter dated October 17, 2001 for Metaxalone Tablets, 400 mg, ANDA 40-445. The letter raised concerns about the

- [Blank]

- [Blank]
in Eon Labs Metaxalone product.

* to FDA, Regulatory Support Branch (Ms. Saundra Middleton) for review if required.

Based on the information submitted herein, are requesting that our Abbreviated New Drug Application for Metaxalone Tablets, 400 mg be accepted for filing since

If you require further information, do not hesitate to let either myself know at (718) 276-8607 x 235, or Ms. Sadie Ciganek at (718) 276-8607 x 330. We will provide the necessary assistance to resolve this matter as quickly as possible.

Sincerely,
Eon Labs Manufacturing, Inc.

Enna Krivitsky
Manager Regulatory Affairs
Bon Labs Manufacturing, Inc.
Attention: Sadie M. Ciganek
227-15 North Conduit Avenue
Laurelton, NY 11413

Dear Madam:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act.

Reference is also made to our "Refuse to Receive" letter dated October 17, 2001 and your amendment dated November 2, 2001.

NAME OF DRUG: Metaxalone Tablets, 400 mg

DATE OF APPLICATION: August 31, 2001

DATE (RECEIVED) ACCEPTABLE FOR FILING: November 7, 2001

We will correspond with you further after we have had the opportunity to review your application.

Please identify any communications concerning this application with the number shown above.

Should you have questions concerning this application contact:

Ruby Yu
Project Manager
(301) 827-5848

Sincerely yours,

Wm Peter Rickman
Acting Director,
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research
ANDA 40-445

cc:  DUP/Jacket
Division File
HFD-82
Field Copy
HFD-330
HFD-610/R.West
HFD-610/P.Rickman
HFD-615/MBennett

Endorsements:  HFD-615/GDavis, RSB
               HFD-615/SMiddleton, CSO
               V:\FIRMSAM\EON\LTRS&REV\40445.ACK
               P/T by StM 11/29/01
               ANDA Acknowledgment Letter!
ANDA for Metaxalone Tablets

Dear Applicant:

This letter is to inform you that the FDA has determined that labeling corresponding to the use (U-189) listed in Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) for U. S. Patent number 6,407,128 (the '128 patent) may be carved out of the metaxalone labeling. Previously, the FDA may have informed you that such omission would not be permitted. A preliminary decision not to permit omission of this labeling was challenged by an ANDA applicant. The applicant has submitted information and analysis that has persuaded FDA that the fed-state bioavailability information may be carved out of the metaxalone labeling without rendering the drug less safe or effective for the remaining conditions of use. Therefore, FDA has concluded that you may submit proposed labeling that omits the use (U-189) described in the Orange Book. Should you adopt this approach, you must accompany this submission with a "section viii statement" to the '128 patent, pursuant to section 505(j)(2)(A)(viii) of the Federal Food, Drug, and Cosmetic Act (Act)

The listed drug at issue is Elan's Skelaxin (metaxalone) Tablets, NDA 13-217.\(^1\) Metaxalone is approved by FDA for use "as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful, musculoskeletal conditions." The '128 patent is listed for Skelaxin in the Orange Book. It is identified as a use patent. The use claimed by the patent is listed in the Orange Book as "enhancement of the bioavailability of the drug substance" (U-189). The question presented to the agency was whether a section viii statement with respect to the '128 patent would be permitted. A section viii statement asserts that the labeling in the ANDA does not include any use claimed by the use patent. Section 505(j)(2)(A)(viii); 21 CFR 314.94(a)(12)(iii). A section viii statement is only appropriate when an applicant can carve information protected by the use patent out of the labeling for the product proposed in the ANDA.

**ANDA Applicants May Omit from Labeling Method of Use Information Claimed by a Patent if the Omission Will Not Render the Drug Less Safe and Effective**

The regulatory principles governing FDA's decision on this matter are well established. FDA has authority to approve ANDAs that omit labeling carried by the listed drug, when such labeling is protected by patent or exclusivity. The Act requires that an ANDA contain "information to show that the conditions of use prescribed, recommended, or suggested in the labeling proposed for the new drug have been previously approved for a [listed drug]." Section 505(j)(2)(A)(i). The Act also requires that an ANDA contain "information to show that the labeling proposed for the new drug is the same as the labeling approved for the listed drug . . . ." Section

\(^1\) This NDA is now owned by Jones Pharma, Inc., a subsidiary of King Pharmaceuticals, Inc.
505(j)(2)(A)(v). The Act specifies two exceptions to this requirement. ANDA labeling may differ from that of the listed drug because changes from the listed drug were approved pursuant to an ANDA suitability petition, or because the drugs are produced or distributed by different manufacturers. Section 505(j)(2)(A)(v).

The Act specifically contemplates that an innovator company may submit to FDA patents claiming an approved method of using a drug and that ANDA applicants may omit from proposed labeling methods of use covered by those patents. Sections 505(b)(1) and (c)(2) of the Act state that innovators may submit patents to FDA that claim the approved drug "or method of using such drug." If a method-of-use patent listed by the innovator does not claim a use for which an ANDA applicant is seeking approval (because it is omitted from the proposed ANDA labeling), the ANDA applicant may submit a "section viii statement" to FDA that it is not seeking approval for a use claimed by a listed patent. Section 505(j)(2)(A)(viii). The statutory provisions addressing patent listing and section viii statements use the same "method of use" terminology, and effectively mirror one another; a method of use claimed by a patent is also a method of use that an ANDA applicant may propose to carve out of labeling.

FDA regulations further describe the differences that are permitted between the proposed labeling in the ANDA and the listed drug. 21 CFR 314.94, "Content and format of an abbreviated application," provides:

Labeling (including the container label and package insert)
proposed for the drug product must be the same as the labeling
approved for the reference listed drug, except for changes required
because of differences approved under a petition filed under §
314.93 or because the drug product and the reference listed drug
are produced or distributed by different manufacturers. Such
differences between the applicant's proposed labeling and labeling
approved for the reference listed drug may include differences in
expiration date, formulation, bioavailability, or pharmacokinetics,
labeling revisions made to comply with current FDA labeling
guidelines or other guidance, or omission of an indication or other
aspect of labeling protected by patent or accorded exclusivity
under section 505(j)(4)(D) of the act.


The regulations further provide that to approve an ANDA that omits an aspect of labeling protected by patent or exclusivity, FDA must find that the "differences do not render the proposed drug product less safe or effective than the listed drug for all remaining, non-protected conditions of use." 21 CFR 314.127(a)(7). Whether a particular ANDA proposing labeling that
omits protected information may be approved depends upon the specific drug product and the labeling at issue. Therefore, whether FDA could approve a metaxalone ANDA that omits certain method of use information from the labeling depends upon whether the agency concludes that the drug will remain safe and effective for all the conditions of use that would remain in the label.

**ANDA Applicants May Omit Labeling Related to Fed-State Bioavailability from Metaxalone Labeling**

The agency has reviewed the labeling for Skelaxin, and determined that information related to the "enhancement of the bioavailability of the drug substance," may be omitted from the labeling for metaxalone products proposed in ANDAs, without rendering those drug products less safe or effective for the conditions of use that would remain in the label.

Metaxalone is approved by FDA only for use "as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful, musculoskeletal conditions." The mode of action of metaxalone has not been clearly identified, but may be related to its sedative properties. The drug has been marketed for approximately 40 years, and is considered to have a favorable safety profile. Until recently, Skelaxin had no information in its labeling related to the effect of administration of the drug with food.

In 2001, Elan conducted a food effect study with metaxalone, and submitted the results to FDA in a labeling supplement. In June 2002, FDA approved changes to the Clinical Pharmacology section of the Skelaxin labeling to incorporate information from the food effect study.² It is this pharmacokinetic information that an applicant seeks to delete from its labeling as corresponding to the use claimed in the '128 patent. The bioavailability data submitted by Elan did not result in new Dosing and Administration labeling information for Skelaxin. Nor did it result in any changes to the warnings, precautions, or contraindications in the Skelaxin labeling.

The pharmacokinetic information submitted by Elan and included in the labeling demonstrated that administration of metaxalone with a high fat meal enhances drug absorption. See attached Skelaxin labeling. The Skelaxin label includes pharmacokinetic information from dosing following a standardized high fat meal. The results from this study showed that food statistically significantly increased the rate (Cmax), and extent of absorption (AUC0-t, AUCinf) of metaxalone. The approved Skelaxin labeling further acknowledges that "[t]he clinical relevance of these effects is unknown."³

The agency's assessment of whether pharmacokinetic information may be omitted from metaxalone labeling without rendering the drug less safe or effective for the remaining uses focused on whether information about enhanced fed-state bioavailability was necessary to the

---

² Elan did not receive three years of exclusivity for this labeling change under section 505(j)(5)(D)(iii) or (iv) because bioavailability studies are not clinical studies that qualify for exclusivity. 21 CFR 314.108(a).

³ If Elan had conducted clinical trials to demonstrate a clinical effect arising from the difference in fed- and non-fed-state bioavailability, the inclusion of such information in labeling might have been considered necessary for the safe and effective use of metaxalone. No such study has been submitted.
safe and effective use of the drug. The agency looked specifically at the relationships between bioavailability and efficacy, and bioavailability and the occurrence of known adverse events, particularly drowsiness.

FDA has concluded that omission of information regarding fed-state bioavailability will not negatively affect the safe use of metaxalone. On May 31, 2002, FDA approved an addition to the Skelaxin Clinical Pharmacology labeling that stated "Given the magnitude of the plasma level changes following a high fat meal, Skelaxin tablets should be administered on an empty stomach." The agency had approved this information because it was concerned about enhanced bioavailability and increased adverse events. However, no related changes were made to the Dosing and Administration portion of the labeling. After discussions with Elan and additional review of the available information, the agency later concluded that there were insufficient data to support a correlation between enhanced drug concentrations and increased adverse events. The label was further revised in June 2002, to remove information regarding dosing on an empty stomach, and to state that the clinical effect of the increased bioavailability is unknown.

Because the clinical effect of the increased bioavailability is unknown, omission of fed-state bioavailability information from the labeling will not render the drug less safe for its approved uses. There are no data to support an increase in adverse events related to increased drug concentrations. Even if it were reasonable to conclude that increased bioavailability relates to an increase in adverse events, the labeling already adequately addresses the primary CNS (central nervous system) adverse events by way of the caution that "SKELAXIN may impair mental and/or physical abilities required for performance of hazardous tasks such as operating machinery or driving a motor vehicle, especially when used with alcohol or other CNS depressants." This caution applies to use of metaxalone without reference to the conditions of administration.

The Skelaxin labeling provides no information that links variations in bioavailability to the effectiveness of the drug. In fact, as noted above, the approved labeling specifically states that the clinical relevance of the food effect is unknown. Thus, because the clinical effect of increased bioavailability is unknown, omission of information on this characteristic of the drug will not affect the effective use of metaxalone.

Finally, FDA notes that metaxalone has a long history of safe use. It has been marketed for decades without dosing adjustment information related to fed-state administration. Few adverse event reports have been entered into the Adverse Event Reporting System. Based upon the data available to the agency, there is no reason to believe that metaxalone will not continue to be safe and effective for use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful, musculoskeletal conditions.

For the reasons described above, FDA has concluded that an ANDA applicant may delete from its labeling information on fed-state bioavailability claimed by the '128 patent because metaxalone products with such labeling will be no less safe or effective for all of the remaining conditions of use.
If you have further questions regarding this issue, please contact Cecelia Parise, Regulatory Policy Advisor to the Director, Office of Generic Drugs, at (301) 827-5845.

Sincerely,

[signature]

Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

Attachment: Skelaxin Labeling

cc: Jones Pharma, Inc.
Daniel E. Troy, OCC
SKELAXIN® (Metaxalone)

DESCRIPTION

SKELAXIN® (metaxalone) has the following chemical structure and name:

\[
\begin{array}{c}
\text{CH}_3 \\
\text{O-CH}_2-\text{CH-CH}_2 \\
\text{O-CH}_3 \\
\end{array}
\]

5-[(3,5-dimethylphenoxy) methyl]-2-oxazolidinone

SKELAXIN (metaxalone) is available as a 400 mg round, pale rose tablet and an 800 mg oval, pink scored tablet.

CLINICAL PHARMACOLOGY

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics: In a single center randomized, two-period crossover study in 42 healthy volunteers (31 males, 11 females), a single 400 mg SKELAXIN (metaxalone) tablet was administered under both fasted and fed conditions.

Under fasted conditions, mean peak plasma concentrations (C_max) of 865.3 ng/mL were achieved within 3.3 +/- 1.2 hours (S.D.) after dosing (T_max). Metaxalone concentrations declined with a mean terminal half-life (t_1/2) of 9.2 +/- 4.8 hours. The mean apparent oral clearance (CL/F) of metaxalone was 68 +/- 34 L/h.

In the same study, following a standardized high fat meal, food statistically significantly increased the rate (C_max) and extent of absorption (AUC_0-\infty, AUC_{int}) of metaxalone from SKELAXIN tablets. Relative to the fasted treatment the observed increases were 177.5%, 123.5%, and 115.4%, respectively. The mean T_max was also increased to 4.3 +/- 2.3 hours, whereas the mean t_1/2 was decreased to 2.4 +/- 1.2 hours. This decrease in half-life over that seen in the fasted subjects is felt to be due to the more complete absorption of metaxalone in the presence of a meal resulting in a
better estimate of half-life. The mean apparent oral clearance (CL/F) of metaxalone was relatively unchanged relative to fasted administration (59 +/- 29 L/hr). Although a higher Cmax and AUC were observed after the administration of SKELAXIN (metaxalone) with a standardized high fat meal, the clinical relevance of these effects is unknown.

In another single center, randomized four-period crossover study in 59 healthy volunteers (37 males, 22 females), the rate and extent of metaxalone absorption were determined after the administration of SKELAXIN tablets under both fasted and fed conditions. Under fasted conditions, the administration of two SKELAXIN 400 mg tablets produced peak plasma metaxalone concentrations (Cmax) of 1653 ng/mL 3.0 + 1.2 hours after dosing (Tmax). Metaxalone concentrations declined with mean terminal half-life (t1/2) of 8.0 + 4.6 hours. The mean apparent oral clearance (CL/F) of metaxalone was 66 + 34 L/hr. Except for a 17% decrease in mean Cmax, these values were not statistically different from those after the administration of one SKELAXIN 800 mg tablet.

In the same study, the administration of two SKELAXIN 400 mg tablets following a standardized high fat meal showed an increase in the mean Cmax, and the area under the curve (AUC0-48) of metaxalone by 194% and 142%, respectively. A high fat meal also increased the mean Tmax to 4.9 +/- 2.3 hours but decreased the mean t1/2 to 4.2 + 2.5 hr. The effect of a high fat meal on the absorption of metaxalone from one SKELAXIN 800 mg tablet was very similar to that on the absorption from two SKELAXIN 400 mg tablets in quality and quantity. The clinical relevance of these effects is unknown.

The absolute bioavailability of metaxalone from SKELAXIN tablets is not known. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites. The impact of age, gender, hepatic, and renal disease on the pharmacokinetics of SKELAXIN (metaxalone) has not been determined. In the absence of such information, SKELAXIN should be used with caution in patients with hepatic and/or renal impairment and in the elderly.

**INDICATIONS AND USAGE**
SKELAXIN (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

**CONTRAINDICATIONS**
Known hypersensitivity to any components of this product.
Known tendency to drug induced, hemolytic, or other anemias.
Significantly impaired renal or hepatic function.

**WARNINGS**
SKELAXIN may enhance the effects of alcohol and other CNS depressants.
PRECAUTIONS
Metaxalone should be administered with great care to patients with pre-existing liver damage. Serial liver function studies should be performed in these patients.

False-positive Benedict’s tests, due to an unknown reducing substance, have been noted. A glucose-specific test will differentiate findings.

Information for Patients
SKELAXIN may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol or other CNS depressants.

Drug Interactions
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.

Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of metaxalone has not been determined.

Pregnancy
Reproduction studies in rats have not revealed evidence of impaired fertility or harm to the fetus due to metaxalone. Post marketing experience has not revealed evidence of fetal injury, but such experience cannot exclude the possibility of infrequent or subtle damage to the human fetus. Safe use of metaxalone has not been established with regard to possible adverse effects upon fetal development. Therefore, metaxalone tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgement of the physician the potential benefits outweigh the possible hazards.

Nursing Mothers
It is not known whether this drug is secreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use
Safety and effectiveness in children 12 years of age and below have not been established.

ADVERSE REACTIONS
The most frequent reactions to metaxalone include:
CNS: drowsiness, dizziness, headache, and nervousness or “iritability”;
Digestive: nausea, vomiting, gastrointestinal upset.
Other adverse reactions are:
Immune System: hypersensitivity reaction, rash with or without pruritus;
Hematologic: leukopenia; hemolytic anemia;
Hepatobiliary: jaundice.
Though rare, anaphylactoid reactions have been reported with metaxalone.
OVERDOSAGE
Deaths by deliberate or accidental overdose have occurred with this class of drugs, particularly in combination with antidepressants and/or alcohol. When determining the LD₅₀ in rats and mice, progressive sedation, hypnosis and finally respiratory failure were noted as the dosage increased. In dogs, no LD₅₀ could be determined as the higher doses produced an emetic action in 15 to 30 minutes. Treatment - Gastric lavage and supportive therapy. Consultation with a regional poison control center is recommended.

DOSAGE AND ADMINISTRATION
The recommended dose for adults and children over 12 years of age is two 400 mg tablets (800 mg) or one 800 mg tablet three to four times a day.

HOW SUPPLIED
SKELAXIN (metaxalone) is available as a 400 mg pale rose tablet, inscribed with 8662 on the scored side and “C” on the other. Available in bottles of 100 (NDC 0086-0062-10) and in bottles of 500 (NDC 0086-0062-50). SKELAXIN (metaxalone) is also available as an 800 mg oval, scored pink tablet inscribed with 8667 on the scored side and “S” on the other. Available in bottles of 100 (NDC 59075-068-10) and in bottles of 500 (NDC 59075-068-50).

Store at Controlled Room Temperature, between 15° C and 30° C (59° F and 86° F).

Rx Only

Revised: August, 2002
November 1, 2004

Gary J. Buehler, Director  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

MAJOR AMENDMENT  
N|AC  
RECEIVED  
NOV 0 4 2004  
OGD / CDER

RE:  Major Amendment to ANDA 40-445  
Metaxalone Tablets, 400 mg and 800 mg

Dear Mr. Buehler:

Pursuant to 21 CFR 314.96 and 21 CFR 314.120, and referencing OGD’s letters to Eon Labs dated December 3, 2002 and March 6, 2003, this filing constitutes a Major Amendment to Eon Labs’ Abbreviated New Drug Application for Metaxalone Tablets, 400 mg, ANDA # 40-445.

In accord with the FDA letter of March 6, 2003, this Major Amendment contains CMC information supporting drug product, fasting and fed bioequivalence studies performed on the 800 mg test product and the Reference Listed Drug, and new labeling to add the 800 mg strength. We also propose a new manufacturing site for these drug products.

Since the supporting information for these changes is substantial, this amendment has been formatted with ANDA sections. The complete volume contents are outlined in the Table of Contents and correspond to the following:

Volume 1  Basis of submission, patent and exclusivity certifications, Section 505(j)(2)(A) information, labeling, bioequivalence data, request for waiver, dissolution profiles, signed disclosure statement, certificates of analysis, components and composition, and raw material control data.

Volume 2  Facility descriptions, cGMP certification, contract labs, and blank and executed manufacturing and packaging records.

Volume 3  Container/closure information, finished product controls, methods validation, stability data, environmental impact statement, and debarment certification.

Mr. G. Buehler  November 1, 2004  1 of 3
Volumes 4 through 11 Bioequivalence study summary and test results. (Also included are two CD-ROMs containing the raw data).

Draft labeling is provided in electronic format (as PDF and DOC files on diskette).

A full table of contents precedes each appropriately paginated volume.

We have also enclosed three (3) copies of the analytical methods validation package in separate volumes.

Please note that we are including new “Paragraph IV” patent certifications (to U.S. Patents 6,407,128 and 6,683,102) for the 800 mg strength of the drug product.

The following is an update to the legal status of the 400 mg strength of the drug product with regard to both patents, since “Paragraph IV” certifications have already been filed for the 400 mg strength:

U.S. Patent 6,407,128: A complaint has been filed by Elan Corporation, plc, against Eon Labs, Inc. as described in the Patent Amendment to this ANDA dated January 15, 2003.

U.S. Patent 6,683,102: A “Paragraph IV” certification was filed to this patent on February 10, 2004. We hereby certify to the FDA that, in accordance with 21 CFR 314.95(b), Patent Certification Notice for U.S. Patent 6,683,102 has been provided to the patent holder, Elan Corporation, plc, and to the holder of the approved NDA 13-217, Jones Pharma, Inc. (subsidiary of King Pharmaceuticals, Inc.) for the reference listed drug, Skelaxin® as defined in 21 CFR 314.95(a). Further, the notices have met the content requirements under 21 CFR 314.95(c). Copies of the return receipts are provided in Section III-Patents/Exclusivity of this filing. We also hereby notify the FDA that a complaint has been filed by Elan Corporation, plc, against Eon Labs, Inc. in the U.S. District Court for the Eastern District of New York, Civil Action No. 03-CV-0006, on Jan. 2, 2003 and amended on Feb. 11, 2004.

In addition to the archival and review copies, we are submitting a certified true copy of the chemistry, manufacturing and controls data to the FDA District Field Office, Atlanta, Georgia.

Subsequent amendments or supplements containing chemistry, manufacturing and controls data will also be submitted to the District Field Office.

If there are any comments or questions about this application, please contact either Mr. Dietrich Bartel at (252) 234-2212 or Mr. Steve Brown, Director, Regulatory Affairs at (252) 234-2224.
Sincerely,

Dietrich Bartel
Assistant Director, Regulatory Affairs
Eon Labs, Inc.

Mr. G. Buehler

November 1, 2004
DATE: November 29, 2004

TO: Director
Division of Bioequivalence (HFD-650)

FROM: Chief, Regulatory Support Branch
Office of Generic Drugs (HFD-615)

SUBJECT: Examination of the bioequivalence study submitted with an ANDA 40-445 for Metaxalone Tablets, 400 mg and 800 mg to determine if the application is substantially complete for filing and/or granting exclusivity pursuant to 21 USC 355(j)(5)(B)(iv). The new strength is 800 mg.

Eon Labs. Inc. has submitted ANDA 40-445 for Metaxalone Tablets, 400 mg and 800 mg. The ANDA contains a certification pursuant to 21 USC 355(j)(5)(B)(iv) stating that patent(s) for the reference listed drug will not be infringed by the manufacturing or sale of the proposed product. Also it is a first generic. In order to accept an ANDA that contains a first generic, the Agency must formally review and make a determination that the application is substantially complete. Included in this review is a determination that the bioequivalence study is complete, and could establish that the product is bioequivalent.

Please evaluate whether the request for study submitted by Eon Labs. Inc. on November 01, 2004 for its Metaxalone product satisfies the statutory requirements of "completeness" so that the ANDA may be filed.

A "complete" bioavailability or bioequivalence study is defined as one that conforms with an appropriate FDA guidance or is reasonable in design and purports to demonstrate that the proposed drug is bioequivalent to the "listed drug".
Telecon Record

Date: 12/9/04

ANDA: 40-445

Firm: Eon Labs, Inc.

Drug: Metaxalone Tablets, 400mg and 800mg

FDA Participants: Iain Margand

Industry Participants: Dietrich Bartel

Phone: 252-234-2212

Agenda:

1. Iain requested the following:

   Please provide a Field Copy Certification with original signature.

   Please provide a contact person for the API manufacturer or their U.S. agent.

   Provide cGMPs for outside firms used in this application.

   Provide a protocol for the Stability of Finished Dosage Form.
December 15, 2004

Mr. Gary Buehler, Director,  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

RE: TELEPHONE AMENDMENT – ANDA 40-445  
Metaxalone Tablets, 400 mg and 800 mg

Dear Mr. Buehler:

Pursuant to Section 505(j) of the federal Food, Drug, and Cosmetic Act, and in accordance with 21 CFR 314.96(a), this submission constitutes a Telephone Amendment to ANDA 40-445. It is being filed in response to a telephone communication from Mr. Iain Margand of the OGD, to Eon Labs, Inc. on December 9, 2004. The OGD telephone request for information referenced the MAJOR AMENDMENT filed on November 1, 2004.

The following is provided in response to the request:

1. As in all prior OGD filings, the Field Copy cover letter with the original signature was sent with the actual Field Copy. The Archival and Review Copies of the ANDA contain a copy only.

2. The U.S. agent and contact name for the API manufacturer, [Redacted], is:

RECEIVED
DEC 16 2004
OGD/CDER

Mr. G. Buehler  December 15, 2004  Page 1 of 2
3. cGMP certificates are provided for all outside contract manufacturers listed in Part X of the Major Amendment (Attachment 1). Internal sites are covered by certifications in Part IX of the ANDA and Major Amendment.

4. Protocols are provided for all stability studies performed on both strengths of the drug product and provided in Part XVI of the Major Amendment (Attachment 2).

We certify that an identical copy of this submission is also being filed to the FDA Atlanta District Office, 60 Eight St. NE, Atlanta, GA 30309.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., by telephone at (252) 234-2212.

Yours truly,

[Signature]

Dietrich Bartel
Assistant Director, Regulatory Affairs,
Eon Labs, Inc.
BIOEQUIVALENCE CHECKLIST for First Generic ANDA FOR APPLICATION COMPLETENESS

ANDA# 40-445 FIRM NAME Eon Labs, Inc.

DRUG NAME Metaxalone Tablets, 400 mg and 800 mg

DOSAGE FORM Tablets
SUBJ: Request for examination of: Bioequivalence Study and Request for Waiver

Requested by: Date:
Chief, Regulatory Support Team, (HFD-615)

<table>
<thead>
<tr>
<th></th>
<th>Summary of Findings by Division of Bioequivalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ]</td>
<td>Study meets statutory requirements</td>
</tr>
<tr>
<td>[ ]</td>
<td>Study does NOT meet statutory requirements</td>
</tr>
<tr>
<td></td>
<td>Reason:</td>
</tr>
<tr>
<td>[ ]</td>
<td>Waiver meets statutory requirements</td>
</tr>
<tr>
<td>[ ]</td>
<td>Waiver does NOT meet statutory requirements</td>
</tr>
<tr>
<td></td>
<td>Reason:</td>
</tr>
</tbody>
</table>

RECOMMENDATION: ☒ COMPLETE ☐ INCOMPLETE

Reviewed by:

[Signature]
Sheryl Gunther
Reviewer

Date: 12/20/2004

[Signature]
Moheb Makary
Team Leader

Date: 12/20/2004
<table>
<thead>
<tr>
<th>Item Verified:</th>
<th>YES</th>
<th>NO</th>
<th>Required Amount</th>
<th>Amount Sent</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assay Methodology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure SOP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Referenced but not provided.</td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Results Ln/Lin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB Approval</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissolution Data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-screening of Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chromatograms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consent Forms</td>
<td></td>
<td></td>
<td>Original</td>
<td></td>
<td>Copy of original</td>
</tr>
<tr>
<td>Composition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary of Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individual Data &amp; Graphs,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linear &amp; Ln</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PK/PD Data Disk Submitted)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EDR</td>
</tr>
<tr>
<td>Randomization Schedule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol Deviations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Discussed in clinical summaries</td>
</tr>
<tr>
<td>Clinical Site</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRACS Institute, Ltd., Fargo, ND 58104</td>
</tr>
<tr>
<td>Analytical Site</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRACS Institute, Ltd., 4666 Amber Valley Parkway, Fargo, ND 58104</td>
</tr>
<tr>
<td>Study Investigators</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Records</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Raw Data</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Article Inventory</td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIO Batch Size</td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assay of Active Content Drug</td>
<td></td>
<td>Test: 99.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reference: 99.1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Content Uniformity</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test: 99.6% (0.5% CV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reference: 99.3% (1.1% CV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Manufacture</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2/2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp. Date of RLD</td>
<td>✔</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4/2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioStudy Lot Numbers</td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test: RDW00470</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reference: ES803121A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statistics</td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary results provided by the firm indicate studies pass BE criteria</td>
<td></td>
<td>For both the fasting and non-fasting studies, summary results for AUC0-t, AUCinf, and Cmax for metaxalone pass 90% CI criteria.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waiver requests for other strengths / supporting data</td>
<td></td>
<td>For the 400 mg strength</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional Comments regarding the ANDA:

The firm has submitted single-dose fasting and non-fasting BE studies to assess the bioequivalence of its Metaxalone Tablets, 800 mg versus the RLD, Skelaxin® Tablets, 800 mg. For both studies, summary results for AUC0-t, AUCinf, and Cmax for metaxalone pass 90% CI criteria of 80-125%. DIW is requested for the 400 mg strength. The 800 mg strength carries a first generic designation.

The firm previously submitted
The current submission contains a
ANDA 40-4049 Final Check List for Branch Chief

1. Check letter date and stamp date of ANDA vs. drafted letter.

2. Check for any NC arriving post stamp date but prior to Reg. Review.

3. Check for gross errors in letter.

4. Check that correct letter format is used. (PIV vs. Other acknowledgment)

5. Check address and contact person on letter vs. 356h.

6. Check for any t-cons and verify date and correspondence date.

7. Check Patent Certification information in entered in COMIS (by Eda) vs. Actual certification. If multiple patent certifications, should be based on PIV if applicable or latest expiring patent.

8. Check for any comments or problems raised by reviewer on Check List.

9. If first generic, copy BE review and file. (Only)

10. Sign Check List.

11. Check electronic Orange Book to verify current patent information and correct RLD. 

12. Check for MOU patents


15. Review Patent Certifications and Exclusivity Statement. (If an expiration of an exclusivity has occurred make a note to the Labeling reviewer.


17. Sign cover letter 503 (j)(2)(A) OK, date, and full signature.

18. Pull USP information. (USP yes / no)

19. Final Grammar review on letter.


21. EES slip.


Signature: [Signature] date: [Date]
ANDA Nbr: 40-445  FIRM NAME: EON LABS

RELATED APPLICATION(S): NA
First Generic Product Received? YES ON 800 MG

DRUG NAME: METAXALONE
DOSAGE FORM: TABLETS, 400 MG AND 800 MG
(NEW STRENGTH 800 MG)

Random Queue: 4
Chem Team Leader: Gill, Dave  PM: Sarah Park  Labeling Reviewer: Debbie Catterson

<table>
<thead>
<tr>
<th>Letter Date: NOVEMBER 01, 2004</th>
<th>Received Date: NOVEMBER 04, 2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comments: EC-1+1=2 YES</td>
<td>On Cards: YES</td>
</tr>
<tr>
<td>Therapeutic Code: 2010100 MUSCLE RELAXANTS</td>
<td></td>
</tr>
<tr>
<td>Archival Format: PAPER Sections I (356H Sections per EDR Email)</td>
<td></td>
</tr>
<tr>
<td>Review copy: YES</td>
<td>E-Media Disposition: YES SENT TO EDR</td>
</tr>
<tr>
<td>Not applicable to electronic sections</td>
<td></td>
</tr>
<tr>
<td>Field Copy Certification (Original Signature) YES</td>
<td></td>
</tr>
<tr>
<td>Methods Validation Package (3 copies PAPER archive) YES</td>
<td></td>
</tr>
<tr>
<td>(Required for Non-USP drugs)</td>
<td></td>
</tr>
<tr>
<td>Cover Letter YES</td>
<td>Table of Contents YES</td>
</tr>
<tr>
<td>PART 3 Combination Product Category N Not a Part3 Combo Product</td>
<td></td>
</tr>
<tr>
<td>(Must be completed for ALL Original Applications)</td>
<td>Refer to the Part 3 Combination Algorithm</td>
</tr>
</tbody>
</table>

Reviewing
CSO/CST: Iain Margand
Date: 12/28/04

Recommendation: FILE

Supervisory Concurrency/Date: 12/24/04
Date: 12/24/04

ADDITIONAL COMMENTS REGARDING THE ANDA:

See T-con dated 12/9/04

Top 200 Drug Product:
<table>
<thead>
<tr>
<th>Sec. I</th>
<th>Signed and Completed Application Form (356h)</th>
<th>YES</th>
<th>(Statement regarding Rx/OTC Status) RX YES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sec. II</td>
<td>Basis for Submission</td>
<td>NDA#: 13-217</td>
<td>Ref Listed Drug: SKELAXIN Firm: JONES PHARMA INC.</td>
</tr>
<tr>
<td></td>
<td>If Yes, then is change subject to PREA (change in dosage form, route, active ingredient)</td>
<td></td>
<td>For products subject to PREA a waiver request must be granted prior to approval of ANDA.</td>
</tr>
<tr>
<td></td>
<td>Wavier Granted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sec. III</td>
<td>Patent Certification</td>
<td></td>
<td>1. Paragraph: IV</td>
</tr>
<tr>
<td></td>
<td>2. Expiration of Patent: 12-03-2021</td>
<td></td>
<td>A. Pediatric Exclusivity Submitted? N/A</td>
</tr>
<tr>
<td></td>
<td>B. Pediatric Exclusivity Tracking System checked?</td>
<td></td>
<td>Exclusivity Statement: YES</td>
</tr>
<tr>
<td>Sec. IV</td>
<td>Comparison between Generic Drug and RLD-505(j)(2)(A)</td>
<td></td>
<td>1. Conditions of use OK</td>
</tr>
<tr>
<td></td>
<td>2. Active ingredients OK</td>
<td></td>
<td>3. Route of administration OK</td>
</tr>
<tr>
<td></td>
<td>4. Dosage Form OK</td>
<td></td>
<td>5. Strength OK</td>
</tr>
<tr>
<td>Sec. V</td>
<td>Labeling</td>
<td>(Multi Copies N/A for E-Submissions)</td>
<td>1. 4 copies of draft (each strength and container) or 12 copies of FPL Y (800mg strength only)</td>
</tr>
<tr>
<td></td>
<td>2. 1 RLD label and 1 RLD container label see previous application for 400mg only</td>
<td></td>
<td>3. 1 side by side labeling comparison with all differences annotated and explained Previously submitted</td>
</tr>
<tr>
<td></td>
<td>4. Was a proprietary name request submitted? NO (If yes, send email to Labeling Rvwr indicating such.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sec. VI</td>
<td>Bioavailability/Bioequivalence</td>
<td></td>
<td>1. Financial Certification (Form FDA 3454) and Disclosure Statement (Form 3455) YES</td>
</tr>
<tr>
<td></td>
<td>2. Request for Waiver of In-Vivo Study(ies): YES ON 400 MG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Formulation data same? (Comparison of all Strengths) (Ophthalmics, Otics, Topicals Perenterals)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Lot Numbers of Products used in BE Study(ies): RDW00469 (400mg) RDW00470 (800mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5. Study Type: IN-VIVO PK STUDY(IES) (Continue with the appropriate study type box below)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Type</td>
<td>IN-VIVO PK STUDY(IES) (i.e., fasting/fed/sprinkle)</td>
<td>FASTING AND FED ON 800 MG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Study(ies) meets BE criteria (90% CI or 80-125, Cmax, AUC) Fast Fed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. EDR Email: Data Files Submitted: YES SENT TO EDR AUC1 91.23 - 103.45 96.52 - 109.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. In-Vitro Dissolution: YES Pg. 25-32 AUC∞ 91.02 - 103.16 94.23 - 105.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cmax 84.1 - 102.64 81.44 - 105.38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Type</td>
<td>IN-VIVO BE STUDY with CLINICAL ENDPOINTS</td>
<td>NO</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------</td>
<td>----</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Properly defined BE endpoints (eval. by Clinical Team)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Summary results meet BE criteria (90% CI within +/- 20% or 80-120)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Summary results indicate superiority of active treatments (test &amp; reference) over vehicle/placebo (p&lt;0.05) (eval. by Clinical Team)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>d. EDR Email: Data Files Submitted</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>TRANSDERMAL DELIVERY SYSTEMS</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a. In-Vivo PK Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Study(ies) meet BE Criteria (90% CI or 80-125, Cmax, AUC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. In-Vitro Dissolution</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. EDR Email: Data Files Submitted</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Adhesion Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Skin Irritation/Sensitization Study</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>NASALLY ADMINISTERED DRUG PRODUCTS</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a. Solutions (Q1/Q2 sameness):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern, Plume Geometry, Priming &amp; Repriming, Tail Off Profile)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Suspensions (Q1/Q2 sameness):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. In-Vivo PK Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Study(ies) meets BE Criteria (90% CI or 80-125, Cmax, AUC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. EDR Email: Data Files Submitted</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. In-Vivo BE Study with Clinical EndPoints</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Properly defined BE endpoints (eval. by Clinical Team)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Summary results meet BE criteria (90% CI within +/- 20% or 80-120)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Summary results indicate superiority of active treatments (test &amp; reference) over vehicle/placebo (p&lt;0.05) (eval. by Clinical Team)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>d. EDR Email: Data Files Submitted</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern, Plume Geometry, Priming &amp; Repriming, Tail Off Profile)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>TOPICAL CORTICOSTEROIDS (VASOCONSTRICTOR STUDIES)</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a. Pilot Study (determination of ED50)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Pivotal Study (study meets BE criteria 90%CI or 80-125)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sec. VII</th>
<th>Components and Composition Statements</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Unit composition and batch formulation Pg. 39</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Inactive ingredients as appropriate Excipients are acceptable per IIG</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
</tbody>
</table>
| VIII: Raw Materials Controls | 1. Active Ingredients  
a. Addresses of bulk manufacturers Y  
b. Type II DMF authorization letters or synthesis DMF# (b)(4)  
c. COA(s) specifications and test results from drug substance mfg(s) Y  
d. Applicant certificate of analysis Y  
e. Testing specifications and data from drug product manufacturer(s) Y  
f. Spectra and chromatograms for reference standards and test samples Y  
g. CFN numbers
2. Inactive Ingredients  
a. Source of inactive ingredients identified Pg. 128A  
b. Testing specifications (including identification and characterization) Y  
c. Suppliers' COA (specifications and test results) Y  
d. Applicant certificate of analysis Y
| IX: Description of Manufacturing Facility | 1. Full Address(es) of the Facility(ies) Pg. 199  
2. CGMP Certification: YES  
3. CFN numbers
| X: Outside Firms Including Contract Testing Laboratories | 1. Full Address Pg. 201  
2. Functions Y  
3. CGMP Certification/GLP Y  
4. CFN numbers
| XI: Manufacturing and Processing Instructions | 1. Description of the Manufacturing Process (including Microbiological Validation, if Appropriate) Y  
2. Master Production Batch Record(s) for largest intended production runs (no more than 10x pilot batch)  
with equipment specified 400mg – 800mg – 800mg – (b)(4)  
3. If sterile product: Aseptic fill / Terminal sterilization N/A  
4. Filter validation (if aseptic fill) N/A  
5. Reprocessing Statement Pg. 292
| XII: In-Process Controls | 1. Copy of Executed Batch Record with Equipment Specified, including Packaging Records (Packaging and Labeling Procedures), Batch Reconciliation and Label Reconciliation  
2. In-process Controls - Specifications and data Y  
| 400mg  
Ty:  
Ay:  
100:  
1000:  
Bulk: (5)(4)  
800mg |
<table>
<thead>
<tr>
<th>Sec.</th>
<th>Container</th>
<th>Controls for the Finished Dosage Form</th>
<th>Stability of Finished Dosage Form</th>
<th>Samples - Statement of Availability and Identification of:</th>
<th>Environmental Impact Analysis Statement</th>
</tr>
</thead>
</table>
| XIII | 1. Summary of Container/Closure System (if new resin, provide data) Y  
2. Components Specification and Test Data (Type III DMF References) Y  
3. Packaging Configuration and Sizes 100, 1000, Bulk  
4. Container/Closure Testing Y  
5. Source of supply and suppliers address Pg. 510 | 1. Testing Specifications and Data Y  
2. Certificate of Analysis for Finished Dosage Form Y | 1. Protocol submitted Y  
2. Post Approval Commitments Y  
3. Expiration Dating Period 2 Years  
4. Stability Data Submitted  
  a. 3 month accelerated stability data Y  
  b. Batch numbers on stability records the same as the test batch Y RDW00469  
  b. Batch numbers on stability records the same as the test batch Y RDW00470 | 1. Drug Substance Y  
2. Finished Dosage Form Y  
3. Same lot numbers Y | Pg. 920 |
| XVIII | GDEA (Generic Drug Enforcement Act)/Other:  
1. Letter of Authorization (U.S. Agent [if needed, countersignature on 356h]) N/A  
2. Debarment Certification (original signature): YES  
3. List of Convictions statement (original signature) N/A  
4. Field Copy Certification (original signature) YES |  |  |  |  |
BIOEQUIVALENcy AMENDED

ANDA 40-445

OFFICE OF GENERIC DRUGS, CDER, FDA
Document Control Room, Metro Park North II
7500 Standish Place, Room 150
Rockville, MD 20855-2773 (301-594-0320)

APPLICANT: Eon Labs, Inc.
ATTN: Dietrich Bartel
FROM: Keri Suh

Dear Sir:

This facsimile is in reference to the bioequivalency data submitted on November 1, 2004, pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 400 mg and 800 mg.

The Division of Bioequivalence has completed its review of the submission(s) referenced above and has identified deficiencies which are presented on the attached page. This facsimile is to be regarded as an official FDA communication and unless requested, a hard-copy will not be mailed.

You should submit a response to these deficiencies in accord with 21 CFR 314.96. Your amendment should respond to all the deficiencies listed. Facsimiles or partial replies will not be considered for review, nor will the review clock be reactivated until all deficiencies have been addressed. Your cover letter should clearly indicate that the response is a “Bioequivalency Amendment” and clearly identify any new studies (i.e., fasting, fed, multiple dose, dissolution data, waiver or dissolution waiver) that might be included for each strength. We also request that you include a copy of this communication with your response. Please submit a copy of your amendment in both an archival (blue) and a review (orange) jacket. Please direct any questions concerning this communication to the project manager identified above.

SPECIAL INSTRUCTIONS:

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.
If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.
BIOEQUIVALENCE DEFICIENCIES TO BE PROVIDED TO THE APPLICANT

ANDA: 40-445
APPLICANT: Ron Labs Inc.

DRUG PRODUCT: Metaxalone tablets; 400 mg and 800 mg

The Division of Bioequivalence has completed its review of your submission(s) acknowledged on the cover sheet. The following deficiency has been identified:

Sincerely yours,

Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research
July 21, 2005

Gary J. Buehler, RPh.
Director, HFD-600
Office of Generic Drugs
Center for Drug Evaluation & Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, MD 20855-2773

- GENERAL CORRESPONDENCE -
CHANGE IN OWNERSHIP OF EON LABS, INC.

Re: Metaxalone Tablets, 400 mg and 800 mg
ANDA 40-445

Dear Mr. Buehler:

Eon Labs, Inc. (Eon Labs), the holder and owner of the above-referenced ANDA, was recently acquired by Sandoz Inc. (Sandoz), 506 Carnegie Center, Suite 400, Princeton, NJ, 08540 in a corporate merger that closed on July 20th, 2005. Effective immediately, Eon will adopt the Sandoz name on all official correspondence to the agency and will begin operating under the Sandoz business structure.

In accordance with 21 CFR 314.72 (a), we are notifying you of the CHANGE IN OWNERSHIP of the corporation and are advising you that all rights, title and interest with regards to our approved and pending applications will be transferred to Sandoz. The corporate headquarters for the new Sandoz will remain at the 506 Carnegie Center, Princeton, NJ address provided above.

In the new Sandoz organization, Regulatory Affairs will be coordinated from four separate locations. Each location will have a fully functional Regulatory Affairs Department headed by a Director (or equivalent) that will have responsibilities for filing ANDAs, annual reports, supplements, FPL labeling, deficiency letter responses, etc. Because of this organizational structure, there will be multiple points of interface between the new Sandoz and the agency. All four sites will report into the corporate Vice President Regulatory Affairs, Ms. Sadie M. Ciganek.

The Regulatory Affairs contact person for each site is provided below. This information will help facilitate future communication between the agency and the new Sandoz:

1) Sandoz (New York)
227-15 North Conduit Avenue, Laurelton NY 11413

Ms. Enna Krivitsky
Ph: (718) 276-8607 x235
Fax: (718) 276-8635
2). Sandoz (North Carolina)  
4700 Eon Labs Drive  
Wilson, NC  27893

Mr. Dietrich Bartel  
Ph: (252) 234-2212  
Fax: (252) 234-2323

3). Sandoz (Colorado)  
2555 W Midway Blvd  
Broomfield, CO  80020

Ms. Beth Brannon  
Ph: (303) 438-4237  
Fax: (303) 438-4600

4). Sandoz (New Jersey)  
2400 Route 130 North  
Dayton, NJ  08810

Ms. Carmelle Lucas  
Ph: (732) 355-4083  
Fax: (732) 355-4828

This is the next phase in the history of Eon Labs. We are looking forward to the coming challenges and intend to provide the agency with the same responsive interaction that was shared in the past. If you require additional information regarding the merger, feel free to call. I can be reached at (516) 478-9713.

Sincerely,
Sadie M. Ciganek

\[\text{Eula Prvitys for}\]
Vice President Regulatory Affairs  
Sandoz Inc.
MINOR AMENDMENT

ANDA 40-445

OFFICE OF GENERIC DRUGS, CDER, FDA
Document Control Room, Metro Park North II
7500 Standish Place, Room 150
Rockville, MD 20855-2773 (301-594-0320)

APPLICANT: Sandoz Inc.
ATTN: Dietrich Bartel
FROM: Thuyanh (Ann) Vu

Dear Sir:

This facsimile is in reference to your abbreviated new drug application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 400 and 800 mg.

Reference is also made to your amendments dated May 10, November 1, and December 15, 2004.

The application is deficient and, therefore, Not Approvable under Section 505 of the Act for the reasons provided in the attachments (2 pages). This facsimile is to be regarded as an official FDA communication and unless requested, a hard copy will not be mailed.

The file on this application is now closed. You are required to take an action described under 21 CFR 314.120 which will either amend or withdraw the application. Your amendment should respond to all of the deficiencies listed. Facsimiles or partial replies will not be considered for review, nor will the review clock be reactivated until all deficiencies have been addressed. The response to this facsimile will be considered to represent a MINOR AMENDMENT and will be reviewed according to current OGD policies and procedures. The designation as a MINOR AMENDMENT should appear prominently in your cover letter. You have been/will be notified in a separate communication from our Division of Bioequivalence of any deficiencies identified during our review of your bioequivalence data. If you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing.

SPECIAL INSTRUCTIONS:
See CMC comments enclosed.

RA 12/2/05

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.
If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.
38. Chemistry Comments to be Provided to the Applicant


DRUG PRODUCT: Metaxalone Tablets, 400 mg and 800 mg

The deficiencies below represent MINOR deficiencies.

A. Deficiencies:

1. Please establish both the
   
   Please provide an updated
   
   (b)(4)

2. Please reconcile
   
   these differences.
   
   (b)(4)

3. Please revise the
   
   for the drug product.
   
   (b)(4)

4. 
   
   data.
   
   (b)(4)

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. Please provide all available long-term stability data.

2. Your Labeling information is pending review. Deficiencies, if any, will be communicated to you separately.
3. Bioequivalence deficiencies were communicated to you via facsimile on May 9, 2005. You should address the issues in the May 9 communication prior to or concurrent with your response to this communication.

Sincerely yours,

[Signature]

Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research
September 6, 2006

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 400 mg and 800 mg

Dear Mr. Buehler:

Reference is made to our unapproved Abbreviated New Drug Application, ANDA 40-445, for Metaxalone Tablets, 400 mg and 800 mg, filed on August 31, 2001. We also refer to Amendments dated May 10, November 1 and December 15, 2004, and FDA's deficiency letters dated March 6, 2003 and May 10, 2005, which addressed the bioequivalence of the 400 mg formulation and

As a result of the FDA’s determinations with regard to the 400 mg strength of the drug product only, we hereby request, under 21 CFR 314.65, that the 400 mg strength be withdrawn from the ANDA. This withdrawal is without prejudice to refilling.

We certify that an identical copy of this submission is also being filed to the FDA Atlanta District Office, 60 Eighth St. NE, Atlanta, GA 30309.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Sincerely,

Dietrich Bartel
Director, Regulatory Affairs,
Sandoz Inc.

RECEIVED
SEP 6 7 2006
OCD/CDER
Sandoz Inc.
Attention: Dietrich Bartel
4700 Sandoz Drive
Wilson, NC 27893

Dear Sir:

We acknowledge the receipt of your communication dated September 6, 2006, requesting withdrawal of your abbreviated new drug application for Metaxalone Tablets, 400 mg.

In compliance with your request and in accordance with Section 314.65 of the regulations under the Federal Food, Drug and Cosmetic Act, the application is regarded as withdrawn. This withdrawal does not prejudice any future filing of the application. You may request that the information in this application be considered in connection with any resubmission.

Sincerely yours,

[Signature]
William Peter Rickman
Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research
cc: ANDA 40-445
Division File
HFD-650/Bio PM
HFD-143
Field Copy
HFD-610/PRickman

Endorsements:
HFD-617/L.Matheny/
HFD-623/D.Gill/
HFD-617/T. Ames, Acting Chief, RSB/

Prepared By Susan E. Pellock

F/T by

V:\FIRMSNZ\Sandoz\LTRS&REV\40445.wd400mg.doc

Withdrawal of Unapproved Application!
October 19, 2006

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

RECEIVED
OCT 20 2006
OGD/CDER

Sandoz
508 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
October 23, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.
October 24, 2006

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
508 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
October 25, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.
October 26, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
October 30, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President, Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
October 31, 2006

Mr. Gary Beuhler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

-PATENT AMENDMENT-

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler,

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

[Signature]
Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

RECEIVED
NOV 01 2006
OGD / CDER
November 1, 2006

Sadie Ciganek  
Vice President, Regulatory Affairs

Phone: 609.627.8728  
Fax: 609.627.8673  
Email: sadie.ciganek@sandoz.com

Mr. Gary Buchler, Director  
The Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs, HFD-600  
Metropark North II  
7500 Standish Place  
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg  
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek  
Vice President Regulatory Affairs  
Sandoz, Inc.

Sandoz  
506 Carnegie Center, Suite 400  
Princeton, NJ 08540  
www.us.sandoz.com  
a Novartis company
November 2, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
November 3, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
November 6, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

[Signature]
Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.
November 7, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

-PATENT AMENDMENT-

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.
Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

RECEIVED
NOV 09 2006
OGD / CDER
November 9, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

ORIG AMENDMENT
N/X P

RECEIVED
NOV 13 2006
OGD / CDER

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
November 13, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
November 14, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Sandoz
500 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

RECEIVED
NOV 15 2006
OGD / CDER

a Novartis company
November 15, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Sandoz
500 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

RECEIVED
NOV 16 2006
OGD / CDER

a Novartis company
November 16, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Buehler,

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com
Mr. Gary Buehler, Director  
The Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs, HFD-600  
Metropark North II  
7500 Standish Place  
Rockville, MD 20855  

- PATENT AMENDMENT -  

Re: Metaxalone Tablets, 800 mg  
ANDA 40-445  

Dear Mr. Beuhler;  

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.  

Sincerely,  

Sadie M. Ciganek  
Vice President Regulatory Affairs  
Sandoz, Inc.  

Sadie Ciganek  
Vice President, Regulatory Affairs  
Phone: 609.627.8728  
Fax: 609.627.8673  
Email: sadie.ciganek@sandoz.com  

Sandoz  
500 Carnegie Center, Suite 400  
Princeton, NJ 08540  
www.us.sandoz.com  

a Novartis company
November 20, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

[Signature]
Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

a Novartis company
November 21, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs
Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
November 22, 2006

Mr. Gary Buehler, Director
The Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs, HFD-600
Metropark North II
7500 Standish Place
Rockville, MD 20855

- PATENT AMENDMENT -

Re: Metaxalone Tablets, 800 mg
ANDA 40-445

Dear Mr. Beuhler;

Submitted herein is a Patent Amendment for Metaxalone Tablets, 800 mg, ANDA 40-445. This amendment provides for certification to a newly listed patent for the base molecule.

Sincerely,

Sadie M. Ciganek
Vice President Regulatory Affairs
Sandoz, Inc.

Sadie Ciganek
Vice President, Regulatory Affairs

Phone: 609.627.8728
Fax: 609.627.8673
Email: sadie.ciganek@sandoz.com

Sandoz
506 Carnegie Center, Suite 400
Princeton, NJ 08540
www.us.sandoz.com

a Novartis company
February 2, 2007

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: MINOR AMENDMENT - ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

In accordance with 21 CFR 314.120, this submission constitutes a Minor Amendment to ANDA 40-445, Metaxalone Tablets, 800 mg. It is being filed in response to a deficiency letter from Rashmikant M. Patel, Ph. D. of the Division of Chemistry I, OGD, to Sandoz Inc. on December 5, 2005 and contains our responses to the deficiencies outlined in that letter.

Please note that, in accordance with 21 CFR 314.85, Sandoz submitted a withdrawal letter to the Agency on September 6, 2006, withdrawing the 400 mg strength of the drug product. Our responses to the OGD’s deficiency comments therefore only address the 800 mg strength.

In the following pages, each of the deficiencies is reiterated, in bold type, followed by our response.

A. Deficiencies:

1. Please establish both the [Redacted]

Please provide an updated [Redacted]

RECEIVED
FEB 0 5 2007

Sandoz Inc. 4700 Sandoz Drive OGD / CDER
Wilson, NC 27893

Following this page, 2 pages withheld in full - (b)(4)
ANDA # 40-445
Metaxalone Tablets, 800 mg

- a dissolution profile report comparing the new batch, (L)RDW00891, to the original 800 mg bio-batch, (L)RDW00470 (previously submitted).

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. Please provide all available long-term stability data.

   Response:
   
   The following stability data is being provided on the new test batch in each of the smallest and largest bottle sizes:
   
   - accelerated stability test data to three months.
   
   - controlled room temperature stability test data to six months.

   See Attachment #5.

2. Your labeling information is pending review. Deficiencies, if any, will be communicated to you separately.

   Response:

   We acknowledge that the labeling is still under review and that we will be notified under separate cover of any deficiencies.

3. Bioequivalence deficiencies were communicated to you via facsimile on May 9, 2005. You should address the issues in the May 9 communication prior to or concurrent with your response to this communication.

   Response:

   We note and acknowledge that bioequivalence deficiencies were communicated via facsimile on May 9, 2005. However, the deficiencies in the letter pertained to the 400 mg strength of the drug product, which has now been withdrawn (reference the withdrawal letter dated Sept. 6, 2006). We consider the deficiency letter moot but will concurrently file a formal Bioequivalence Amendment to close the file.
We certify that an identical copy of this MINOR AMENDMENT is also being filed to the FDA Atlanta District Office, 60 Eighth St. NE, Atlanta, GA 30309.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Sincerely,

Dietrich Bartel
Director, Regulatory Affairs
Sandoz Inc.
December 10, 2007

Mr. Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration
Metro Park North II
7500 Standish Place, Room 150
Rockville, MD. 20855-2793

Re: ANDA 40-445: Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

We are writing with regard to our pending ANDA 40-445 for Metaxalone Tablets, 800 mg. For the reasons discussed below, we request a meeting with you and other appropriate Agency staff to discuss the status of this long pending application.

By way of brief background, Sandoz Inc. (then known in relevant part as Eon Labs, Inc.) submitted its ANDA for Metaxalone Tablets, 400 mg on August 31, 2001. The FDA notified Sandoz on November 30, 2001 that the ANDA had been accepted for review. On November 1, 2004, Sandoz amended the ANDA to include an 800 mg strength, including a new bioequivalence study to support approval of this strength. On September 6, 2006, Sandoz amended the ANDA to withdraw the 400 mg strength.

In a recent telephone discussion with your staff, Sandoz was informed that the Agency will not review Sandoz Inc.’s bioequivalency study until after a decision is made on several pending citizen petitions. To the best of our knowledge, the pending petitions include the following:

- Citizen petition submitted on behalf of Sandoz, January 28, 2003, Docket No. 03P-0027

- Citizen petition and accompanying petition for stay of action submitted on behalf of King Pharmaceuticals, Inc., the sponsor of the RLD, Skelaxin®, March 18, 2004, Docket No. 2004P-0140

Metaxalone Tablets, 800 mg  
ANDA # 40-445

In one way or another, these petitions are all related to the food effect of administration of Metaxalone Tablets.

Sandoz believes that the Agency’s apparent refusal to proceed with review of our bioequivalency study until after a decision is made on these pending citizen petitions violates both the spirit and the letter of new Section 505(q) of the FDC Act, as added by the Food and Drug Administration Amendments Act of 2007. Section 505(q) prohibits FDA from delaying the approval of a pending ANDA because of a citizen petition unless FDA concludes that a delay is “necessary to protect the public health.” If FDA determines that a delay in ANDA approval is necessary, FDA is required to notify the applicant within 30 days and provide, among other information, a brief summary of the specific substantive issues raised in the petition that form the basis of the Agency’s determination. There was no effective date or transitional provision for new Section 505(q) of the FDC Act; therefore, our lawyers have advised us that the new requirements are already in effect and apply to all pending petitions, such as the three pending Metaxalone petitions.

Sandoz seeks a meeting with you and other appropriate Agency representatives to discuss this important matter. We will contact your office in the near future to schedule a meeting at a mutually convenient time.

We appreciate your attention to this important matter. If the Agency has questions about this matter, please contact me at the office at (609) 627-8882 or on my mobile phone at (516) 304-8780.

Respectfully submitted,

Jindrich Bartl

Kalpana Rao Vanam  
Vice President, Regulatory Affairs

Sandoz Inc. 4700 Sandoz Drive Wilson, NC 27893
January 26, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

In accordance with 21 CFR 314.96, this submission constitutes a labeling amendment to ANDA 40-445, Metaxalone Tablets, 800 mg. It is being filed in response to a telephone conversation between Rita Hassal of the OGD, CDER and Sandoz Inc. on January 17, 2008. As requested Sandoz labeling is being updated to the current reference listed drug (SKELEAXIN, dated Aug. 2006) posted on the CDER website Drugs@FDA.

All labeling was originally submitted in the Eon Labs format. The labeling (package outsert and bottle labels) is being resubmitted in the current Sandoz (formerly Eon Labs) format.

Please note that, in accordance with 21 CFR 314.65, Sandoz submitted a withdrawal letter to the Agency on September 6, 2006, withdrawing the 400 mg strength of the drug product. The labeling submitted only address the 800 mg strength.

Per the Guidance for Industry: Providing Regulatory Submission in Electronic Format; the draft labeling and annotated changes are being submitted in Adobe Acrobat (*.pdf) format on the enclosed CD. In addition, the labeling content is provided in MS Word (.doc), as well as SPL (.xml), formats.

Sandoz Inc.
4700 Sandoz Drive
OGD
Wilson, NC 27893
Side-by-Side comparisons, annotations, and DeltaView (DV) comparisons are also provided. The CD contains the following folders and files:

Folder: Package Outsert
Files: - Comparison.pdf
- OS7750 Issued 01-08 Content.doc
- OS7750 Issued 01-08 Mac Draft.pdf

Folder: spl
Files: metaxalone-metaxaloneos7750Issued01-08.xml
metaxalone-01.jpg
metaxalone-02.jpg

Folder: Container Labels
Files: - Container Label Annotations.pdf
- Container Label SbS.pdf
- L8917 Iss. 01-08 800 mg x 100.ai.pdf
- L8931 Iss. 01-08 800 mg x 1000.ai.pdf

A Letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212 or by facsimile at (252) 234-2323.

Sincerely,

Sandoz Inc.

E. Jean Herald
Regulatory Affairs Associate
February 27, 2008

*W - 000 - XP*

Gary J. Buehler, RPh.
Office of Generic Drugs (HFD-600)
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855-2773

Re: Abbreviated New Drug Application No. 40-445 for 800 mg Metaxalone Tablets

Dear Sir or Madam:

We write on behalf of King Pharmaceuticals, Inc. and King Pharmaceuticals Research and Development, Inc. (collectively, “King”). We write to inform the FDA that the 30-month stay of FDA approval of the above-identified ANDA 40-455 expires on August 23, 2009.


At Eon’s request, the parties agreed to stay the above-referenced Civil Action Case No. 04-CV-5540 and toll the 30-month stay. On January 10, 2005, the Court entered an order staying the action and tolling the 30-month stay. See January 10, 2005 Order, attached hereto as Exhibit 1. The stay of the action and the tolling of the 30-month stay was subsequently lifted as of April 30, 2007. See May 2, 2007 Order, attached hereto as Exhibit 2. Thus, the 30-month stay of approval of Eon’s ANDA No. 40-455 was tolled for 27 months and 20 days.

Office of Generic Drugs (HFD-600)
February 27, 2008
Page 2

(i.e., 30 months from November 3, 2004, taking into account the tolled period of January 10, 2005 to April 30, 2007.)

Very truly yours,

F. Dominic Cerrito
JONES DAY
Counsel for King Pharmaceuticals, Inc. and
King Pharmaceuticals Research &
Development, Inc.

Enclosures
FROM: Liang-Lii Huang, Ph.D.
DATE: June 27, 2008
ANDA: 40-445

NAME/TITLE OF INDIVIDUAL from FDA: Liang-Lii Huang, Ph.D.
Review Chemist
FIRM: Sandoz
NAME/TITLE OF INDIVIDUAL from the firm: Griha Mangru, Reg. Affair

PRODUCT NAME:
ANDA: 40-445
Mataxalone tablets 800 mg
TEL #: 252-234-2206

Record of t-con of 6/27/08
FDA initiated this t-con

Effective 7/1/08, all ANDAs applicants have to demonstrate that their drug products are in compliance with USP<467> residual solvents for the drug products.

(1) I called Sandoz to tell them that if their ANDAs are not approved prior to July 1, 2008, they will need to submit a telephone amendment to address the new USP <467> issue.

(2) I told them that their DP release specifications should be revised to include "Residual Solvents" with an acceptance criterion as "Complies with USP <467>". I also told Sandoz that information and test data are necessary to fulfill this requirement.

(3) I told Sandoz that they may refer to OGD website at


Also, I told Sandoz that if their ANDAs are approved prior to July 1, 2008, they may provide this information in their first Annual Report(s).
SIGNATURE OF OGD REPRESENTATIVES:
   Liang-Lii Huang, Ph.D., Review chemist

Location of Electronic Copy:
V:\Chemistry Division I\Team 3\T-CONS\40-445 6-27-08 TCON.doc
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Liang Lii Huang
7/17/2008 04:08:35 PM
CHEMIST
August 29, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

TELEPHONE AMENDMENT

Re: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

In accordance with 21 CFR 314.120, this submission constitutes a Telephone Amendment to our Abbreviated New Drug Application 40-445, Metaxalone Tablets, 800 mg. It is being filed in response to a telephone communication from Dr. Liang-Lii Huang, OGD, CDER, FDA to Sandoz Inc. on June 27, 2008. The communication provided deficiency comments and specified that the response should be categorized as a Telephone Amendment.

The deficiency comments are reiterated below (in **bold type**), followed by our response.

**Deficiency:**

Please submit the residual solvents data for Metaxalone Tablets, 800 mg in accordance with the revised USP General Chapter <467>, which becomes official on July 1, 2008. We request that you demonstrate that the levels of residual solvents in your drug product are within the safety recommendations of this USP General Chapter.

**Response:**

To ensure the compliance of Metaxalone Tablets, 800 mg, to the guidelines set forth in the USP General Chapter <467>, the product was evaluated to meet the criteria stated in the FDA announcement, which are reiterated below:

---

**RECEIVED**

SEP 02 2008

Sandoz Inc.
4700 Sandoz Drive
Wilson, NC 27898

OGD
• Ensure that all drug substance and excipient components of the drug product, have residual solvent acceptance limits that fall within the ICH Q3C (option 1) limit (this approach requires that the total daily dose of the drug product be less than 10 g/day), or
• Ensure that all drug substance and excipient components of the drug product, weighted by their amount in the drug product, results in a cumulative daily exposure for residual solvents that falls within the ICH Q3C (option 2) limit, or
• Ensure via direct testing of the drug product, that the total daily exposure for the residual solvents falls with the ICH Q3C (option 2) limit (direct testing for residual solvents in the drug product (or via applicable in-process tests) should be employed for those solvents used in the manufacturing process of the drug product).

The evaluation of Metaxalone Tablets, 800 mg, for residual solvents content concludes that the product is within the safety recommendations and meets the criteria for compliance. This conclusion was derived from both the information gathered from each of the excipient suppliers, and the knowledge that the drug product

Based on the information obtained from each of the excipient suppliers,

Additionally, the statement received from the manufacturer

Following this page, 1 page withheld in full - (b)(4)
USP acceptance criteria, published in USP.

specification sheet has been included in ATTACHMENT-C.

ATTACHMENT-C:

1.
2.
3.
4.
5.
6.
7.
8.

Furthermore, Sandoz makes the commitment to re-assess this product’s compliance with USP <467> if there is a change to ingredient suppliers for the products in the post approval period, including revision controls, if appropriate.

A Letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Best Regards,

Ellen Camos
Regulatory Affairs Associate III
Sandoz, Inc.
November 5, 2008

Mr. Gary Buehler, Director,  
Office of Generic Drugs, HPD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

RE: ANDA 40-445  
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Stamford, CT 06901</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Richard Roberts, MD, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,
Director, Regulatory Affairs
November 6, 2008

Mr. Gary Buehler, Director,  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

RE:  ANDA 40-445  
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Richard Roberts, MD, Ph.D.</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

[Stamp] PATENT AMENDMENT

RE:  ANDA 40-445
      Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Company</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>King Pharmaceuticals, Inc.</td>
<td>501 Fifth St. 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St. 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
<td>677 Washington Blvd 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St. 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel, Director, Regulatory Affairs
November 10, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel
Director, Regulatory Affairs
November 12, 2008

Mr. Gary Buehler, Director,  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

RE: ANDA 40-445  
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>King Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td>501 Fifth St.</td>
</tr>
<tr>
<td></td>
<td>Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td></td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td></td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td></td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td></td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td></td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,
Director, Regulatory Affairs
November 13, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.

NOV 18 2008

Sandoz Inc.
4760 Sandoz Drive
Wilson, NC 27893
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>King Pharmaceuticals, Inc. 501 Fifth St. Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Mutual Pharmaceutical Company, Inc. 1100 Orthodox St. Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>King Pharmaceuticals, Inc. 501 Fifth St. Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch 677 Washington Blvd Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Mutual Pharmaceutical Company, Inc. 1100 Orthodox St. Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch c/o Latham &amp; Watkins LLP 650 Town Center Dr., 20th Floor Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,
Director, Regulatory Affairs
November 14, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELEXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

| Brian Markison, President & CEO                  | Chief Legal Officer                  |
| King Pharmaceuticals, Inc.                      | Mutual Pharmaceutical Company, Inc.  |
| 501 Fifth St.                                   | 1100 Orthodox St.                   |
| Bristol, TN 37620                               | Philadelphia, PA 19124              |

| Chief Legal Officer                              | Chief Legal Officer                  |
| King Pharmaceuticals, Inc.                      | UBS AG, Stamford Branch              |
| 501 Fifth St.                                   | 677 Washington Blvd                  |
| Bristol, TN 37620                               | Stamford, CT 06901                   |

| Richard Roberts, MD, Ph.D.                       | Chief Legal Officer                  |
| Mutual Pharmaceutical Company, Inc.             | UBS AG, Stamford Branch              |
| 1100 Orthodox St.                               | c/o Latham & Watkins LLP             |
| Philadelphia, PA 19124                          | 650 Town Center Dr., 20th Floor      |
|                                               | Costa Mesa, CA 92626                 |

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]
Dietrich Bartel,
Director, Regulatory Affairs
November 17, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.

RECEIVED
NOV 17 2008

OGD
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Company</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison</td>
<td>President &amp; CEO</td>
<td>King Pharmaceuticals, Inc.</td>
<td>501 Fifth St. Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td></td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St. Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td></td>
<td>King Pharmaceuticals, Inc.</td>
<td>501 Fifth St. Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td></td>
<td>UBS AG, Stamford Branch</td>
<td>677 Washington Blvd Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td></td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St. Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td></td>
<td>UBS AG, Stamford Branch</td>
<td>c/o Latham &amp; Watkins LLP 650 Town Center Dr., 20th Floor Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel, B.S.
Director, Regulatory Affairs

Sandoz Inc. 4700 Sandoz Drive Wilson, NC 27893
November 18, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
</table>
| Brian Markison, President & CEO | King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 |
| Chief Legal Officer         | Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 |
| Chief Legal Officer         | King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 |
| Chief Legal Officer         | UBS AG, Stamford Branch  
677 Washington Blvd  
Stamford, CT 06901 |
| Richard Roberts, MD, Ph.D.  | Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 |
| Chief Legal Officer         | UBS AG, Stamford Branch  
c/o Latham & Watkins LLP  
650 Town Center Dr., 20th Floor  
Costa Mesa, CA 92626 |

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,  
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
</table>
| Brian Markison, President & CEO | King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 |
| Chief Legal Officer           | Chief Legal Officer  
Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 |
| Chief Legal Officer           | Chief Legal Officer  
King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 |
| Chief Legal Officer           | Chief Legal Officer  
UBS AG, Stamford Branch  
677 Washington Blvd  
Stamford, CT 06901 |
| Richard Roberts, MD, Ph.D.    | Chief Legal Officer  
Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 |
| Chief Legal Officer           | Chief Legal Officer  
UBS AG, Stamford Branch  
c/o Latham & Watkins LLP  
650 Town Center Dr., 20th Floor  
Costa Mesa, CA 92626 |

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]
Dietrich Bartel,  
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

November 20, 2008

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>King Pharmaceuticals, Inc.</td>
<td>Chief Legal Officer</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td></td>
<td>501 Fifth St.</td>
<td></td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td></td>
<td>Bristol, TN 37620</td>
<td></td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>King Pharmaceuticals, Inc.</td>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td></td>
<td>501 Fifth St.</td>
<td></td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td></td>
<td>Bristol, TN 37620</td>
<td></td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td></td>
<td>1100 Orthodox St.</td>
<td></td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA 19124</td>
<td></td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel, B.S.
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

Patent Amendment

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]

Dietrich Bartel,
Director, Regulatory Affairs
Mr. Gary Buehler, Director,  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445  
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Richard Roberts, MD, Ph.D.</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]

Dietrich Bartel, B.S.
Director, Regulatory Affairs

RECEIVED
NOV 24 2008
OGD
Mr. Gary Buehler, Director,  
Office of Generic Drugs, HFD-600  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Document Control Room  
Metro Park North II  
7500 Standish Place, Room 150  
Rockville, Maryland 20855-2773

RE: ANDA 40-445  
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,  
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.

Sandoz Inc.
4700 Sandoz Drive
Wilson, NC 27893
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
</table>
| Brian Markison, President & CEO | King Pharmaceuticals, Inc.  
                      501 Fifth St.  
                      Bristol, TN 37620                          |
| Chief Legal Officer         | Mutual Pharmaceutical Company, Inc.  
                      1100 Orthodox St.  
                      Philadelphia, PA 19124                     |
| Chief Legal Officer         | UBS AG, Stamford Branch  
                      677 Washington Blvd  
                      Stamford, CT 06901                           |
| Richard Roberts, MD, Ph.D.  | Mutual Pharmaceutical Company, Inc.  
                      1100 Orthodox St.  
                      Philadelphia, PA 19124                     |
| Chief Legal Officer         | UBS AG, Stamford Branch  
                      c/o Latham & Watkins LLP  
                      650 Town Center Dr., 20th Floor  
                      Costa Mesa, CA 92626                         |

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,  
Director, Regulatory Affairs

Sandoz Inc.  
4700 Sandoz Drive  
Wilson, NC 27893
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]
Dietrich Bartel,
Director, Regulatory Affairs
December 1, 2008

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
</table>
| Brian Markison, President & CEO | King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 | Chief Legal Officer  
Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 |
| Chief Legal Officer  
King Pharmaceuticals, Inc.  
501 Fifth St.  
Bristol, TN 37620 | Chief Legal Officer  
UBS AG, Stamford Branch  
677 Washington Blvd  
Stamford, CT 06901 |
| Richard Roberts, MD, Ph.D.  
Mutual Pharmaceutical Company, Inc.  
1100 Orthodox St.  
Philadelphia, PA 19124 | Chief Legal Officer  
UBS AG, Stamford Branch  
c/o Latham & Watkins LLP  
650 Town Center Dr., 20th Floor  
Costa Mesa, CA 92626 |

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]

Dietrich Bartel,  
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

PATENT AMENDMENT

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

December 2, 2008

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.

RECEIVED
DEC 02 2008
OGD

Sandoz Inc. 4700 Sandoz Drive Wilson, NC 27893
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Chief Legal Officer</td>
</tr>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

[Signature]

Dietrich Bartel,
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELAXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Markison, President &amp; CEO</td>
<td>King Pharmaceuticals, Inc.</td>
<td>501 Fifth St.</td>
<td>Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St.</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>King Pharmaceuticals, Inc.</td>
<td>501 Fifth St.</td>
<td>Bristol, TN 37620</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
<td>677 Washington Blvd</td>
<td>Stamford, CT 06901</td>
</tr>
<tr>
<td>Richard Roberts, MD, Ph.D.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>1100 Orthodox St.</td>
<td>Philadelphia, PA 19124</td>
</tr>
<tr>
<td>Chief Legal Officer</td>
<td>UBS AG, Stamford Branch</td>
<td>c/o Latham &amp; Watkins LLP</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel,
Director, Regulatory Affairs
Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

December 4, 2008

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445

In accordance with 21 CFR 314.94(a)(12)(i)(A)(4) and Section 505(j)(2)(A)(vii)(IV) of the Act, Sandoz wishes to amend its application by providing a revised Patent certification. We are revising our Patent Certification to include a Paragraph IV Certification for U.S. Patent Numbers 6,407,128, 6,683,102, 7,122,566 and 7,378,434. In support of this revision, a revised signed Patent Certification is provided in Attachment 1.

In accordance with 21 CFR 314.95(b), we certify that we have provided Patent Certification Notice to the patent holder and to the holder of the approved NDA application (as defined in 21 CFR 314.95(a)), for the reference listed drug, SKELEXIN® Tablets, and that the notice has met the content requirements under 21 CFR 314.95(c). A copy of the notice is provided in Attachment 2.

RECEIVED
DEC 04 2008
OGD

Sandoz Inc. 4700 Sandoz Drive
Wilson, NC 27893
The notice has been sent to the following 6 recipients:

<table>
<thead>
<tr>
<th>Brian Markison, President &amp; CEO</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>Mutual Pharmaceutical Company, Inc.</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>1100 Orthodox St.</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Philadelphia, PA 19124</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chief Legal Officer</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>King Pharmaceuticals, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>501 Fifth St.</td>
<td>677 Washington Blvd</td>
</tr>
<tr>
<td>Bristol, TN 37620</td>
<td>Stamford, CT 06901</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Richard Roberts, MD, Ph.D.</th>
<th>Chief Legal Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual Pharmaceutical Company, Inc.</td>
<td>UBS AG, Stamford Branch</td>
</tr>
<tr>
<td>1100 Orthodox St.</td>
<td>c/o Latham &amp; Watkins LLP</td>
</tr>
<tr>
<td>Philadelphia, PA 19124</td>
<td>650 Town Center Dr., 20th Floor</td>
</tr>
<tr>
<td></td>
<td>Costa Mesa, CA 92626</td>
</tr>
</tbody>
</table>

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Dietrich Bartel
Director, Regulatory Affairs
June 26, 2009

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metaxalone Tablets, 800 mg; ANDA 40-445.

With regard to our ANDA No. 40-445 ("Sandoz ANDA") for an 800 mg strength generic Metaxalone Tablets, please be advised that on June 4, 2009, final judgment was entered in our favor that all claims of Orange Book-listed U.S. Patents Nos. 6,407,128 and 6,683,102 ("the patents") are invalid. As such, pursuant to 21 U.S.C. § 355(j)(5)(B)(iii)(I)(aa) and 21 C.F.R. § 314.107(b)(3)(B)(ii), there is no longer an automatic (30-month) stay of approval as to Sandoz's ANDA.

More specifically, on November 3, 2004, Sandoz's predecessor-in-interest in the Sandoz ANDA, Eon Labs, Inc. ("Eon"), * sent Paragraph IV certification notices to the required recipients concerning the patents. The notice was received by the last entity to receive same on November 9, 2004. 21 U.S.C. § 355(j)(2)(B). Copies of the certified mail return receipts confirming receipt of the notices by the required recipients are Attachment A.

* The subject ANDA was previously owned by Eon Labs, Inc. A July 21, 2005 letter to FDA confirmed change in ownership from Eon Labs, Inc. to Sandoz Inc.

On January 20, 2009, the Court held that all of the claims of the patents are invalid, *King Pharmaceuticals, Inc. v. Eon Labs, Inc.*, 593 F. Supp.2d 501, 515 (E.D.N.Y. 2009) (Attachment C) and on June 4, 2009 the Court entered judgment on the above holding (Attachment D). Therefore, as mentioned above, there is no longer an automatic stay of approval as to our ANDA. As previously advised, there is a second case pending against Sandoz regarding this product, which was filed on December 5, 2008 in the District of New Jersey (docket no. 08-5974), asserting U.S. Patent No. 7,122,566 in response to Sandoz’s Paragraph IV notice letter. As this patent issued and became Orange Book-listed well after Sandoz’s ANDA had been filed, this case does not impinge on the automatic stay.

This submission is submitted for your review and approval.

A letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact Mr. Dietrich Bartel, B.S., Director, Regulatory Affairs, by telephone at (252) 234-2212.

Yours truly,

Sandoz Inc.

Griha L. Mangru, M.S.
Manager, Regulatory Affairs
OVERNIGHT DELIVERY

Gary Buehler, Director
Office of Generic Drugs
Center for Drug Evaluation and Research
Metro Park North 2, Room 150
7500 Standish Place
Rockville, MD 20855

November 23, 2009

RE: ANDA 40-445 Metaxolone Tablets, 800 mg
Labeling Amendment and Request for Final Approval

Dear Mr. Buehler:

Reference is made to our Abbreviated New Drug Application dated August 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Metaxolone Tablets, 800 mg, ANDA 40-445. This letter is a follow-up to several telephone discussions between Sandoz representatives and your staff.

LABELING AMENDMENT

In an October 10, 2009 discussion, Sandoz informed Mr. Robert West that the pending ANDA is not based on a proposed labeling "carve out," and that Sandoz would be submitting revised proposed labeling and a request for final approval. This letter provides that information.

We enclose an amendment to our pending ANDA that includes revised proposed labeling that is identical in all substantive respects to the labeling of the Reference Listed Drug, Skelaxin®. Sandoz proposed labeling includes all indications and conditions of use set forth in the RLD labeling, and does not propose a "carve out" of any information in Skelaxin®’s labeling that is protected by one or more patents.

The Sandoz pending ANDA includes Paragraph IV certifications to all three patents currently listed in the Orange Book in connection with Skelaxin®, namely, U.S. Patent Nos. 6,407,128 (the '128 patent), 6,683,102 (the '102 patent), and 7,122,566 (the '566 patent). Sandoz’s ANDA does not include any "(viii) statements" that seek to omit patent-protected labeling information in the labeling of the RLD.
REQUEST FOR FINAL ANDA APPROVAL

To the best of Sandoz knowledge, there are no outstanding bioequivalency or CMC issues with its pending ANDA. Sandoz will manufacture Metaxalone tablets at its Wilson, North Carolina facility. That facility was just inspected in August 2009. Based on that inspection, Sandoz understands that the facility generally, and pending ANDA 40-445 in particular, are regarded as having an acceptable compliance status.

Final approval of the Sandoz ANDA is not delayed by any non-patent exclusivity periods or by the 180-day exclusivity rights of a generic competitor. Final ANDA approval is also not delayed by any litigation stays resulting from lawsuits pursuant to receipt of notices of Sandoz Paragraph IV certifications. With regard to the '128 and '102 patents, the 30-month litigation delays of final ANDA have long expired. As stated and documented in the Sandoz Patent Amendment dated June 26, 2009, the last notice of Paragraph IV certification was received on November 9, 2004. Moreover, as also stated and documented in that Patent Amendment, the federal district court held, on January 20, 2009, that all claims of both patents are invalid.

The '566 patent did not issue until October 17, 2006, long after the Sandoz ANDA was submitted to FDA and accepted for substantive review.¹ Thus, no litigation stay is available with regard to the '566 patent. See 21 U.S.C. § 355(j)(5)(B)(iii) (as amended by MMA § 1101(a)(2)(A)(ii)(I), applicable to patent information submitted to FDA for Orange Book listing on or after August 18, 2003, see MMA § 1101(c)(3)).

Sandoz understands, based on several informal discussions with your staff that the FDA is in the process of ascertaining whether to permit ANDA sponsors to “carve out” labeling information protected by the '128, '102, and/or '566 patents. Sandoz further understands that such a decision is related to a pending March 18, 2004 citizen petition (Docket No. FDA-2004-P-0426 (old 2004P-0140)) that asks the agency to rescind a March 1, 2004 “Dear Applicant” letter regarding Metaxalone labeling. As a result of these pending matters, Sandoz understands that your office has generally advised ANDA applicants not to submit proposed Metaxalone labeling until these issues have been resolved and (if appropriate) until a “carved out” labeling “template” has been developed by the agency. Sandoz appreciates that complex and difficult scientific, medical, legal, and policy questions are involved in deciding whether to allow a labeling “carve out.” Sandoz also appreciates that the submission of proposed “carved out” labeling by those ANDA sponsors that have chosen to proceed by means of “(viii) statements” on some or all of the three Orange Book patents before an agency decision on these matters would serve no useful purpose whatsoever. Importantly, however, the informal advice that Metaxalone ANDA applicants should not submit proposed labeling at this time has no application to Sandoz, which does not seek approval based on “carved out” labeling.

In addition to the pending March 18, 2004 citizen petition discussed above, a May 13, 2009 citizen petition submitted by Mutual Pharmaceutical Co. (Docket No. FDA-2009-P-0223) is also pending. On its face, Mutual's 2009 petition asks for, among other relief, certain changes in the labeling of Skelaxin® to reflect a delayed relief product, revision of the dissolution method for

¹ Sandoz's ANDA was initially filed on August 31, 2001. It was amended to include the 800mg strength for which Sandoz currently seeks approval on November 1, 2004. Both dates well predate the issuance and Orange Book listing of the '566 patent.
Skelaxin®, and application of the SUPAC-MR guidance for scale-up and post approval changes to Skelaxin® and to ANDAs relying upon Skelaxin® as the RLD. Mutual’s petition does not seek to block or delay the approval of any ANDAs or 505(b)(2) NDAs. Therefore, Mutual’s petition is not within the scope of the 180-day decision timeframe in section 505(q) of the FDC Act for petitions that seek to block or delay ANDA or 505(b)(2) NDA approvals. Based on Sandoz’s informal discussions with Ms. Cecelia Parise of your staff on November 13, 2009, we understand that the agency agrees that Mutual’s new petition is outside the scope of section 505(q) of the FDC Act. Since both the plain language of the petition itself and the agency’s initial review of the petition lead to the conclusion that the petition does not seek to block or delay the approval of any ANDAs for generic versions of Skelaxin®, the agency’s consideration of the petition should have no effect on final approval of the Sandoz pending ANDA for Metaxalone Tablets, 800 mg.²

Based on our informal discussion with Ms. Parise on November 13, 2009, we also understand that the agency is attempting to determine whether 180-day exclusivity rights for Metaxalone Tablets, 800 mg, are governed by pre- or post-MMA law. (Sandoz assumes the pre- versus post-MMA law question is relevant because Sandoz was the first ANDA sponsor to submit a Paragraph IV ANDA for Metaxalone Tablets, 800 mg, and because the Sandoz ANDA was initially submitted before enactment of the MMA but was amended after the MMA’s effective date to include the 800 mg strength.) Sandoz respectfully submits that it is not necessary for the agency to make that determination at this time.

FDA has repeatedly stated that it will not make 180-day exclusivity decisions until necessary, namely, until a “subsequent” Paragraph IV ANDA sponsor is eligible for final approval, but possibly for the existence of a 180-day exclusivity. Here, as stated above, Sandoz is currently eligible for, and requests, final ANDA approval. To the best of Sandoz knowledge, Sandoz was the first ANDA sponsor to submit a Paragraph IV ANDA for Metaxalone Tablets, 800 mg. As noted above, FDA’s apparent interest in the pre- versus post-MMA law question appears to corroborate the view of Sandoz. Based on a careful search of publicly available documents, Sandoz is not aware of any other ANDA sponsor that has a pending ANDA for Metaxalone Tablets, 800 mg, much less a Paragraph IV ANDA for that drug product.³ There does not appear to be any ANDA sponsor that will be affected by 180-day exclusivity rights of Sandoz.

---

² It seems that the relief requested by Mutual could, if granted, have some effect on ANDAs for generic versions of Skelaxin®. Any future changes that affect approved ANDAs should be handled, in the regular course of business, as post approval changes.

³ See SEC Form 10-Q for the quarter ending September 30, 2009. King Pharmaceuticals, Inc. at page 21 (discussing in detail matters involving Skelaxin® and in particular the Eon Labs/ Sandoz ANDA for the 800 mg strength, but no other ANDAs for that strength), available at http://www.sec.gov/Archives/edgar/data/1047699/000095012309058553/t20793e10q.htm.
CONCLUSION

For these reasons, Sandoz respectfully requests that the enclosed Labeling Amendment be reviewed, and that this Sandoz ANDA receive final approval, as expeditiously as possible.

In support of these changes, the following documents are provided on the enclosed CD:
- Final Printed Labeling – Patient Insert (PDF and Word)
- Side-by-Side Comparison of the Patient Insert (Sandoz vs. RLD)
- SPL

This submission is in electronic format. One CD is provided which includes the content described below. Accordingly, Sandoz confirms that this CD is virus free and that a letter of non repudiation agreement was submitted by Sandoz Inc. on November 30, 2007.

<table>
<thead>
<tr>
<th>Document</th>
<th>Filename</th>
</tr>
</thead>
<tbody>
<tr>
<td>356h Form (scanned)</td>
<td>356h.pdf</td>
</tr>
<tr>
<td>Sandoz Cover Letter (scanned)</td>
<td>cover.pdf</td>
</tr>
<tr>
<td>Supportive Labeling Documents</td>
<td>Labeling folder:</td>
</tr>
<tr>
<td></td>
<td>Side-by-side.pdf</td>
</tr>
<tr>
<td></td>
<td>OS7750 Issued 10-09 Content.doc</td>
</tr>
<tr>
<td></td>
<td>OS7750 Issued 10-09 Mac Final.pdf</td>
</tr>
<tr>
<td></td>
<td>SPL Folder</td>
</tr>
</tbody>
</table>

This information is submitted for your review and approval.

Please acknowledge receipt of this document by signing and dating the enclosed copy of the cover letter and returning it in the self-addressed stamped envelope.

Sandoz appreciates the agency’s attention to this important matter. If there are any questions concerning this Labeling Amendment or request for final approval, please contact Marcy Macdonald at 303-438-4599.

Respectfully submitted,

SANDOZ, INC.

[Signature]

Joseph Carrado, M.Sc., R.Ph.
Vice President, Regulatory Affairs

Enclosure (Labeling Amendment)
cc: Mr. Robert L. West
    Mr. Wm. Peter Rickman
    Ms. Cecelia Parise
December 8, 2009

Dr. Burhan Nour
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

RE:  ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Dr. Nour:

Per your request, I have corrected the Metaxalone Tablets, 800 mg SPL file to reflect “milligrams” in the product data.

The CD contains the following folders and files:

Folder: spl
Files: 1cf511f7-f6fc-409c-8acf-a6d7ab6d523f.xml
       1cf511f7-f6fc-409c-8acf-a6d7ab6d523f-01.jpg
       1cf511f7-f6fc-409c-8acf-a6d7ab6d523f-02.jpg
       1cf511f7-f6fc-409c-8acf-a6d7ab6d523f-03.jpg
       1cf511f7-f6fc-409c-8acf-a6d7ab6d523f-04.jpg

If there are any questions concerning these files, please contact me at (252) 234-2207.

Sincerely,
Sandoz Inc.

Deborah Y. Goff, B.S., R.A.C.
Regulatory Affairs Associate III
deborah.goff@sandoz.com

Sandoz Inc.
4700 Sandoz Drive
Wilson, NC 27893

RECEIVED
DEC 09 2009
OGD
December 10, 2009

RE: ANDA 40-445 Metaxalone Tablets 800 mg
Patent Amendment – Certified Mail Receipts and Notification of Litigation
(US Patent 7,122,566)

Dear Mr. Buehler:

Sandoz Inc. is hereby submitting a patent amendment to pending Abbreviated New Drug Application 40-445 for Metaxalone Tablets 800 mg in accord with Section 505 (j) of the Federal Food, Drug, and Cosmetic Act and with 21 CFR Part 314.96.

In accordance with 21 CFR 314.95(e), Sandoz also wishes to inform FDA that the Notice to the Patent Owner and to the NDA Holder was received on November 26, 2008 which corresponds to the date by which the Agency received U.S. Patent No. 7,122,566 according to Mary Ann Holovac of FDA. Enclosed as Ex. A please find receipt documentation in the form of certified mail receipts for each address notified.

Sandoz also wishes to inform FDA that the Notice to the Patent Owner and to the NDA Holder were sent on a rolling basis. Thus multiple return receipt cards were obtained. Accordingly, enclosed as Ex. B please find receipt documentation in the form of certified mail receipts for each address notified for the additional days as well.

Sandoz Inc. is also providing notice that King Pharmaceuticals, Inc. filed Civil Action 3:08-cv-05974-GB-JJH in New Jersey on December 5, 2008. This suit is with respect to U.S. Patent No. 7,122,566. In accord with 21 U.S.C. § 355(j)(5)(B)(iii), this suit does not give rise to any additional 30-month stay and so does not affect approval of Sandoz’s ANDA. In addition, any stay associated with Sandoz’s certifications against U.S. Patent Nos. 6,407,128 and/or 6,683,102 have since expired and in any event terminated pursuant to the June 4, 2009 Judgment in Civil Action No. 04-5540, Eastern District of New York, holding all claims of U.S. Patent Nos. 6,407,128 and/or 6,683,102 invalid.

As this submission is in electronic format- one CD is provided which includes the content described below. Accordingly, Sandoz confirms that this CD is virus free and that a letter of non repudiation agreement was submitted by Sandoz Inc. on November 30, 2007.
This information is submitted for your review and approval.

Sincerely,

Sandoz Inc.

Marcy Macdonald, Director
Regulatory Affairs
Enclosures

MM/ags
OVERNIGHT DELIVERY
Gary Buehler, Director
Office of Generic Drugs
Center for Drug Evaluation and Research
Metro Park North 2, Room 150
7500 Standish Place
Rockville, MD 20855

DECEMBER 23, 2009

TELEPHONE AMENDMENT
CMC
(Electronic Submission)

RE: ANDA 40-445 Metaxalone Tablets 800 mg
Telephone Amendment – Response to 12/10/09 CMC Request

Dear Mr. Buehler:

Sandoz Inc. is hereby submitting a telephone amendment to pending Abbreviated New Drug Application 40-445 for Metaxalone Tablets 800 mg in accord with Section 505 (j) of the Federal Food, Drug, and Cosmetic Act and with 21 CFR Part 314.96.

Reference is made to the discussion between FDA and Sandoz on December 10, 2009 with respect to the Sandoz CMC amendment dated August 29, 2008.

Provided is a complete response to all deficiencies.

1) **FDA Comment:** With Revise Drug Product specification sheet to include a compliance statement for USP <467>.

**Sandoz Response:** This item was resolved on the phone with FDA.

2) **FDA Comment:** Clarify the FMR pages submitted. Please explain why the [REDACTED] Please submit all changes to the manufacturing process and with explanations.

**Sandoz Response:** It is Sandoz practice to include a copy of the [REDACTED] from the manufacturing record in our USP <467> compliance statements for ease of internal review.

Enclosed please find a copy of the current proposed commercial manufacturing record.

The current manufacturing record contains [REDACTED] as well as additional minor clarifications and changes. A complete summary, rationale and supportive data for these changes is included.

DECEMBER 24, 2009

OGD
As this submission is in electronic format— one CD is provided which includes the content described below. Accordingly, Sandoz confirms that this CD is virus free and that a letter of non repudiation agreement was submitted by Sandoz Inc. on November 30, 2007.

<table>
<thead>
<tr>
<th>Document</th>
<th>ANDA 40-445</th>
</tr>
</thead>
<tbody>
<tr>
<td>356(h) Form (scanned)</td>
<td>356h.pdf</td>
</tr>
<tr>
<td>Sandoz Cover Letter (scanned)</td>
<td>cover.pdf</td>
</tr>
<tr>
<td>Telephone amendment-</td>
<td>cmc folder</td>
</tr>
<tr>
<td>Deficiency Response</td>
<td>telephone amendment.pdf (bookmarked)</td>
</tr>
</tbody>
</table>

This information is submitted for your review and approval.

Please acknowledge receipt of this document by signing and dating the enclosed copy of the cover letter and returning it in the self-addressed stamped envelope.

Sincerely,

Sandoz Inc.

Marcy Macdonald, Director
Regulatory Affairs
Enclosures

MM/ags
OVERNIGHT DELIVERY
Gary Buehler, Director
Office of Generic Drugs
Center for Drug Evaluation and Research
Metro Park North 2, Room 150
7500 Standish Place
Rockville, MD 20855

January 14, 2010

RE: ANDA 040445 Metaxalone Tablets 800 mg
Telephone Amendment:
Follow up to Jan 13, 2010 T-Con: Clarification of Manufacturing Process

Dear Mr. Buehler:

Sandoz Inc. is hereby submitting a Telephone amendment to pending Abbreviated New Drug Application 040445 for Metaxalone Tablets 800 mg in accord with Section 505 (j) of the Federal Food, Drug, and Cosmetic Act and with 21 CFR Part 314.96.

Reference is made to a teleconference discussion on January 13, 2010 with the following participants:
Sandoz: Alison Sherwood, [REDACTED]
FDA: Dr. Liang Lii Huang, Dr. Paul Schwartz, Dr. James Fan, Trang Tran

Pursuant to this discussion Sandoz is providing written clarification of the [REDACTED]

Prior to the December 23, 2009 amendment, the proposed [REDACTED]

Overview of Submission History:
The previous filed [REDACTED] were submitted in our November 1, 2004 major amendment which included a bioequivalence study for the 800 mg
strength. For ease of reference, the formula pages of these batch records are provided in Attachment 1. The batch size for the [redacted] was [redacted].

The previous filed [redacted](b)(4) was submitted in our February 2, 2007 amendment. For ease of review the formula pages of these batch records are provided in Attachment 2. The exhibit batch size for [redacted](b)(4) and the exhibit batch size for tablets was [redacted] tablets. The proposed record was for [redacted](b)(4) Tablets and consisted of 3 Parts (A, B, C) with approx [redacted] for each.

The current Metaxalone Tablets blank record submitted on December 23, 2009 is provided again as Attachment 3. [redacted](b)(4) is bookmarked for ease of review.

As this submission is in electronic format- one CD is provided which includes the content described below. Accordingly, Sandoz confirms that this CD is virus free and that a letter of non repudiation agreement was submitted by Sandoz Inc. on November 30, 2007.

<table>
<thead>
<tr>
<th>Document</th>
<th>ANDA 040445</th>
</tr>
</thead>
<tbody>
<tr>
<td>356(h) Form (scanned)</td>
<td>356h.pdf</td>
</tr>
<tr>
<td>Sandoz Cover Letter (scanned)</td>
<td>cover.pdf</td>
</tr>
<tr>
<td>Telephone amendment- Chemistry Deficiency</td>
<td>cmc folder amendment.pdf (bookmarked)</td>
</tr>
</tbody>
</table>

This information is submitted for your review and approval.

Sincerely,

Sandoz Inc.

[Signature]

Marcy Macdonald, Director

Regulatory Affairs

Enclosures

MM/ags
January 27, 2010

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

Re: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

In accordance with 21 CFR 314.96, this submission constitutes a Telephone Amendment to our Abbreviated New Drug Application 40-445, Metaxalone Tablets, 800 mg. Sandoz Inc. would like to request, the withdrawal of the following contract testing laboratory from our ANDA 40-445, Metaxalone Tablets, 800 mg:

(b) (4)

was included as a contract testing laboratory in Section 10 of the Major Amendment, filed on November 1, 2004. Reference is also made to the Telephone Amendment, filed on December 15, 2004 which included the cGMP statement for this laboratory. This laboratory was not used for any of the analytical procedures performed to support this application. The decision to withdraw this contract facility is without prejudice to re-filing.

A Letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on 11/30/07.

If there are any questions concerning this amendment, please contact me by telephone at (252) 234-2413, by fax at (252) 234-2323, or email at ellen.camos@sandoz.com.

Best Regards,

Ellen Camos
Regulatory Affairs, Senior Associate
Sandoz Inc.
March 9, 2010

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

TELEPHONE AMENDMENT

Re: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

In accordance with 21 CFR 314.96, this submission constitutes a Telephone Amendment to our Abbreviated New Drug Application 40-445, Metaxalone Tablets, 800 mg. It is being filed in response to a telephone communication from Dr. Liang-Lii Huang, OGD, CDER, FDA to Sandoz Inc. on February 25, 2010. Dr. Huang also indicated to submit the response as a Telephone Amendment.

The deficiency comment is reiterated below (in bold type), followed by our response.

Deficiency:

Please provide information for the (b)(4) Please indicate whether the (b)(4)

Response:

There are (b)(4) and are the following:

1) 
2) 
3) 

Following this page, 1 page withheld in full - (b)(4)

Wilson, NC 27893
Page 1 of 3
Drug Product (Metaxalone Tablets, 800 mg):

Please refer to ATTACHMENT-B for copies of the updated, revised specifications can also be found in ATTACHMENT-B.

ATTACHMENT-B:

A Letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on November 30, 2007.

If there are any questions concerning this amendment, please contact me by telephone at (252) 234-2413, by fax at (252) 234-2323, or email at ellen.camos@sandoz.com.

Best Regards,

Ellen Camos
Regulatory Affairs, Senior Associate
Sandoz Inc.
DATE: March 29, 2010

FROM: Martin Shimer
Branch Chief, Regulatory Support Branch
Office of Generic Drugs (HFD-600)

TO: ANDA 040445

SUBJECT: Background for Sandoz’ Metaxalone Tablets, 800 mg; Decision regarding non-forfeiture of 180-day exclusivity

The purpose of this memorandum is to document the status of Sandoz’s ANDA 040445 for Metaxalone Tablets, 800 mg, as of the date of approval, and to document the agency’s decision regarding whether Sandoz forfeited its 180-day generic drug exclusivity because it did not obtain tentative approval within 30 months. Sandoz’ new strength amendment for the 800 mg strength was submitted on November 4, 2004, and contained paragraph IV certifications to the ‘128 and ‘102 patents. The paragraph IV certifications made Sandoz eligible for 180-day generic drug exclusivity. However, Sandoz did not receive tentative approval within 30 months.

I. FACTUAL BACKGROUND

The following is a timeline of ANDA 040445:

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/05/01</td>
<td>ANDA submitted</td>
</tr>
<tr>
<td>10/17/01</td>
<td>Refuse to receive</td>
</tr>
<tr>
<td>11/07/01</td>
<td>Amendment; this is the receipt date of the ANDA</td>
</tr>
<tr>
<td>11/30/01</td>
<td>Amendment</td>
</tr>
<tr>
<td>4/03/02</td>
<td>Chemistry review #1 (deficient), chemistry deficiencies faxed</td>
</tr>
<tr>
<td>6/20/02</td>
<td>Bioequivalence amendment</td>
</tr>
<tr>
<td>6/24/02</td>
<td>Chemistry amendment</td>
</tr>
<tr>
<td>7/19/02</td>
<td>Bioequivalence amendment</td>
</tr>
<tr>
<td>10/25/02</td>
<td>Chemistry amendment</td>
</tr>
<tr>
<td>11/18/02</td>
<td>Chemistry amendment</td>
</tr>
<tr>
<td>12/06/02</td>
<td>Chemistry amendment</td>
</tr>
<tr>
<td>1/08/03</td>
<td>Labeling amendment</td>
</tr>
<tr>
<td>3/06/03</td>
<td>Chemistry review #2 (deficient – major), chemistry deficiencies faxed</td>
</tr>
<tr>
<td>4/15/03</td>
<td>Correspondence</td>
</tr>
</tbody>
</table>
4/15/03  Correspondence
2/10/04  Patent amendment
5/13/04  Amendment (chemistry)
11/04/04 Amendment adding 800 mg strength; included PIV certifications to the ‘128 and ‘102 patents
12/16/04  Telephone amendment (chemistry)
5/09/05  Bioequivalence review (deficient), bioequivalence deficiencies faxed
12/05/05 Chemistry review #3 (deficient), chemistry deficiencies faxed
9/06/06  Firm withdrew 400 mg strength
9/07/06  Bioequivalence (amendment)
10/20/06-  Serial patent amendments to the ‘566 patent (but this patent was not listed until 11/26/08)
11/24/06  Patent amendment
2/05/07  Chemistry amendment
5/04/07  11/04/04 plus 30 months
11/09/07 Bioequivalence review (acceptable)
12/11/07 Correspondence
1/29/08  Labeling amendment
2/28/08  Patent amendment
7/17/08  Telecon (chemistry)
9/02/08  Telephone amendment (chemistry)
10/01/08  Labeling review (acceptable)
11/05/08-  Serial patent amendments to the ‘566 patent, which was listed on 11/26/08
12/05/08  11/26/08
6/29/09  Patent amendment
11/24/09 Labeling amendment
12/08/09  Labeling review (acceptable)
12/09/09 Labeling amendment
12/11/09 Patent amendment
12/24/09 Telephone amendment (chemistry)
1/15/10  Telephone amendment (chemistry)
1/28/10  Telephone amendment (chemistry)
The following chart lists the many citizen petitions that have been submitted regarding metaxalone:

<table>
<thead>
<tr>
<th>Citizen Petition Number</th>
<th>Date Submitted</th>
<th>Action Requested</th>
<th>Action Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-2001-P-0001 (formerly 01P-0117), submitted by Mutual</td>
<td>3/06/01</td>
<td>Reclassify metaxalone tablets as a drug product with potential or actual bioequivalence problems and make inclusion of an in vivo fasting bioequivalence study a condition of approval for an ANDA</td>
<td>Granted 1/30/02</td>
</tr>
<tr>
<td>01P-0481, submitted by Elan</td>
<td>10/17/01</td>
<td>That FDA require, as a condition for generic approval of solid oral dosage forms of metaxalone, an acceptable in vivo fasting and fed BE study.</td>
<td>Granted 3/21/02</td>
</tr>
<tr>
<td>FDA-2003-P-0081 (formerly 03P-0027), submitted by Eon (now Sandoz)</td>
<td>1/28/03</td>
<td>Restore the labeling for Skelaxin that was approved as of May 31, 2002; or in the alternative, determine that the May 31, 2002 labeling was not withdrawn for safety or effectiveness reasons.</td>
<td>Withdrawn 1/17/08</td>
</tr>
<tr>
<td>FDA-2004-P-0426 (formerly 04P-0140), CP1 and PSA1 submitted by RLD-holder King Pharmaceutical PSA2 submitted by Mutual</td>
<td>3/18/04 (CP1 &amp; PSA1)</td>
<td>CP1 &amp; PSA1; (1) Rescind the March 1, 2004, “Dear Applicant” letter regarding metaxalone labeling, (2) require applicants seeking approval to market generic metaxalone products that rely on Skelaxin to submit a patent certification, and (3) prohibit the removal from generic labeling of the pharmacokinetics information that appears in the Skelaxin labeling. PSA2: Stay any final approval of NDA 13-217/S-046 or any other labeling supplement for Skelaxin</td>
<td>Pending</td>
</tr>
<tr>
<td>FDA-2007-P-0017 (formerly 07P-0296), submitted by Mutual</td>
<td>7/27/07</td>
<td>Require potential drug-drug interaction (DDI)-related labeling changes for Skelaxin</td>
<td>Denied 7/18/08</td>
</tr>
<tr>
<td>FDA-2008-P-0052, submitted by Mutual</td>
<td>1/22/08</td>
<td>Refrain from approval of any ANDAs for metaxalone products until (1) certain in vivo DDI studies of Skelaxin are conducted and any relevant results are included in Skelaxin’s labeling, and (2) the Agency establishes statistical criteria related to $T_{\text{max}}$ if $T_{\text{max}}$ is determined to be a relevant safety consideration, and requires all applicants seeking approval of a generic version of metaxalone to demonstrate equivalence either by satisfying the criteria or submitted the results of certain in vivo DDI studies.</td>
<td>Denied 7/18/08</td>
</tr>
<tr>
<td>FDA-2009-P-0223, submitted by Mutual</td>
<td>5/15/09</td>
<td>Declare that Skelaxin (metaxalone tablets 800 mg) is a delayed dosage form and take other related actions.</td>
<td>Pending</td>
</tr>
</tbody>
</table>
II. STATUTORY AND REGULATORY BACKGROUND

A question could be raised about whether exclusivity for the 800 mg product should be determined under the pre-Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) or post-MMA regime. This question arises because ANDA 040445 was submitted pre-MMA (for the 400 mg strength), but the amendment for the 800 mg strength was submitted post-MMA. This latter fact, coupled with the fact that, for purposes of exclusivity, each strength of each dosage form is regarded as a separate product, seems to point toward a post-MMA analysis as the appropriate regime, and this memorandum is based on that assumption. However, it is acknowledged that because of the submission date of the original ANDA 040445, using a pre-MMA regime is not out of the question.

This memorandum does not closely examine the pre- versus post-MMA question because this memorandum is limited to the situation at the time of approval of ANDA 040445, and we reach the same conclusion regardless of whether a pre- or post-MMA analysis is used: under a pre-MMA analysis, Sandoz is entitled to exclusivity (there is no forfeiture pre-MMA), and as discussed below, under the post-MMA regime we have determined that metaxalone falls under the “change in or a review of the requirements for approval” exception to the forfeiture provision at section 505(j)(5)(D)(i)(IV). Because under either analysis it is determined that Sandoz is eligible for 180-day exclusivity, it is not necessary at this time to firmly establish which regime should apply.

The MMA describes, among other things, certain events which can result in the forfeiture of a first applicant’s 180-day generic drug exclusivity as described in section 505(j)(5)(B)(iv). The forfeiture provisions of the MMA now appear at section 505(j)(5)(D) of the Federal Food, Drug, and Cosmetic Act (the Act). Included among these is section 505(j)(5)(D)(i)(IV), which states the following:

FAILURE TO OBTAIN TENTATIVE APPROVAL.--The first applicant fails to obtain tentative approval of the application within 30 months after the date on which the application is filed, unless the failure is caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application is filed.

A “first applicant” is eligible for 180-day exclusivity by virtue of submitting a substantially complete ANDA with a paragraph IV certification on the first day on which such an ANDA is submitted. Section 505(j)(5)(B)(iv)(II)(bb). If only one such ANDA is submitted on the first day, there is only one first applicant; if two or more such ANDAs are filed on the first day, first applicant status is shared.
“Tentative approval” means, generally, that an ANDA otherwise meets the requirements for approval under the Act, but cannot be fully approved for marketing because of patent or exclusivity protections. Section 505(j)(5)(B)(iv)(II)(dd). The “failure to obtain tentative approval” forfeiture provision establishes a bright line standard: If within 30 months an ANDA has been determined by the agency to meet the statutory standards for approval and it is only patent and/or exclusivity protection that prevents full approval, then an applicant maintains eligibility for 180-day exclusivity. If this standard is not met in 30 months, eligibility for 180-day exclusivity is forfeited. It should be noted that the 30-month timeframe generally is without regard to the length of time the ANDA was under review by the Agency. One exception to this general rule, described in section 505(j)(5)(D)(i)(IV), states that forfeiture will not occur if "the failure [to obtain a tentative approval] is caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application is filed".

A second exception is found in new section 505(q)(1)(G) of the Act, enacted as part of the Food and Drug Administration Amendments Act of 2007 (Pub. Law 110-85)(FDAAA). This section, however, is not relevant here because the still-pending petitions regarding metaxalone are not 505(q) petitions. Therefore, only the first exception described above might provide a basis for finding that Sandoz has not forfeited its 180-day exclusivity. It was FDA’s policy, prior to passage of the FDAAA, generally to regard a citizen petition that seeks to impose conditions on the approval of ANDAs (such as the citizen petition submitted by King) as creating a “review of the requirements for approval.”

II. DISCUSSION

Sandoz’ new strength amendment for the 800 mg strength was submitted on November 4, 2004, and was never tentatively approved. The date of submission of the new strength amendment plus 30 months was May 4, 2007; therefore, Sandoz’ ANDA was not tentatively approved within 30 months.

---

2 This provides that

If the filing of an application resulted in first-applicant status under subsection (j)(5)(D)(i)(IV) and approval of the application was delayed because of a [505(q)] petition, the 30-month period under such subsection is deemed to be extended by a period of time equal to the period beginning on the date on which the Secretary received the petition and ending on the date of final agency action on the petition (inclusive of such beginning and ending dates), without regard to whether the Secretary grants, in whole or in part, or denies, in whole or in part, the petition.

Pursuant to this provision, therefore, the 30-month period will be extended for the prescribed period during the review of a related petition subject to section 505(q).

3 The petition and petition for stay of action in FDA-2004-P-0426 were submitted well before passage of the FDAAA, and the petition in FDA-2009-P-0223 does not contain a request to take any form of action relating to a pending 505(b)(2) or 505(j) application.
The following patents are listed for Skelaxin, 800 mg:

<table>
<thead>
<tr>
<th>Patent Number</th>
<th>Expiration Date</th>
<th>Listed in OB</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,407,128 (‘128)</td>
<td>December 3, 2021</td>
<td>June 2002</td>
</tr>
<tr>
<td>6,683,102 (‘102)</td>
<td>December 3, 2021</td>
<td>September 2004</td>
</tr>
<tr>
<td>7,122,566 (‘566)</td>
<td>February 6, 2026</td>
<td>November 2008</td>
</tr>
</tbody>
</table>

All three of these patents are method of use patents. Sandoz filed PIV certifications for all three patents.

So the question of whether Sandoz forfeits its exclusivity is almost entirely academic. To date, seven dockets have been opened for petitions regarding metaxalone. Five of these dockets have been closed. Currently, docket numbers FDA-2004-P-0426 and FDA-2009-P-0223 remain open. The only pending petition that seeks to impose conditions on the approval of ANDAs is that of King (Docket No. 2004-P-0426/CP1 and PSA1). That petition is moot with respect to ANDA 040445: Sandoz certified to the listed patents and its labeling is identical to that of Skelaxin.

The ‘128 and ‘102 patents -- which have as their Use Code “Enhancement of the bioavailability of the drug substance,” and were the basis of the pharmacokinetic data in Skelaxin’s labeling that was at issue in the King petition -- were determined in a 2009 decision to be invalid in an infringement case brought by King against Sandoz. The patents and the labeling of the reference listed drug Skelaxin pertaining to the use of metaxalone under fed and fasted conditions created a dilemma for both the agency and ANDA applicants. Namely, it was questionable whether certain labeling could be carved out. That a carve-out was not permissible was the central argument of King’s 2004 citizen petition. The dilemma was deepened when, 24 months after the submission of Sandoz’ amendment for the 800 mg strength, the agency approved, on November
24, 2006, labeling changes for Skelaxin that included, among other changes, the following information in the Precautions section:

Taking SKELAXIN with food may enhance general CNS depression; elderly patients may be especially susceptible to this CNS effect.

Skelaxin has only one indication (as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions), so everything in the Precautions section applies to that one use. Carving out patent-protected language from the Precautions section of a label that pertains to a labeled use would generally not be permitted.

When an ANDA is tentatively approved, the proposed labeling must be acceptable to the agency. It was not possible, therefore, because of the patent-protected language, to tentatively approve Sandoz’ 800 mg product prior to the resolution of the patent case involving these patents. Sandoz submitted its amendment for the 800 mg strength on November 4, 2004, and 30 months from that date is May 4, 2007. During that entire time the agency had pending before it King’s citizen petition that prompted a review of a requirement for approval of a generic drug application, namely, what the appropriate labeling should be. The court’s finding that the two patents are invalid essentially renders the matter moot, for it permitted Sandoz to amend its proposed labeling so that it is identical to that of Skelaxin.

III. CONCLUSION

Sandoz was the first ANDA applicant to submit a substantially complete ANDA for Metaxalone Tablets, 800 mg, with a paragraph IV certification to the ‘128 and ‘102 patents. Therefore, Sandoz is eligible for 180 days of generic drug exclusivity for Metaxalone Tablets, 800 mg. Although Sandoz failed to obtain tentative approval of their ANDA within 30 months after the date on which the supplement for the 800 mg strength was filed, we have determined that this was caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application was filed.
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA-40445</td>
<td>ORIG-1</td>
<td>SANDOZ INC</td>
<td>METAXALONE</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARTIN H Shimer
03/29/2010
Dear EES:

Please refer to the email sent to CDER EESQUESTIONS on February 1, 2010 (copy below) regarding OGD's planned approval of Sandoz's ANDA 40-445 for Metaxalone Tablets.

At this time, there does not appear to be any indication in EES that an inspection of the facility in (b)(4) has been scheduled or initiated.

In the absence of information from the Office of Compliance documenting safety issues associated with the (b)(4) at the (b)(4) facility, OGD plans to grant approval to Sandoz's ANDA 40-445 for Metaxalone Tablets 800 mg by noon on Wednesday, March 31, 2010. As noted below, this site appears to have an acceptable inspectional history and there are no "OAI" alerts indicated. All other sites associated with the manufacture of this drug product have "Acceptable" recommendations made since September 2009.

Thank you,

Bob
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA-40445</td>
<td>ORIG-1</td>
<td>SANDOZ INC</td>
<td>METAXALONE</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TRANG Q TRAN
03/31/2010
OGD APPROVAL ROUTING SUMMARY

ANDA # 40-445 Applicant: Sandoz, Inc.
Drug: Metaxalone Tablets Strength(s): 800 mg

APPROVAL □ TENTATIVE APPROVAL □ SUPPLEMENTAL APPROVAL (NEW STRENGTH) □ OTHER □

REVIEWER: DRAFT Package FINAL Package

1. Martin Shimer
Chief, Reg. Support Branch

Contains GDEA certification: Yes ☒ No ☐
(required if sub after 6/1/92)

Pediatric Exclusivity System
RLD = Skelaxin NDA# 13-217

Patent/Exclusivity Certification: Yes ☒ No ☐

If Para. IV Certification- did applicant
Notify patent holder/NDA holder Yes ☒ No ☐

Was applicant sued w/in 45 days: Yes ☒ No ☐

Has case been settled: Yes ☒ No ☐

Is applicant eligible for 180 day
Generic Drugs Exclusivity for each strength: Yes ☒ No ☐

Date of latest Labeling Review/Approval Summary
Any filing status changes requiring addition Labeling Review Yes ☒ No ☐

Type of Letter: Full Approval.
Comments: 800 mg strength was submitted as a New Strength Amendment to ANDA 40-445 on 11/4/2004, BOS=Skelaxin NDA 13-217, PIV to '128 and '102. As this strength was submitted as an amendment there is no outgoing filing letter. There is both a filing review checklist indicating that the application is substantially complete and a DBE checklist which indicates that Fasting and Fed studies were conducted and are acceptable for the purpose of filing the ANDA. Applicant sent a letter w/d the 400 mg strength from this ANDA on 9/6/2006- this correspondence was formally acknowledged and the Agency's W/D Letter was issued on 9/20/2006. Firm submitted PIV certs to the '128 and '102 (from looking at this PIV cert it appears that Sandoz's intent was to provide a PIV to the '566 but their certification does not come out and state this. The same patent cert was provided again on 10/24, 10/25, 10/26, 10/27, 10/30, 11/13, 11/14, 11/15, 11/16, 11/17, 11/20, 11/21, 11/22. On June 26, 2009 the sponsor submitted a patent amendment which included- RR from Elan Pharmaceuticals signed and dated 11/8/2004, RR from Jones Pharma signed and dated 11/9/2004, RR from King signed and dated 11/8/2004, notice was sent on 11/3/2004, CA 04-5540 was filed in the Eastern D of NY on 12/17/2004 for infringement of the '128 and '102 patents, 30 month stay of approval will expire on 5/9/2007. The 6/26/2009 (in the EDR) amendment also included a copy of an Order signed by the DC for the Eastern District of NY on 6/3/2009 which found that the '128 and '102 patents are INVALID and the case was dismissed. Sandoz provided a PIV cert to the '566 patent on 11/5/2008, 11/6, 11/7, 11/10, 11/12, 11/13, 11/14, 11/17, 11/19, 11/20, 11/21, 11/24, 11/25, 11/26, 11/28, 12/1, 12/2, 12/3, 12/4, and 12/5/2008. Sandoz submitted a patent amendment on 12/11/2009-RR from UBS AG Stamford signed and dated 11/8/2008, RR from King Pharmaceuticals in Bristol TN signed and dated 11/10/2008, RR from UBS AG Stamford in Costa Mesa CA signed and dated 11/17/2008 again 11/18/2008...after reviewing this patent amendment it is clear that Sandoz sent notice to the appropriate parties on a daily basis as they submitted their serial certifications to the '566 patent. The 12/11/09 patent amendment contains multiple RRs from the same parties with dates on the RRs between 11/10/2008 and 12/8/2008. CA 08 CV 5974 was filed in the D of NJ on 12/5/2008 for infringement of the '566 patent.

Normally it would be necessary to ascertain the date upon which the '566 was listed in the OB in order to figure out which of the serial certifications was the first valid certification. However, because there can be no 30 month stay of approval related to the '566 patent and because there is no opportunity for 180 day exclusivity related to the '566 patent this information is unnecessary. Furthermore, we know that notice was adequately served to the appropriate parties as suit was brought in the D of NJ.
This application is subject to post-MMA (this amendment submitted by Sandoz was the first submitted for the 800 mg strength and was submitted after implementation of MMA) rules concerning 180 day exclusivity and eligibility for approval. Therefore, there is no 30 month stay of approval associated with the suit on the '566 patent, the '566 is not a barrier to approval at this time. The DC issued a ruling in favor of Sandoz with respect to the '128 and '102 patents so neither of these patents is a barrier to approval. Under MMA the first applicant is required to secure TA within 30 months of the submission date that qualifies that applicant for 180 day exclusivity. The NSA for the 800 mg product was submitted on 11/4/2004, became eligible for exclusivity as of this date but was not TA'd before 5/4/2007. Therefore at first pass it would appear that Sandoz has forfeited eligibility for 180 day exclusivity. The Agency will need to make a formal determination regarding whether either of the pending Citizen's Petitions for this drug product resulted in a tolling of the forfeiture period such that Sandoz would still be considered eligible for 180 day exclusivity.

Addendum: The agency has determined that Sandoz is eligible for 180-day generic drug exclusivity for Metaxalone Tablets, 800 mg. See Memorandum to the Record dated March 29, 2010 and entered into DARRTS./RLWest 3/30/10.

### 2. Project Manager, Nitin Patel Team 3

<table>
<thead>
<tr>
<th>Team 3</th>
<th>Review Support Branch</th>
<th>Date 12/11/2009</th>
<th>Date 3/31/10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Initials NP</td>
<td>Initials TTforNP</td>
</tr>
<tr>
<td>Original Rec'd date 8/31/2001</td>
<td>EER Status Pending ☑ Acceptable ☐ OAI ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Acceptable for Filing 11/7/2001</td>
<td>Date of EER Status Please see Memo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Patent/Exclus.expires 2/6/2026</td>
<td>Date of Labeling Approv. Sum 12/8/2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citizens' Petition/Legal Case Yes ☑ No ☐</td>
<td>Labeling Acceptable Email Rec'd Yes ☑ No ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(If YES, attach email from PM to CP coord)</td>
<td>Labeling Acceptable Email filed Yes ☑ No ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First Generic Yes ☑ No ☐</td>
<td>Date of Sterility Assur. App. NA.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority Approval Yes ☑ No ☐</td>
<td>Methods Val. Samples Pending Yes ☑ No ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(If yes, prepare Draft Press Release, Email it to Cecelia Parise)</td>
<td>MV Commitment Rcd. from Firm Yes ☑ No ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceptable Bio reviews tabbed Yes ☑ No ☐</td>
<td>Modified-release dosage form: Yes ☑ No ☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bio Review Filed Electronically:Yes ☑ No ☐</td>
<td>Interim Dissol. Specs in AP Ltr: Yes ☑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suitability Petition/Pediatric Waiver Yes ☑</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pediatric Waiver Request Accepted ☐ . Rejected ☐ . Pending ☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previously reviewed and tentatively approved ☐</td>
<td>Date ______</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previously reviewed and CGMP def. /NA Minor issued ☐</td>
<td>Date ______</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:PM will put CP note here.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3. Labeling Endorsement

<table>
<thead>
<tr>
<th>Reviewer:</th>
<th>Labeling Team Leader:</th>
<th>Date 3/18/10</th>
<th>Date 3/22/10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Name/Initials BN</td>
<td>Name/Initials JG</td>
</tr>
</tbody>
</table>

From: Grace, John F
Sent: Monday, March 22, 2010 9:44 AM
To: Nour, Burhan; Tran, Trang; Hoppes, Charles V
Subject: RE: Request for labeling endorsement for ANDA-040445 Product Name: METAXALONE Dosage Form: TABLET Applicant: SANDOZ INC
concur.

From: Nour, Burhan
Sent: Thursday, March 18, 2010 4:53 PM
To: Tran, Trang; Hoppes, Charles V
Cc: Grace, John F
Subject: RE: Request for labeling endorsement for ANDA-040445 Product Name: METAXALONE Dosage Form: TABLET Applicant: SANDOZ INC

Charlie,

There are no changes or updates.

Burhan

From: Tran, Trang
Sent: Thursday, March 18, 2010 4:03 PM
To: Nour, Burhan; Grace, John F
Subject: Request for labeling endorsement for ANDA-040445 Product Name: METAXALONE Dosage Form: TABLET Applicant: SANDOZ INC

Hi Burhan and John,

Could you please send me the labeling endorsement for the above ANDA? Attached are the copies of the Labeling Approval Summary and the AP letter.

Thanks,

Trang

4. David Read (PP IVs Only) Pre-MMA Language included □ Date 3/30/10
   OGD Regulatory Counsel, Post-MMA Language Included □ Initials rlw/for
   Comments: Text of approval letter has been reviewed by D.Read.

5. Div. Dir./Deputy Dir. Chemistry Div. I Date 3/12/10
   Initials PS
   Comments: cmc ok.

6. Frank Holcombe First Generics Only Date 3/30/10
   Assoc. Dir. For Chemistry Initials rlw/for Comments: (First generic drug review)
   N/A. CorePharma's ANDA 40-486 was granted tentative approval on 6/11/03.
7. Vacant

RLD = Skelaxin Tablets, 800 mg
King Pharmaceuticals, Inc. NDA 13-217

8. Peter Rickman
Director, DLPS
Para.IV Patent Cert: Yes No; Pending Legal Action: Yes No; Petition: Yes No
Comments: Bioequivalence studies (fasting and non-fasting) found acceptable. In-vitro dissolution testing also found acceptable. Bio study sites have acceptable DSI inspectional histories. Office-level bio endorsed 11/9/07. Final-printed labeling (FPL) found acceptable for approval (Approval Summary #3) 12/8/09, as endorsed 3/22/10. CMC found acceptable for approval (Chemistry Review #4).

OR

8. Robert L. West
Deputy Director, OGD
Para.IV Patent Cert: Yes No; Pending Legal Action: Yes No; Petition: Yes No
Press Release Acceptable
Comments: Refer to M.Shimer's discussion above regarding the '128, '102 and '566 patents and why they do not block approval of this ANDA. There are no additional patents or exclusivity listed in the current "Orange Book" for this drug product.

EES deemed to be Acceptable. All facilities have a current "Acceptable" recommendation in EES with the exception of [redacted] in (b)(4). This facility appears not to have been scheduled for a reinspection. As documented in my email memorandum to OC dated February 1, 2010 and again on March 28, 2010, OGD will proceed to approved this ANDA in the absence of information from OC. OC has not responded to the March 28, 2010 email. Copy of email filed in DARRTS for this ANDA.

This ANDA is recommended for approval.

9. Gary Buehler
Director, OGD
Comments: First-generic approval for this drug product.
First Generic Approval PD or Clinical for BE Special Scientific or Reg.Issue
Press Release Acceptable □

10. Project Manager, Nitin Patel Team 3 Date 3/31/10

Review Support Branch Initials

Date PETS checked for first generic drug (just prior to notification to firm)

Applicant notification:
3/31/10 Date notified of approval by phone
3/31/10 Date approval letter faxed

FDA Notification:
3/31/10 Date e-mail message sent to "CDER-OGDAPPROVALS" distribution list.

Date Approval letter copied to \CDS014\DRUGAPP\ directory.

EER DATA:
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TRANG Q TRAN
03/31/2010
April 1, 2010

Mr. Gary Buehler, Director,
Office of Generic Drugs, HFD-600
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville, Maryland 20855-2773

NOTIFICATION OF COMMERCIAL MARKETING DATE

Re: ANDA 40-445
Metaxalone Tablets, 800 mg

Dear Mr. Buehler:

This communication is in response to the Approval Letter received on March 31, 2010 for Sandoz, Inc.'s Abbreviated New Drug Application for Metaxalone Tablets, 800 mg; ANDA 40-445. The Approval Letter instructs Sandoz, Inc. that a communication should be submitted to the agency to inform of the date commercial marketing begins. Therefore, Sandoz, Inc. hereby notifies the Office of Generic Drugs, Center for Drug Evaluation and Research, the Food and Drug Administration that commercial marketing of ANDA 40-445, Metaxalone Tablets, 800 mg, began on March 31, 2010.

A Letter of Non-Repudiation Agreement was submitted by Sandoz Inc. to the FDA on November 30, 2007.

If there are any questions concerning this communication, please contact me by telephone at (252) 234-2413, by fax at (252) 234-2323, or email at ellen.camos@sandoz.com.

Best Regards,

Ellen Camos
Regulatory Affairs, Senior Associate
Sandoz Inc.